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Abstract
 In the quest for novel anticancer small molecules, one of two major complementary 
strategies, either a target- or phenotype-based approach, is generally  utilized. Target-based 
approaches, in which targets are first identified based on their cellular function and an inhibitor is 
subsequently  developed, are effective in some areas, but are not universally successful. 
Phenotype-based approaches have consistently lead to the discovery of successful drugs and with 
recent improvements in target-identification methods, these approaches are regaining popularity. 
Described herein is the target-based development of poly(ADP-ribose) glycohydrolase (PARG) 
inhibitors as putative anticancer compounds as well as the discovery of a class of potent 
anticancer tetracyclic indoles through a phenotypic screen.
 PARG plays a crucial role in DNA damage repair, and lack of PARG activity  after DNA 
damage prevents repair and causes a build-up  of toxic PAR chains. As such, PARG inhibitors 
have been pursued for decades as anticancer compounds. In this document, the structure-activity 
relationship  of the rhodanine-based PARG inhibitors (RBPIs) is investigated. Additionally, the 
RBPIs were found to be specific inhibitors of PARG over both related and unrelated proteins and 
demonstrated significant activity  in cellular lysate. Due to their lack of activity  in whole cells, 
computational lead hopping searches and docking screens were conducted on virtual compound 
libraries to identify structures that could serve as cell-permeable PARG inhibitors.
 In a phenotype-based approach, the tetracyclic indole 1257, was identified as a new 
anticancer compound via a high-throughput screen for cancer cell death. This compound’s 
activity was characterized with respect to its potency, speed of induced cell death, Hill slope 
value, Emax value, and type of cell death induced. The activity of 1257 was determined to depend 
upon early induction of endoplasmic reticulum stress leading to caspase-independent cell death.
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Chapter 1: Identifying New Lead Compounds In Silico and In Vitro
1.1 Lead-hopping in the context of drug development
In most drug discovery programs, the goal is to progress a candidate smoothly from 
screen to validated hit, through structure-activity-relationship (SAR) studies, and then through 
pre-clinical evaluation into clinical trials (Figure 1.1). Throughout this process, there are a 
number of criteria that a drug candidate must meet before resources are devoted to testing it in 
human patients. Potency and specificity  against the intended target are very important and are 
often the focus of initial structure-activity-relationship (SAR) efforts. Additionally, lack of 
toxicity  in whole organisms, including small mammals, is an critical hurdle. Additional 
important factors include solubility, which influences how the potential drug can be formulated, 
as well as pharmacokinetic properties such as absorption, distribution, metabolism, and excretion 
(ADME). If, through optimization of an initial hit  compound, a compound can be identified that 
meets all these criteria, it may become a drug candidate and be advanced into a clinical trial.
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Figure 1.1. Flow chart of drug discovery progression depicting possible uses of lead hopping to overcome 
undesirable properties of lead compounds.
Unfortunately, in many cases the primary hit compound cannot, despite extensive efforts, 
be optimized to yield an analog that meets every criteria. In these cases, lead hopping serves as a 
virtual technique for identifying new scaffolds for the same target, in the hopes that they can be 
optimized to meet all drug candidate criteria. As depicted in Figure 1.1, lead hopping can be 
utilized at  various points during the drug development process. This section will discuss when 
lead-hopping should be used and the pros and cons of pursuing such an approach.
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1.1.1 Appropriate use of lead hopping
 Lead hopping (also called scaffold hopping or ligand-based virtual screening) is a 
computational technique used to identify compounds similar to an existing lead compound.1 In 
contrast to structure-based methods, which utilize the three-dimensional structure of a protein 
target usually  by  docking, lead hopping relies solely upon the structure of the lead compound.2 
Through a variety  of different metrics, lead hopping methods search libraries of virtual 
compounds for structures which are similar to the existing lead compound, or query molecule. 
These similar compounds are then tested for activity, in the hopes that they will not only 
maintain target-binding activity but also lack the problems, such as high toxicity or rapid 
metabolism, of the query  molecule. Depending on the context, the entire lead molecule can be 
queried, or specific problematic portions can be queried, in an approach termed fragment 
hopping.3
 In almost every case, further optimization of a lead compound is the first choice for 
addressing an undesirable property. If the lead compound was identified through a high-
throughput screen, another fruitful approach is the optimization of other primary  hit compounds 
in the hopes of developing a better lead compound. In cases where returning to screen results or 
running a new screen is either undesirable or unfeasible, lead-hopping is a useful technique. 
Additionally, lead-hopping can be used to transition from small peptides to more drug-like 
compounds.4  In a commercial setting, lead-hopping is an attractive way to identify  chemical 
space not covered by existing patents.
 One of the main advantages of lead-hopping is that  no target  structure is required. Often, 
medicinally  interesting protein targets are challenging to crystallize, and viable drug candidates 
for these targets are desired well before a three-dimensional structure becomes available. 
Quantitative structure-activity  relationship  (QSAR) analysis is also often used without target 
structural information, but a high-quality QSAR analysis requires a large amount of structure-
activity data, which can be a significant barrier in many cases.5  Similarly, generation of three-
dimensional pharmacophores, which are a collection of positionally-defined chemical features, 
such as aromatic groups or H-bond donors/acceptors, require a large amount of structure-activity 
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data. Thus, lead hopping is a good choice when target structural information and extensive SAR 
information is unavailable.
1.1.2 Available programs for lead hopping
 A number of lead hopping programs have been described in the literature or are produced 
by scientific software companies. This chapter will focus only  on commercially-available or 
freely-distributed software, as purpose-built programs developed within specific groups are 
neither easily  accessible nor widely tested and thus are not as useful to our group. Lead hopping 
programs fall into two major categories based on whether they represent molecules in either a 
two- or three-dimensional manner. While there are significant differences between these 
approaches both computationally  and conceptually, neither has been demonstrated to give 
consistently better results than the other. Most  lead hopping programs are designed and 
optimized to allow for the discovery of an entirely new molecule, but many are also capable of 
fragment hopping. As this field progresses, the programs discussed below will most certainly be 
improved, updated, and re-evaluated, and the introduction of new programs is also likely. 
 Lead and fragment hopping approaches require different libraries with which to conduct 
searches. For lead hopping, where an entirely  new molecule is the goal, virtual versions of 
existing compounds are the best compound library option, since these databases are readily 
available (usually  free of charge) and the physical compounds are easy to obtain. In contrast, 
fragment hopping requires the use of a fragment library  where the molecules are not only of a 
generally  smaller size, but must have clearly indicated points of connectivity. Additionally, the 
structures identified by a fragment hopping search will likely  need to be synthesized before 
testing for biological activity. Further, fragment hopping can be used to find new scaffolds on 
which to append critical side-chains, or it can be used as a hypothesis-generating exercise for 
optimization of lead compounds. At the end of this section, programs designed for fragment 
hopping only will be outlined.
Three-Dimensional Lead Hopping Programs
 OpenEye produces the popular lead hopping program ROCS, which utilize three-
dimensional shape-based matching methods.6 In addition to determining the volume overlap of 
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each query, ROCS can also utilize a color-based scoring system. In color matching, each atom is 
classified into a different color based on its functionality and the match or mismatch between 
atom colors is included in scoring.7  The search function within the Cambridge Structure 
Database can be used to search for certain molecular topologies.8 Molecular Discovery produces 
the program SHOP which allows for whole compound and fragment hopping.9 Cresset’s Blaze 
program employs three-dimensional shape and electrostatics comparisons.10  Within the drug 
discovery  software package produced by Schrödinger is the program Phase Shape, which uses its 
own 3D method for similarity comparisons.11 In general, 3D shape-based methods require the 
enumeration of multiple conformers of each library molecule, either before or during the shape-
comparison step, which increases the computational burden of this method.
Two-Dimensional Lead Hopping Programs
 Two-dimensional molecular fingerprints, which are virtual representations of the 
connectivity of the atoms, ring, or functional groups within a molecule, are often used in 
conjunction with various similarities measures to conduct lead-hopping. The most popular of 
these are Daylight Fingerprints12  and Extended Connectivity Fingerprints (ECFPs). Daylight 
Fingerprints are constructed by exhaustively enumerating all of the linear patterns of atom 
connectivity with a molecule. ECFP fingerprints are constructed by exhaustively enumerating 
circular connectivity  from each atom within each molecule, and can extend to a 2, 4, or 6 bond 
diameter (ECFP_2, ECFP_4, or ECFP_6, respectively).13  Tanimoto coefficients, which are a 
simple measure of the overlap between two data sets, are the most popular way to compare either 
ECFP or Daylight Fingerprints. Due to the relative ease of calculation, these descriptors are not 
confined to specific software programs, and can be implemented within a variety  of drug 
discovery  platforms. Another option is BioSolveIT’s two-dimensional Feature Trees (FTrees) 
Visual Similarity algorithm, which can be used to query either the entire molecule or 
fragments.14
Fragment Hopping Only Programs
 A variety of fragment hopping programs are available and many are provided with an 
accompanying fragment library. If desired, users may  also generate their own fragment libraries 
for use in each of these programs. MORPH, a free software designed by scientists at Bristol-
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Meyer Squibb, is capable of replacing aromatic rings with similar rings.15 BioSolveIT sells the 
program ReCore, which specifically  works to replace the core of a molecule.16  Schrödinger 
software includes the program Core-Hopping which can replace either interior or exterior 
fragments and includes fragments with multiple attachment points in its library.17  In addition, 
OpenEye’s BROOD is capable of searching for replacements of side chains or interior 
fragments.18 
 
1.1.3 Lead hopping campaigns in the literature
 The literature has many examples of the use of lead hopping techniques to identify new 
lead scaffolds. Highlighted below are examples that effectively demonstrate various aspects of 
lead hopping.
A new scaffold for tubulin-binding vascular disrupting agents (VDAs) was identified 
through the use of a three-dimensional lead hopping approach.19 To overcome the high toxicity 
and low stability of current VDAs, a search of the ZINC database was carried out using ROCS, 
where the compounds were scored by both shape and color. Two query molecules, DAMA-
colchicine, and  TN-16, which both bind in the same pocket of tubulin, were used (Figure 1.2). 
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Figure 1.2. Lead hopping results using ROCS with either DAMA-colchicine or TN-16 for the query molecule in a 
search of the ZINC library. 
The top-ranked compounds from DAMA-colchicine consisted of colchicine analogs and other 
previously-identified tubulin inhibitors and thus were not pursued. The top-ranked compounds 
identified using TN-16 were grouped into structural families and six compounds, each 
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representative of one of these families, were tested for activity. Only compound 1.1 displayed the 
desired antiproliferative activity in both MBEC (mouse brain endothelial) and L1210 (murine 
leukemia) cells. Optimization of 1.1 through a traditional structure-activity relationship approach 
led to the identification of 1.2 as a highly potent tubulin binder with strong activity in whole cells 
and high stability in liver extracts. This example demonstrates the ability of lead hopping to 
identify new structures with better physicochemical properties, while also underscoring how 
results can vary with different query molecules.
In a unique approach towards identifying Toll-like receptor (TLR) antagonists, two 
rounds of lead hopping were carried out in which the first round utilized TLR agonists as a query 
and validated hits from the first round were used as query molecules in the second round.20 In the 
first round, three TLR agonists (1.3-1.5, Figure 1.3) were employed as the query molecule since 
no TLR antagonists were known at the time and the researchers reasoned that compounds similar 
to agonists could bind to the same pocket and elicit  the opposite activity. After searching the 
National Cancer Institute (NCI) database of compounds, they tested 39 candidate compounds 
and identified four TLR antagonists (1.6-1.9, Figure 1.3). To identify  further scaffolds, two of 
these newly identified compounds, 1.7 and 1.8, were employed in a second round of lead 
hopping, in which a 2.8 million compound commercial library was searched. Upon testing 22 
candidates, this led to the identification of three further TLR antagonists (1.10, 1.11, and 1.12, 
Figure 1.3). Five of the seven compounds identified contain a urea motif, although the other 
portions of these structures are fairly  distinct from each other. Overall, this bold strategy to 
search for TLR antagonists with TLR agonists and then to further expand the number of 
scaffolds by conducting another search, proved to be very successful. While lead hopping is 
generally  used to find compounds with the same activity  as the query molecule, this example 
demonstrates that if the opposite activity  can be achieved by  binding to the same pocket, lead 
hopping can be used to find such activity.
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Figure 1.3. Results of lead-hopping with TLR antagonists using two different compound libraries. Dashed box 
indicates structures used as query molecules in the second round of lead hopping.
 In an exploratory  effort, compounds similar to an melanoma-specific anticancer agent 
without a known target were identified using both two- and three-dimensional methods.21 The 
lead compound, LY-1-100 (Figure 1.4), had shown selective nanomolar activity against 
melanoma cell lines when tested against the NCI-60 cancer cell line panel. When Schrödinger’s 
Phase Shape program was used to search the University  of Cincinnati Drug Discovery  Center 
Compound Library  (UC Database, which contains over 300,000 structures) and 88 compounds 
were tested, only two active compounds were identified (1.13 and 1.14, Figure 1.4). In contrast, 
similarity searches of the same library using five different two-dimensional fingerprints 
(Accelerys) yielded a total of eight active compounds (including 1.15-1.17, Figure 1.4). All of 
the newly identified active compounds had IC50 values against A375 (human melanoma) and 
B16-F1 (murine melanoma) cell lines in the low micromolar range. Although all of the new 
active compounds contain the same trimethoxybenzene structure, the molecules identified from 
the two-dimensional similarity searches are more structurally  distinct from the query  molecule 
than the molecules identified by  the three-dimensional search. The authors did not determine the 
target of any of these compounds, so whether all of these compounds bind to the same target is 
currently unknown. This example demonstrates the complementarity of the two- and three-
dimensional lead hopping techniques, as searches of the same library  with different methods 
gave different results.
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Figure 1.4. Structures of query molecule and results from both 2D and 3D searches of the same library with 
LY-1-100 as the query molecule. 
In order to rapidly identify new drug-like inhibitors of trypanothione reductase (TryR), a 
highly  sought-after target for the treatment of many forms of trypanosomiasis, a sequential lead-
hopping/docking strategy  was reported.22 Due to the wide shape of the TryR binding site and the 
high variability in binding orientations, the authors decided that docking alone would not be a 
sufficient screening method. Starting with a collection of reported TryR inhibitors, many with 
significant structural liabilities (1.18-1.21, Figure 1.5), a substructure similarity search was 
conducted on the ZINC library. Next, the resulting compounds were filtered for drug-like 
properties and then docked into the TryR active site. From the 19 ligands identified through this 
effort, nine displayed good activity  against both T. cruzi and T. brucei parasites in vitro 
(including 1.22-1.25, Figure 1.5). This example demonstrates that lead hopping techniques can 
be used to successfully supplement docking campaigns.
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Figure 1.5. Representative structures of query molecules and validated active TryR inhibitors from sequential 2D 
similarity and docking screening of the ZINC library.
1.1.4 Limitations of common lead hopping approaches
 There are a number of potential pitfalls that must be considered when undertaking a lead 
hopping endeavor. As is the case with docking methods, some lead hopping programs and 
approaches work well for some queries but not for others, and there is no way  to predict  which 
program will give the best results.23  Over, the best two-dimensional similarity  metric is 
ECFP_224 and the best three-dimensional similarity  program is ROCS with color matching,25 but 
this does not mean that these programs will give good results in all cases. To compensate for this 
uncertainty, the use of multiple metrics and software programs in parallel is recommended.26
 An additional consideration is the balance of similarity and diversity  in the lead hopping 
output. In general, lead hopping efforts aim to identify  compounds from within a database that 
are very similar to the query molecule, this can lead to results that are too similar to the query to 
be useful. This was seen in the previously discussed example where the DAMA-colchicine query 
only gave close analogs of colchicine. Since the natural inclination of a similarity  measure is to 
return these types of close structural analogs with high scores, this is somewhat at  odds with the 
desire to obtain distinct  structures from such a search. Undesired structures which are too closely 
related to the query  molecule can either be disregarded when selecting output compounds to test, 
or they can be purposefully eliminated from the library. This can be accomplished by conducting 
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a substructure search for portions of the query  structure on the initial library  and removing the 
resulting compounds.
 One point of consideration for three-dimensional shape-based lead hopping is the 
relationship  between volume overlap and binding pose. A lead hopping campaign which searches 
for the maximum overlap between the query  and database compounds is essentially only 
searching for compounds which bind in the same binding site and with the same general pose.26 
Of course, two potent compounds can bind to the same target and even the same binding site 
with very  low volume overlap. Three-dimensional methods are therefore unable to identify 
ligands that cannot adopt the same pose as the query. This inherent bias of shape-based methods 
should be taken into consideration when such an approach is performed.
 As with any computational method, the more information that can be input at the 
beginning, the better the final output. In particular, the importance of each part of the query 
molecule should be considered. By default, equal importance is placed on each part of the query 
molecule, when in reality, certain parts of the query molecule (e.g. a hydrogen bond-donating 
hydroxy) contribute more to binding than other parts (e.g. an alkyl group  which does not fill a 
hydrophobic pocket).26 Strategies such as placing constraints or specifying certain features in the 
output molecules can be used to effectively weight different parts of the query molecule and 
increase the quality of the final output. Similarly, the use of multiple query  molecules or the use 
of pharmacophore queries will also serve to increase the quality of the output.
1.1.5 Summary of lead hopping for drug discovery
 As demonstrated in this section, there are many ways to conduct lead hopping and a 
multitude of factors that  can impact its success. It may be tempting to assume that structure-
based virtual screens, which are generally conducted by  docking database compounds into the 
binding pocket  of a target, are usually  more successful than ligand-based approaches. While 
docking does benefit from more complete consideration of the ligand-target  interaction and 
affords some advantages over lead hopping, head-to-head comparisons of both methods have 
repeatedly shown that lead hopping can outperform or at least equals docking.23,27,28,29  These 
methods can often give complementary results, which is why  in many  cases, they  are used in 
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parallel or sequentially, to further enrich the results. Additionally, optimization and customization 
of either method for a specific situation may mean that  one method performs significantly better 
than the other. Overall, due to the prior success of ligand-based methods, this method is a strong 
tool for a drug discovery laboratory’s toolbox.
1.2 Identifying lead compounds from phenotypic screens
 The discovery of most drug candidates begins with a screen, typically an assay  that can 
be done quickly  and easily, and can process multiple test compounds per run. Discovery screens 
can be either low- or high-throughput and are generally classified as either target-based or 
phenotypic. The distinction between target-based and phenotypic screens is very important, as it 
affects what kinds of compounds will be identified as primary  hits and what is required during 
further drug development. Both types of screens have historically been successful,30  but this 
section will concentrate on the unique advantages and challenges of phenotypic screens. Further, 
this section will delineate factors other than potency to consider when choosing which primary 
hit to pursue from a anticancer phenotypic screen, particularly in the context of screens for 
anticancer cell death.
1.2.1 Use of phenotypic screens
 The term phenotypic screen can refer to a wide variety of assays, the main feature of 
these assays being that they occur within a complex system, such as whole cells or in whole 
organisms, and that their read-out is a reflection of the overall desired effect of the drug. For 
example, a screen designed to identify  an antiviral agent could use fluorophore-labeled viral 
particles with cultured human cells and a hit could be defined as lack of fluorescence within the 
human cells. On the other hand, a screen that employs an expressed and purified viral enzyme 
then assesses whether the compound inhibits that enzyme’s function would be classified as a 
target-based screen, since the overall desired outcome is not enzyme inhibition but disruption of 
the viral replication cycle. Some of the main disadvantages of target-based screens is that they 
often identify aggregating compounds, compounds with poor target selectivity, or compounds 
with very poor pharmacokinetic properties.31  Phenotypic screens account for many of these 
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problems by requiring that hit  compounds be able to reach their molecular target within a cell or 
organism and that compounds have at  least a modest level of selectivity for their target, 
otherwise these compounds would not present as hits in such a screen.
 One of the main features of a phenotypic screen is that it is unbiased with respect to 
molecular targets. Therefore, they are generally used in situations where no good targets have 
been identified or where identifying a new target would be beneficial. Target-based screens are 
more suited to the discovery of new compounds that bind to well-characterized and validated 
targets. Indeed, where a phenotypic screen can excel is in the discovery of a single molecule 
which affects multiple targets, most or all of which contribute to the desired phenotype. This 
mode-of-action, often called polypharmacology, is in contrast to the general assumption that 
drugs have their effect through a specific interaction with one cellular target.32  Somewhat 
surprisingly, approved drugs have been shown to have on average six known targets.33
 Phenotypic screening is an efficient way to identify a compound that produces the desired 
overall effect, or phenotype. The main disadvantage of this approach is that  for a deeper 
understanding of a primary hit  and for ease of optimization, the molecular target must be 
determined. While there are many sophisticated methods for target identification, most of these 
methods are complex and laborious and require multiple follow-up  studies to confirm a putative 
target.34  Even with this added challenge, phenotypic screens have a relatively high rate of 
discovering successful lead compounds.35,36
 
1.2.2 Counter-screens and secondary assays
 Appropriate counter-screens and secondary assays are critical aspects of primary hit 
validation. Determination of which assays should be conducted on primary hits is carried out 
based on the format of the initial screen assay. Many phenotypic screens are performed in cells 
or small organisms in which fluorescent reporter genes have been inserted. Primary hit 
compounds could artificially increase or decrease the fluorescence signal by giving off a 
fluorescent signal themselves or by quenching the reporter’s fluorescence. In addition, a primary 
hit could have a direct stabilizing or destabilizing effect on the fluorescent reporter protein 
itself.37 Thus, when a fluorescent reporter is used, follow-up assays must assess the fluorescent 
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and quenching properties of the small molecule itself, as well as determine whether the 
compound affects the fluorescent reporter itself, possibly by employing a different reporter.38
 Very  reactive and generically  toxic compounds will often present as primary hits in 
screens looking for antibacterial, antiparasitic, and anticancer activity. Thus, with these types of 
screens, follow-up assays to assess the scope of toxicity are especially important. In many 
situations, simply  testing primary hits against cultured non-cancerous human cells will reveal 
whether they are selectively toxic against  the target organism or not. For anticancer compounds, 
such an assay  will be less useful, as most approved cancer drugs display toxicity against these 
cultured non-cancerous cells. Thus, other aspects of a primary  anticancer hit’s activity must be 
evaluated before the decision to invest significant time in determining its cellular target is made. 
Eventually, toxicity of an anticancer compound can be more confidently assessed in small 
mammals, such as mice or rats. 
1.2.3 Shape of cytotoxicity curves of anticancer compounds
 After a phenotypic screen for cytotoxicity in cultured cancer cells is complete, the 
primary hit compounds are usually retested over a range of concentrations. A true positive hit is 
one that shows a dose-response relationship, where the amount of cell death increases as the 
compound concentration increases. Generally, dose-response data points are fit to a sigmoidal 
dose response curve, which then provides a standard potency metric such as IC50 or EC50.39 
While the potency of a compound is very  important, the shape of the fitted dose-response curve 
can be further analyzed through other metrics to help predict how effective a compound may be 
in the treatment of cancer.
 One parameter of this sigmoidal dose response curve that can vary  widely between 
compounds is the Hill slope (HS), which is the slope of the curve through the inflection point.40 
When simple enzymatic systems are fitted in this way, the HS value is equal to one for most 
systems, and only exceeds one when the enzyme displays cooperativity  (e.g. binding of oxygen 
to hemoglobin). In the more complex environment of whole cells, the HS value can be less than, 
equal to, or greater than, one. Shown in Figure 1.6 are examples curves with HS values less than 
or greater than one, with curve I having a HS of 4 and curve II having a HS of 0.5. Qualitatively, 
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the relationship can be described as a smaller or larger gain in the amount of cell death upon a 
given increase in the compound concentration. In the example shown, curve I shows a large 
increase (90% to 0% cells alive) in cell death when the concentration increases from 0.1 to 1 µM, 
while the same increase in concentration in curve II gives rise to a relatively small increase (70% 
to 35% cells alive) in cell death (dashed lines, Figure 1.6).
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Figure 1.6. Generalized cytotoxicity dose-response curve shapes with either large Hill Slope (curve I, blue) or small 
Hill Slope (curve II, red), dashed lines indicate compound concentrations and corresponding percent viable cells.
 A recent study of the cytotoxicity curves of 64 anticancer drugs by  Sorger and coworkers 
in 53 breast cancer cell lines found that HS values vary with drug class.41 For example, they 
determined that the HS values for mTOR inhibitors (everolimus, PP242, and temsirolimus) over 
all cell lines averaged to 0.41 while for HDAC inhibitors (LBH589, oxamflatin, vorinostat, 
trichostatin A, and valproic acid) the average HS value was 1.5. Thus, the average HS value for a 
cytotoxin is related to its mode of action.
 HS values greater than one could reflect cooperativity in drug binding to the molecular 
target, though they could also reflect the presence of polypharmacology effects which work 
synergistically  to increase cytotoxicity. Sorger and coworkers determined that a large contributor 
to shallow dose response curves (where the HS value is below one) was a high degree of cell-to-
cell variability in response to the cytotoxin. Even at high concentrations where all cells are 
expected to encounter a large amount of compound, wide variations in response to certain drugs 
were observed. This uneven effect on the cancer cell population is concerning, because this could 
create selective pressure for the proliferation of cells which are not affected by  the 
chemotherapeutic. As such, steeper dose-response curves and HS values greater than one may be 
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more attractive due to the low variability among the cancer cell population in response to the 
cytotoxin. On the other hand, numerous successful cancer therapeutics display  shallow 
cytotoxicity curves, so a low HS value should not eliminate an otherwise promising candidate 
from consideration. 
 Another important parameter of cytotoxicity curves is the Emax, or the amount of cells 
surviving after the dose response curve plateaus at high concentrations. Shown in Figure 1.7 are 
examples curves with Emax values equal to or greater than zero, with curve II having an Emax of 0 
and curve III having an Emax of 30. If percent cell death is plotted instead of percent cells alive, 
this value can range from less than or equal to 100. This parameter is important in determining 
how effective a compound is at killing cells at high concentrations. As with HS values, the 
average value of Emax over a panel of cell lines is correlated with drug type, and thus is related to 
the compound’s mode of action.41 For example, DNA crosslinking drugs (carboplatin, cisplatin, 
and oxaliplatin) all displayed strong cell killing with Emax values close to zero, while EGFR 
inhibitors (AG1478, erlotinib, and gefitinib) showed wide variation in Emax values across the cell 
line panel.41
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Figure 1.7. Generalized cytotoxicity dose-response curve shapes with small Emax (curve II, red), and large Emax 
(curve III, green), dashed line indicates Emax for curve C.
 Sorger and coworkers demonstrated that the cells that survived treatment with 
compounds with large Emax values did not develop  resistance upon regrowth, but retained the 
same overall level of sensitivity to that cytotoxin.41 This type of fractional killing leaves behind 
unaffected cells which can readily  regrow after the chemotherapeutic is removed. Thus, a 
compound with an Emax value close to zero is ideal because it does not inherently leave a portion 
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of the cancer cell population unaffected. Some currently used chemotherapies do have high Emax 
values in many  cell lines, so this feature can be overcome, but it could additionally contribute to 
the rise of resistance.
 One important note is that HS and Emax are features of drug classes when a large panel of 
cell lines are analyzed. These values vary  to a greater or lesser degree across cell lines and 
Sorger and coworkers noted a few cases in which single cell lines displayed outlier values. These 
variations could reflect functional differences in each cell line’s response to the drug. Further 
analysis of the cytotoxicity drugs of chemotherapeutics with clinical data could reveal whether 
there is a relationship  between the HS and Emax of a cytotoxin and overall clinical efficacy. 
Additionally, since most chemotherapeutics are utilized in combination with other drugs or 
radiation, a similar analysis of drug combinations may  provide greater clarity as to the efficacy 
of these treatments.
 The importance of HS and Emax values in the clinic has been demonstrated in the field of 
HIV-targeted antiretrovirals. Siliciano and coworkers found that changes in either Emax or HS 
upon mutation of the drug target have a critical role in determining how effective a drug is 
clinically.42 In some cases, a mutation will only  slightly affect a drug’s IC50 value, but also cause 
a decrease in the HS value, which drastically  reduces the efficacy of the drug at concentrations 
above the IC50.42
 Additionally, the HS and Emax values of BCR-ABL inhibitors, used in the treatment of 
myeloid leukemia, has been demonstrated to have clinical correlations.43 A study of BCR-ABL 
inhibitors in cell lines harboring 15 different BCR-ABL kinase domain mutations by Druker and 
coworkers revealed a strong correlation between clinical response and IPP, a metric that 
combines the HS and IC50 parameters.43 Lower HS values were associated with poorer clinical 
outcomes while higher HS were associated with better clinical outcomes. Additionally, they 
noted that clinical resistance to BCR-ABL inhibitors with high HS values could be overcome in 
many cases by a simple increase in dose. Thus, analysis of a cytotoxin’s dose-response curve 
shape can have significant implications for guiding clinical treatment decisions. 
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1.2.4 Timing of cell death
In addition to potency, Hill slope, and Emax, another dimension of a cytotoxin’s activity 
that should be considered during development is the timing of cell death. Certain anticancer 
drugs, such as paclitaxel and topotecan, assert their effects through arrest of progression through 
the cell cycle and this arrest signals for apoptosis. As such, their effects are phase-specific and 
rely  on a cell reaching a certain point in its cycle before signaling for cell death is initiated. In 
contrast, other anticancer drugs, such as gemcitabine and bortezomib, are not phase-specific and 
are able to induce apoptosis regardless of the cell cycle phase.44 This distinction is important as it 
can affect optimal dosing schedules and the success of combination therapies. For example, 
continuous exposure to a low dose of topotecan, a phase-specific drug, was demonstrated to be 
more effective in the treatment of recurrent ovarian cancer than a short exposure to a high dose.45 
Additionally, combinations of chemotherapeutics with immunotherapy only  increased the 
effectiveness of phase-specific chemotherapeutics.46  The authors of this study attributed this 
difference to the fractional killing of cancer cells by phase-specific drugs due to their short  half-
lives and dependence upon cell cycle. Cells which survive treatment with a phase-specific 
chemotherapeutic are more vulnerable to immunotherapy, whereas non-phase-specific 
chemotherapuetics did not induce fractional killing, thus eliminating any benefit  from the 
immunotherapy.
Speed of the induction of apoptosis is thought to depend heavily upon pre-mitochondrial 
events, and once MOMP (mitochondrial outer membrane permeabilization) is induced, cell death 
is rapid and irreversible.47  However, natural variations in protein levels can lead to dual 
outcomes upon apoptosis-inducing treatment, where some cells eventually  signal for MOMP, 
while others never do and continue to survive.48 Thus, a slower rate of cell death induction, with 
any type of cell death, may  indicate a high level of variability  in response to the cytotoxin 
between cells. Conversely, a faster rate of cell death may indicate less variability  in the response 
to the cytotoxin and fewer cells escaping the point-of-no-return.
No studies on the relationship between in vitro speed of cell death and clinical outcomes 
have been reported, but work in our lab shows that FDA-approved drugs for cancer indications 
vary greatly on this measure.49 Thus both rapid and slow induction of cell death in vitro can be 
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developed into an effective treatment  in human cancer patients. Whether an increased speed of in 
vitro cell death is advantageous has yet to be confirmed, but there are a few reasons that suggest 
it may  be. Rapid cell death implies that the point-of-no-return for cell death upon cytotoxin 
treatment occurs even more rapidly, implying that a very  short  exposure time is needed to induce 
irreversible cell death. This is advantageous in that upon treatment, more of the cancerous cells 
are likely to be exposed to an effective concentration of the cytotoxin for an appropriate amount 
of time. Even if a cytotoxin has poor pharmacokinetics, this could be compensated for by  a rapid 
mode of action. Of course, a cytotoxin with slow induction of cell death could also reach the 
point-of-no-return rapidly, but this would have to assessed separately. Furthermore, rapid 
induction of cell death could also decrease the chance of developing resistance, by limiting the 
amount of time each cell has to adapt to and overcome the cytotoxin’s insult. 
1.2.5 Summary of phenotypic screening
 Phenotypic screens are ideally  suited for the discovery of new compounds with new 
mechanisms of action. Their ability to identify high quality  high compounds coupled with 
increasing methods for target identification has spurred a renewed appreciation for their utility in 
drug discovery.50  To fully  appreciate the activity  of a lead anticancer compound from a 
cytotoxicity screen, many factors beyond simple measures of potency should be taken into 
consideration. Increasing attention is being paid to curve shape in the literature, which will 
hopefully lead to more studies demonstrating how Hill slope and Emax values can best be used to 
evaluate candidate cytotoxins in vitro. While approved anticancer drugs display a wide range of 
speeds for cell death induction, analysis of this parameter of a candidate drugs action should 
yield useful information as to its mode of action and the best ways to dose a drug once it reaches 
clinical testing. 
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Chapter 2: Rhodanine-Based PARG Inhibitors (RBPIs)
Portions are reprinted with permission from Finch, K. E.; Knezevic, C. E.; Nottbohm, A. C.; 
Partlow, K. C.; Hergenrother, P. J. “Selective Small Molecule Inhibition of Poly(ADP-ribose) 
Glycohydrolase (PARG)” ACS Chem. Biol. 2012, 7, 563-570, and from Dunstan, M. S.; 
Barkauskaite, E.; Lafite, P.; Knezevic, C. E.: Brassington, A.; Ahel, M.; Hergenrother, P. J.; Leys, 
D.; Ahel, I. “Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase” Nat. 
Commun. 2012, 3, 878, doi: 10.1038/ncomms1889.
2.1 Background on PARG and RBPI discovery
 The metabolism of poly(ADP-ribose), a unique biopolymer and post-translational 
modification, plays a critical role in a variety of key cellular processes, such as DNA repair, 
chromatin superstructure, and cell death (Figure 2.1). Approximately  90% of cellular PAR is 
produced by the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) upon binding to 
various DNA structures, which activate PARP-1’s enzymatic activity to differing degrees.1 
Figure 2.1. Metabolism of poly(ADP-ribose) (PAR) in response to DNA damage
 PARP-1 utilizes ß-NAD+ to generate polymers of ADP-ribose connected by a unique 
1’’-2’ glycosidic linkage (Figure 2.2). Most of the polymer is covalently  attached to aspartate or 
glutamate residues on PARP-1 itself, though other nuclear proteins, such as histones, DNA 
ligases, and transcription factors are also modified. PARP-mediated recruitment of DNA damage 
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response proteins to sites of DNA damage via non-covalent binding to PAR is a key step in the 
base excision repair and nucleotide excision repair pathways. High levels of PARsylation on 
PARP-1 serve to deactivate the enzyme by inducing dissociation from DNA through electrostatic 
repulsion, as both DNA and PAR are highly  negatively charged. PAR signaling is negatively 
regulated by the action of poly(ADP-ribose) glycohydrolase (PARG) which resides both in the 
nucleus and the cytoplasm of cell. PARG cleaves the glycosidic bond to release free PAR 
oligomers and ADP-ribose monomers via both endo- and exo-glycosidic activity.2,3  PAR 
oligomers are then further hydrolyzed by PARG to ADP-ribose. The proximal ADP-ribose unit  is 
removed by ADP-ribosyl lyases such as TARG,4 MacroD1 or MacroD2,!5 not by  PARG, which is 
unable to cleave the glutamate/aspartate-ribose ester bond. The activity  of these enzymes yields 
an unmodified PARP-1 molecule, which can then bind other DNA structures and continue 
producing PAR signaling polymers.
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 Since one of PARP-1’s major cellular functions is to mediate DNA repair in response to 
damage, PARP inhibitors have been intensely investigated for their ability to magnify the 
cytotoxic effects of DNA-damaging chemotherapeutics or endogenous DNA damage. Currently, 
close to 100 clinical trials are underway looking at single-agent or combination therapies with 
PARP inhibitors, including six phase III trials.6 The efficacy of PARP inhibitors is based on the 
premise that  inhibition of PARP-1 (and to a lesser extent PARP-2, which is at least partially 
affected by all known PARP inhibitors7) prevents PARP-mediated DNA repair, leads ultimately 
to replication fork collapse and thus results in cell death. DNA damage can be induced either by 
exogenous insult with a chemotherapeutic or by pre-existing dysfunction in other DNA repair 
pathways.
2.1.1 History of PARG as a putative anti-cancer target 
 Soon after the discovery  of PARG, its potential as an anticancer target was recognized, 
and efforts were undertaken to understand its role in more detail. PARG has a number of features 
which make it an attractive pharmacological target. In contrast the PARP family of enzymes, 
there is only one gene for PARG which gives rise to a number of isoforms upon variations in 
mRNA splicing.8  Due to this variable splicing, in which nuclear localization and export 
sequences are either lost or retained, different isoforms of PARG have different subcellular 
localizations (Figure 2.3). All known isoforms of PARG are catalytically  active, including the 
caspase cleavage products. As all PARGs contain the same catalytic active site, they will likely 
all be inhibited by a specific PARG inhibitor. Additionally, PAR, a highly charged biopolymer 
with both linear and branched structures, is a unique enzymatic substrate, suggesting that 
achieving specificity for PARG over other enzymes may be easier than it has been for PARP, 
where activity  against unrelated ß-NAD+-binding proteins is a concern. Additionally, PARG is 
present at a very low level in cells and has been measured at 2,000 molecules per cell.9 Despite 
the many attractive pharmacological features of PARG as a target for inhibition by  a small 
molecule, the high specific activity  of the enzyme presents a challenge. While pursuing RNAi 
PARG knock-down in both human and murine cells, it  was observed that knock-down to just 
10% of normal PARG protein levels was sufficient to maintain normal cellular functions, 
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including DNA repair and cell proliferation.10 This implies that a successful PARG inhibitor must 
be extremely potent to achieve complete PARG inhibition and affect PAR metabolism in a 
cellular context.
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Figure 2.3. Isoforms of PARG result from differential splicing of the mRNA transcript and from caspase cleavage, 
resulting in isoform-specific cellular localization. All isoforms are catalytically active in vitro. NLS = nuclear 
localization sequence; NES = nuclear export sequence; REG = regulatory domain; MTS = mitochondrial targeting 
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 A number of biochemical studies have investigated the consequences of loss of PARG 
function through knockdown and isoform-specific knockout. In general, cells with genetic 
depletion or RNAi silencing of PARG are more susceptible to radiation,11  DNA-alkylating 
agents,12 and chemotherapeutics such as cisplatin and epirubicin.13  In the course of efforts to 
generate PARG-/- mice, it was discovered that full loss of PARG function is embryonic lethal at 
very early  stages of embryo development.12 Fortunately, this does not necessarily mean that 
temporary loss of PARG function will be fatally  toxic to an adult organism, as not all proteins 
critical to embryo development are also critical to normal cellular function. Unfortunately, the 
inability to obtain PARG knockout mice limits the ease with which PARG function can be 
studied in vivo.
 Recently, a specific type of PAR-dependent cell death, termed parthanatos, has been 
defined, both in the nomenclature14  and biochemically.15  In this pathway, hyperactivation of 
PARP-1 leads to a toxic build-up of PAR in the cell (Figure 2.4). PAR oligomers, which may be 
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covalently attached to a histone (personal communication, Prof. Ted Dawson), translocate from 
the nucleus to the cytoplasm where they bind to apoptosis-inducing factor (AIF), a flavoprotein 
which resides partially  in the outer mitochondrial membrane.16 Upon binding to PAR, AIF travels 
into the nucleus where it  induces widespread chromatin condensation and then cell death. As 
such, inhibition of PARG is thought to induce a build-up of PAR upon DNA damage, thus 
inducing AIF translocation and cell death.
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Figure 2.4. PAR-dependent DNA repair and cell death or parthanatos.
 Additionally, as PAR plays an important role in chromatin structure,17 PARG inhibition 
may also increase the amount of DNA that is physically exposed and available for modification 
by DNA-alkylating and cross-linking chemotherapeutics. The addition of PAR onto histones 
plays a role in the unpacking of chromatin for DNA repair,18  but in the absence of PAR 
hydrolysis, the chromatin may remain unpackaged after routine repair activities, thus leaving it 
more vulnerable to structurally-damaging agents. Indeed, this effect has been demonstrated using 
PARG knockout embryonic trophoblast cells.19
 Overall, studies indicate that lack of PARG activity, especially  in conjunction with 
cellular insult such as damage from a chemotherapeutic, results in a greater degree of DNA 
damage, decreased DNA repair, and increased cell death. For these reasons, our lab and others 
have pursued the discovery and development of small molecule PARG inhibitors.
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2.1.2 Challenges in discovery and development of PARG inhibitors
There are a number of challenges facing the discovery  and development of PARG 
inhibitors. Most important is the lack of robust and inexpensive assays for PARG activity, 
including a lack of assays that are amenable to high throughput screening. Current  in vitro PARG 
assays rely either on the use of a radiolabeled substrate,20  expensive histone-coated wells for 
ELISA assay,21 or quantification of ADP-ribose through high-temperature reaction of its reducing 
sugar.22  The radiometric assay is one of the most utilized in the literature due to its sensitivity 
and direct read-out of substrate and product quantities. Unfortunately, the operational complexity 
and safety concerns associated with working with 32P-labeled materials make this assay low 
through-put and more suited for use as a secondary assay. The ELISA-based PARG assay is very 
expensive ($485 for 96 wells) and introduces concerns about test compound color and 
interactions between test compound and the wells or histones. The reducing sugar quantification 
assay requires incubation at 100 ˚C and will yield false positive results with aldehyde or reducing 
sugar-containing compounds. None of the aforementioned assays are amenable for high 
throughput screening formats.  
Until September of 2011, no crystal structure of PARG had been reported, and thus all 
PARG inhibitor development efforts were conducted without the benefit of structural knowledge. 
Since the discovery  and crystallization of bacterial Thermomonospora curvata PARG,23 several 
other PARGs have been crystalized, including Tetrahymena thermophila,24  mouse,25 rat26 and 
human PARG,27 with various ligands, including ADP-ribose, ADP-HPD, RBPI-3, and short PAR 
chains (see section 2.5.1). With an increasing number of available crystal structures, a clearer 
molecular picture of this enzyme is developing which will hopefully guide researchers to more 
productive searches for drug-like PARG inhibitors.
Another challenge faced when searching for PARG inhibitors is the difficulty associated 
with obtaining reasonable quantities of active mammalian PARG enzyme. Commercially 
available bovine PARG, which shares a high degree of similarity with human PARG, is 
extremely expensive, at $275 for 300 µg.28 Expression and purification of the catalytic domain of 
human PARG is extremely  difficult, and yielded only  low yields of active but impure protein in 
our hands (Dr. Kathy  Partlow). The recently discovered bacterial and protozoan PARGs are 
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reportedly easier to express and certain modifications have been discovered to facilitate the 
expression of soluble and active human PARG, so these difficulties may be lessened in the 
future. 
 
2.1.3 Current PARG inhibitors and their characteristics
 At the outset  of our group’s investigation into PARG inhibitors, only one potent and 
specific PARG inhibitor was known:  adenosine 5'-diphosphate (hydroxymethyl) pyrrolidinediol 
(ADP-HPD), which has an IC50 of 0.12 µM  against full-length PARG (Figure 2.5A).29  This 
inhibitor was developed by modifying the structure of ADP-ribose (Figure 2.5B), the product of 
the PARG reaction, which inhibits PARG with an IC50 of 120 µM.
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Figure 2.5. A) structure and IC50  of ADP-HPD; B) structure and IC50 of  ADP-ribose.
 ADP-HPD has facilitated a variety  of studies, such as photocrosslinking to determine the 
inhibitor binding site,30,31 identification of the catalytic residues of PARG,32 inhibition kinetics,33 
and investigations into the role of PAR in spindle structure.34,35,36 While ADP-HPD has proved 
valuable in a number of studies, the pyrophosphate group prevents this compound from diffusing 
through the cell membrane and displaying activity  in cell culture. Additional barriers to the use 
of ADP-HPD are its extremely high cost, with current  prices at $159 for 60 µg (or $2,650 for 1 
mg),37  and difficult synthesis.29 Replacement of the pyrophosphate group with a variety of 
aliphatic linkers results in loss of activity,38  indicating that the pyrophosphate is critical for 
inhibition.  
 Historically, other compounds such as DNA intercalators, tannins, and certain cyclic 
peptides have also been considered PARG inhibitors. As stated in previous reviews,39  and 
elucidated in recent studies,40  these classes of molecules either have unsubstantiated activity 
against PARG or are extremely promiscuous in their molecular interactions, and thus are not 
commonly used to study PARG. 
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 In 2011, the Jacobson group reported the use of target-related affinity profiling (TRAP) to 
circumvent the lack of a robust high throughput PARG activity screening method.41 This method 
relies upon rounds of low throughput in vitro screening with small groups of compounds (~70 
compounds per round) and, based on the “affinity fingerprints” of the best inhibitors, chooses the 
next round of compounds for testing. They  identified modified salicylanilides as dual PARG and 
PARP inhibitors with mid-to-low micromolar IC50 values, and reported weak activity in cultured 
cells when treated at  high concentrations (1 mM). As part of our investigation into the attributes 
of reported PARG inhibitors, we tested their best compound, 6a, and found that  it was a 
promiscuous aggregator. These results will be discussed further in section 2.4.1.
 The pharmaceutical company Astra Zeneca has also been pursuing PARG inhibitors for 
anticancer indications and may report their progress on the identification of a cell-permeable 
PARG inhibitor in 2014 (personal communication).
2.1.4 Targeted screening and discovery of RBPIs
 Due to the critical nature of the ADP-HPD pyrophosphate for PARG inhibition, small 
molecule phosphate mimics or replacements were investigated for their ability to inhibit PARG. 
Rhodanine, a known phosphate replacement,42  was chosen for study first by  Dr. Amanda 
Nottbohm.
 A collection of 224 rhodanine-containing compounds from the in-house Marvel and 
HTSF libraries were screened using a TLC-based 32P-PAR degradation assay. From this, 
compound RBPI-1 (rhodanine-based PARG inhibitor-1) was determined to be promising lead 
with an IC50 value of 47 µM  (Figure 2.6A). Based on RBPI-1, a library of 40 compounds, 
prepared from commercially-available substituted isatins and benzyl halides, was synthesized 
and tested, revealing four similar compounds that inhibited at concentrations lower than 10 µM. 
Next, a focused library of 60 compounds was prepared from commercially-available materials 
and based on the relative potencies of these library compounds, an initial structure-activity 
relationship (SAR) was developed (Figure 2.6B).  
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values against PARG (prepared and tested by Dr. Amanda Nottbohm and Dr. Kristin Finch). 
 Briefly, 5-substitution on the isatin with either bromine or chlorine along with 2,6-
dihalide substitution (dichoro or chloro/fluoro) on the benzyl ring resulted in the most potent 
compounds. The length of the methylene linker to the carboxylic acid also affects activity, with 
two methylenes yielding the best specificity  and potency. Three of the most potent compounds 
are shown in Figure 2.6C, along with two structurally similar inactive compounds.
 We aimed to more thoroughly explore the SAR of this class of inhibitors while possibly 
improving their potency and/or the cell permeability. The specificity of the RBPIs for their 
intended target over other related and unrelated proteins was also assessed.
2.2 Synthesis of RBPI analogs
 To probe the role and necessity of different functional groups in this class of PARG 
inhibitors, a variety of derivatives were synthesized. The activities of these new compounds were 
assessed via a TLC-based 32P-PAR degradation assay and cell lysate assays.
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2.2.1 Core Modifications
 As the rhodanine structure was initially chosen based on its ability to act as a phosphate 
mimic, the necessity of this ring was probed. Compounds 2-2 and 2-3 were condensed to form a 
thiohydantoin derivative (2-4, Scheme 2.1A) to investigate how replacing the endocyclic sulfur 
with a nitrogen affects potency. Unfortunately, efforts to prepare the analogous oxazolidinedione 
(2-5) or hydantoin (2.6) compounds resulted only in decomposition of the heterocycle and 
recovery of benzyl isatin starting material (Scheme 2.1B). Replacement of the entire rhodanine 
with a triazole was accomplished by addition of ethynyl magnesium bromide to the isatin 
carbonyl of 2-7, yielding alkyne 2-8, followed by [3+2] cycloaddition with 3-azidopropionic acid 
to give compound 2-9 (Scheme 2.1C). 
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 In the initial SAR development, the isatin moiety was not varied, so the essential 
components of this ring system were probed. A benzaldehyde-derived compound (2-12, Scheme 
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2.2) was prepared in four steps: N-alkylation of an aminobenzyl alcohol, following by oxidation 
to an aldehyde (2-10) and N-methylation (2-11), and lastly, condensation with rhodanine-3-
propionic acid.
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In an effort to probe the necessity of the conjugated double bond between the isatin and the 
rhodanine, RBPI-2 was subjected to lithium borohydride treatment to access dihydro-RBPI-2 
(2H-RBPI-2, Scheme 2.3).
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While compound 2H-RBPI-2 could be purified by  C18 column chromatography, upon 
concentration and brief exposure to ambient air, it was observed to rapidly convert back to the 
starting compound and several unidentified by-products. This was easily monitored by visual 
inspection of the compound appearance, as 2H-RBPI-2 appears as a colorless solid and upon 
oxidation and re-establishment of the extended pi-system, the characteristic red color of 
compound RBPI-2 is observed. 1H-NMR data clearly indicated the presence of the desired 
product, but due to the compound’s instability, spectral characterization of the pure compound 
was not possible.
2.2.2 Carboxylic acid modifications
 To address the minimal cell permeability of the lead RBPIs, synthetic efforts were 
directed at modifying the carboxylic acid, whose localized negative charge may contribute to the 
lack of cell permeability. A number of carboxylic acid mimics are known, including 
carboxamides, sulfonamides, sulfonates, and phosphates, but tetrazoles were chosen for their 
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high lipophilicity  and metabolic stability. Tetrazoles have roughly  the same pKa as carboxylic 
acids (4.5 - 4.9 for tetrazoles, 4.2 - 4.4 for acids) but are estimated to be ten times more lipophilic 
due to delocalization of the negative charge throughout the ring.43  Tetrazoles have been 
successfully  used to replace carboxylic acids in a number of medicinal chemistry endeavors, 
most notably in the development of angiotensin II receptor antagonists.44,45  The requisite 
precursor for tetrazole-containing RBPIs was prepared by protection of 3-aminopropionitrile to 
form 2-13, then cyclization to form the tetrazole and deprotection to form the corresponding 
aminotetrazole 2-14 (Scheme 2.4). Base-promoted formation of the carbamodithioic acid was 
followed by  cyclization with bromoacetyl bromide to produce the desired intermediate, 2-15. 
The synthesis of 2-15 has been carried out on a 4 mmol scale with an overall yield of 58%. 
Gratifyingly, condensation of 2-15 with a variety  of isatins proceeded smoothly, yielding red-
brown products that were easily isolated via filtration in moderate-to-excellent yields. Five 
tetrazole-containing compounds, RBPI-5, RBPI-6, 2-16, 2-17, and 2-18 were synthesized 
through analogous routes.
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 To probe whether the negative charge on the tetrazole ring was necessary  for activity, we 
also attempted to prepare the N-methyl tetrazole derivative of RBPI-6. This was accomplished 
by methylation of tetrazole 2-19 in which the amine is protected by  a carboxybenzyl group. This 
reaction results in a separable mixture of the 1- and 2-methyl tetrazoles (2-20 and 2-21, Scheme 
2.5). Next, 2-methyl tetrazole 2-21 was deprotected and the free amine was elaborated to the 
rhodanine ring (2-22) before condensation with 2-7 to afford Me-RBPI-6 in low yield. 
Unfortunately, this analog was completely insoluble in both dimethylsulfoxide and ethanol and 
thus could not be tested for the ability to inhibit PARG.
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 To probe the necessity of an acidic group, such as a carboxylic acid or tetrazole, the polar 
but non-protic nitrile functional group was appended to the rhodanine. Beginning with 3-
aminopropionitrile again, rhodanine formation gave compound 2-23 which was condensed with 
2-3 to yield compound 2-24 (Scheme 2.6).
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To investigate the possibility  of enhancing RBPI cellular uptake using a prodrug approach, we 
attempted to prepare a glucose derivative of RBPI-3 by appending the carboxylic acid to the 3’ 
alcohol of glucose (Scheme 2.7). This was accomplished by the use of a Steglich esterification to 
couple commercial N-propionic acid rhodanine with an isopropylidene-protected glucofuranose 
to yield 2-25 in good yield. Standard condensation conditions gave the protected glucose 
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derivative 2-26, which could be purified by column chromatography using a methanol/
chloroform solvent system. Unfortunately  we found that upon removal of the isopropylidene 
groups with trifluoroacetic acid, the resulting free glucose derivative Glu-RBPI-3 was insoluble 
in dimethylsulfoxide as well as other common solvents, and could not be evaluated further.
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To further probe the functional group requirements at the acid position, a methyl amide analog 
was prepared (Scheme 2.8). ß-alanine methyl ester was converted to the corresponding methyl 
amide (2-27) using methyl amine and the free amine was further elaborated to the rhodanine 
(2-28). Standard condensation conditions yielded compound 2-29.
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2.2.3 Benzyl and isatin substitution modifications
 As the initial SAR study determined that  5-substitution on the isatin was required for 
activity, two derivatives were synthesized for possible photocrosslinking, which would identify 
where the RBPIs may bind to PARG. The synthesis of 2-31 and 2-32 proceeded through the 
preparation of 5-azidoisatin, which was then alkylated to access 2-30 and condensed either with 
2-15 or rhodanine-3-propionic acid to give the final products in excellent yields (Scheme 2.9). 
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 To investigate the possibility of appending handles such as biotin or fluorophores, which 
could be used in pull-down or fluorescence polarization experiments, a 5-acetamido derivative, 
2-35, was synthesized (Scheme 2.10). The synthesis of 2-35 proceeded through 5-
acetamidoisatin (2-33), which was N-alkylated (2-34) and condensed with 2-15 to yield the final 
product in fair yield.
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Most of the derivatives in the first  generation of RBPIs contained either 2- or 2,6- substitution on 
the benzyl ring. Through the use of different commercial benzyl halides containing meta- or 
para-substitution as well as ortho-halogens, the effect of additional substitution patterns was 
probed.  
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 Four different benzyl bromides were used to N-alkylate 5-chloroisatin, then the resulting 
benzyl isatin was condensed with 2-15 to give compounds 2-36, 2-37, 2-38, and 2-39 in high 
yields (Scheme 2.11). 
 To investigate the effect of the methylene linker length between the isatin and the 2,6-
dihalogenated phenyl group, a phenethyl derivative was prepared (Scheme 2.12). An Appel 
reaction was conducted on 2,6-dichlorophenethylalcohol to yield the corresponding primary 
iodide, which was subsequently  used to N-alkylate 5-chloroisatin with sodium hydride in 
dimethylformamide. The resulting phenethylisatin (2-40) was condensed with 2-15 under 
standard conditions to yield 2-41.
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2.3 Structure-activity-relationship (SAR) of RBPIs
2.3.1 In vitro evaluation
 Each of the compounds described in the previous section was tested for in vitro activity 
against PARG in a radiometric TLC-based assay (Figure 2.7). Briefly, the assay involves pre-
incubation of PARG enzyme with compound, then incubation with radiolabeled PARsylated 
PARP for 2 hours at 37 ˚C. The final reaction is quenched either by heating or addition of an 
anionic detergent and spotted on a TLC plate that is run in a basic iPrOH/water solvent system to 
separate intact PAR from ADP-ribose.
ADP-ribose
intact PAR
Figure 2.7. Graphical representation of 32P-PAR TLC assay.  Assay mixture is spotted at the bottom of TLC plate 
and plate is developed, separating ADP-ribose monomers from intact PAR. The plate is visualized by 
phosphorimaging.
 The expanded SAR of RBPIs can be understood by comparing these new derivatives to 
members of the first  generation and to each other (Figure 2.8, first generation compounds shown 
in box). The thiohydantoin-containing derivative (2-4) has an IC50 of approximately 13 µM, 
which is about 4-fold less potent than the analogous rhodanine-based compound, RBPI-2, with 
an IC50 of 2.9 µM. This result suggests that the identity of the rhodanine heteroatoms is 
important and that the rhodanine may play  a role larger than simply  holding other functional 
groups in their relative positions. Use of a triazole, albeit with an sp3 carbon on the isatin, 
resulted in a complete loss in activity (2-9, IC50 >50 µM), as did disruption of the isatin lactam 
(2-12, IC50 > 100 µM). These results further suggest that the initial conjugated rhodanine-isatin 
core is critical for potency.
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Figure 2.8. Structures and in vitro IC50 values for newly synthesized RBPIs.  First-generation RBPIs are boxed. 
n=3, when indicated error is s.e.m.
 The necessity of a protic functional group is demonstrated by the loss of activity  upon 
replacement of the acid with a nitrile (2-24, IC50 > 50 µM) and the activity, albeit  low, of 
replacement with a methyl amide (2-29, 10 < IC50 < 25). Comparison of tetrazole-containing 
compounds RBPI-5 and RBPI-6 to the corresponding carboxylic acids RBPI-2 and RBPI-3 
reveals that this modification either has no effect  on activity or results in a small loss of activity 
(4.5 vs 2.9 and 12.0 vs 5.0 µM). As predicted, the tetrazole-containing versions (2-17 and 2-18) 
of two inactive acid derivatives (2-1 and Inactive-1) were also found to be inactive (>100 µM), 
supporting the prediction that the tetrazole acts as a carboxylic acid bioisostere. Comparison of 
the tetrazole and acid versions of the 5-azido derivatives, 2-31 and 2-32 respectively, shows that 
the tetrazole compound is only about 50% less potent than the acid (9.9 and 6.4 µM, 
respectively). Qualitatively, the tetrazole compounds were observed to be more soluble in 
DMSO, aqueous buffer and media. Overall, replacement of the carboxylic acid with a tetrazole 
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seems to have beneficial effects on solubility, and has either no effect on or results in a small loss 
in potency.  
 The N-acetyl compound (2-35) is less potent by approximately 2-fold when compared to 
the corresponding 5-bromo compound (RBPI-5) (11.0 and 4.5 µM). On the other hand, 2-35 has 
approximately the same potency  as the corresponding 5-chloro compound (RBPI-6) (11.0 vs 
12.3 µM). Compared to 5-bromo compound RBPI-2, the 5-azido compound 2-33 is 
approximately 2-fold less potent (2.9 and 6.4 µM), although it is about equipotent to 5-chloro 
compound RBPI-3 (5.0 µM). The 5-azido tetrazole-containing compound 2-32 shows a similar 
pattern when compared to the corresponding 5-bromo and 5-chloro tetrazole-containing 
compounds RBPI-5 and RBPI-6 (9.9 vs 4.5 and 12.3 µM, respectively). These relative 
potencies, along with the good potency of the 5-acetylamine (2-35), suggest that while 
substitution on the 5-position of the isatin is important, there is a small degree of flexibility that 
allows for the presence of different functional groups, although 5-bromo substitution consistently 
yields more potent compounds.
 In the initial SAR, certain 2,6-dihalogen substitution patterns were found to be key  for 
increased potency, however, very few compounds with meta or para substitution were tested. The 
addition of a meta-methoxy group seems to have no effect on potency, as 2-36 has almost equal 
activity as a similar compound lacking the methoxy group, 2-16 (14.8 vs 18 µM). This opens up 
the possibility  for the preparation of various meta-substituted derivatives that may  show 
improved potency  or be useful for attachment of biological handles. Compounds 2-37, 2-38 and 
2-39 were not active against PARG at concentrations up to 50 µM. The inactivity  of compound 
2-38 confirms the importance of the identity of the ortho substituents, an effect also seen in the 
first generation (compare RBPI-2 vs 2-1). Though the substitution patterns of 2-38 and 2-39 did 
not yield active compounds, this result does not preclude the possibility of an active compound 
with a single para substituent. Comparison of phenethyl compound 2-41 with RBPI-6 (15.9 vs 
12.3 µM) suggests that the benzyl group’s position is somewhat flexible, as significant activity  is 
retained upon extending the methylene linker. With the knowledge gleaned from these analogs 
and first-generation analogs, certain modifications to the benzyl ring can be made with 
reasonable confidence as to how they will affect activity. Though this empirical knowledge is 
40
useful, it  has not furnished an detailed molecular understanding of the role of this moiety  in 
RBPI binding.
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Figure 2.9. Summary of expanded structure-activity relationship of RBPIs
 Overall, these results provide a more comprehensive structure-activity relationship for 
this class of rhodanine-containing PARG inhibitors (Figure 2.9). An appended protic 
functionality and the rhodanine-isatin core were found to be required, while some flexibility at 
the 5-isatin and meta-benzyl positions was revealed. Additionally, tetrazole-containing 
compounds were found to have good potency and favorable solubility properties, making them 
good candidates for further biological experiments.
2.3.2 Evaluation in cellular lysate
 Two of the active compounds discussed above, RBPI-4 and RBPI-5, were further tested 
to determine their potency in the presence of cellular proteins and other components. Cell lysate 
generated from wild-type mouse embryonic fibroblasts (WT-MEF) was used to determine if 
these PARG inhibitors could retain activity in the presence of cellular proteins. 32P-PAR was 
added to cell lysate, which was then treated either with DMSO, ADP-HPD, RBPI-4, RBPI-5, or 
Inactive-1 (25 µM) and the degradation of 32P-PAR was monitored over one hour. The same 
TLC-based analysis as the in vitro assay was used. As Figure 2.10 shows, both RBPI-4 and 
RBPI-5 prevented degradation of PAR up to 60 minutes, and ADP-HPD displayed similar 
activity, whereas PAR was almost completely  consumed by 60 minutes in lysate treated with 
vehicle (DMSO). Dr. Kristin Finch tested Inactive-1 and found that it had no effect on the rate of 
PAR degradation (Figure 2.10C).
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Figure 2.10. Percent degradation of 32P-PAR vs. time in cellular lysate from mouse embryonic fibroblast cells. 
Compound (25 µM) and 32P-PAR were added to cell lysate, the mixture was incubated at 37 ˚C and quenched with 
SDS at indicated times, then spotted on TLC plate and analyzed as before. A) RBPI-4 and ADP-HPD compared to 
vehicle; B) RBPI-5 compared to vehicle; C) Performed by Dr. Kristin Finch - Inactive-1 compared to vehicle.
Inhibition of PAR degradation was also investigated in a variety of human and mouse cancer cell 
lines, and RBPI-4 significantly delayed 32P-PAR degradation in each lysate (Figure 2.11).
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Figure 2.11. Percent degradation of 32P-PAR vs. time in cellular lysate from indicated cell lines. RBPI-4 (25 µM) 
(or DMSO vehicle) and 32P-PAR were added to cell lysate, the mixture was incubated at 37 ˚C and quenched with 
SDS at indicated times, then spotted on TLC plate and analyzed as before. A) U-937, human lymphoma; B) HeLa, 
human cervical cancer; C) A549, human lung cancer; D) B16-F10, murine melanoma; E) MCF-7, human breast 
cancer. Data is representative of three independent replicates.
 This data shows that the RBPIs are selective for PARG and are able to efficiently inhibit PARG 
even in the presence of abundant cellular proteins. 
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2.3.3 Evaluation of PARG knockout lysate
 Biochemical and in vivo investigations into the effects of PARG deficiency are hindered by 
the embryonic lethality  of complete PARG gene knockout. Although a number of studies have 
been conducted using knockout of only  the full-length nuclear isoform of PARG, these results do 
not give a clear picture on the effects of loss of all PARG activity. The Koh laboratory at 
Washington State University  has developed a murine embryonic trophoblast cell line with full 
PARG gene knockout.12 They generously  sent us frozen cell pellets of both PARG-/- and wild 
type cells to aid in our RBPI investigation. With these we attempted to assess the rate of PAR 
breakdown in the absence of PARG. Cells were lysed in buffer containing detergent and 32P-PAR 
was added to the lysate and monitored over time at 37 ˚C. Using equal amounts of wild type and 
PARG-/- lysate (4.5 µg), we observed that PAR was completely degraded after 1 h by wild type 
lysate but remained totally intact after 4 h in PARG-/- lysate (Figure 2.12A). Increasing the 
amount of knockout lysate up to 44.1 µg similarly did not result in any measurable PAR 
degradation after 2 h incubation at 37 ˚C (Figure 2.12B). 
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Figure 2.12. A) Time-course of 32P-PAR degradation in 4.5 µg WT or PARG-/- embryonic trophoblast cellular lysate 
over 4 h; B) Time-course of 32P-PAR degradation in 10-44.1 µg PARG-/- embryonic trophoblast cellular lysate over 
42 h.
These results suggest that PARG is may be solely  responsible for cellular degradation of PAR, 
although further investigations, especially with respect to the potential role of ADP-ribosyl 
hydrolase-3’s (ARH3) limited PAR hydrolysis activity (discussed further in section 2.4.2), will 
be needed to validate this claim.
43
A B
2.4 Specificity of RBPIs and other reported PARG inhibitors
 One important factor to consider when developing compounds originating from an in 
vitro screen is selectivity and specificity. Positive results in an in vitro screen can be observed 
from compounds that aggregate into large multi-molecule particles or by  compounds that are so 
hydrophobic that they bind to any hydrophobic protein pocket with little differentiation between 
proteins. The standard PARG assay buffer contains 0.1% Triton X-100 detergent, which would 
break up any robust small molecule aggregates,46 indicating that the RBPIs likely do not inhibit 
via promiscuous aggregation. Dr. Kristin Finch also demonstrated that the RBPIs do not have 
inhibitory activity toward the enzyme ß-lactamase,47  further suggesting that the RBPIs do not 
unselectively bind to any hydrophobic protein pocket. This section will describe further 
experiments to assess the selectivity of the RBPIs over other similar and related enzymes as well 
as addressing the selectivity of ADP-HPD and the Jacobson salicylanilide 6a.
2.4.1 Evaluation for PARP inhibition
 Due to the structural similarity between ß-NAD+ and poly(ADP-ribose), the natural PARP 
and PARG substrates respectively, RBPI-6 was evaluated for PARP inhibition in a radiometric 
assay, using the known PARP inhibitor PJ34 as a positive control. Inhibition could not be 
assessed with the commercial Trevigen PARP assay  because the RBPIs interacted with the 
histone-coated well and gave false-positive readings. Over a number of trials, RBPI-6 did not 
inhibit PARP activity  up to 100 µM (Figure 2.13), the highest concentration tested, while full 
inhibition with PJ34 was consistently observed. Unfortunately  the noise associated with the 
assay was quite high. 
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Figure 2.13. Inhibition of PARP-1-mediated 32P-PAR synthesis by PJ34 and RBPI-6.
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 Since the Jacobson PARG inhibitor, 6a (Figure 2.14A), was described as having dual 
PARG/PARP inhibitory activity,41 we sought to replicate their results and compare 6a to the 
RBPIs. Salicylanilide 6a was synthesized according to the published protocol and assessed for 
PARP inhibition using the commercial ELISA assay (Figure 2.14B). PJ34 and weak PARP 
inhibitor 3-aminobenzamide (3-AB) were used as positive controls and each displayed the 
expected degree of PARP inhibition. 6a inhibited PARP at 200 and 400 µM and while these 
value are slightly higher than expected, they are generally consistent with the reported IC50 of 
120 µM.
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Figure 2.14. A) Structure and reported enzyme inhibition IC50 values of Jacobson salicylanilide 6a; B) Inhibition of 
PARP-1-mediated PAR synthesis by 3-aminobenzamide (3-AB), PJ34, and increasing concentrations of 
salicylanilide 6a as assessed by commercial ELISA assay.
 We next attempted to replicate their PARG inhibition results. Using the radiometric assay 
conditions described by  the Jacobson group, Dr. Kathy Partlow observed partial inhibition of 
PARG at 50 µM, and full inhibition at 100 µM  and above (Figure 2.15A). Again, these values are 
slightly higher than expected, but mostly  consistent with the reported activity. However, when 
detergent was added to the buffer, inhibition by 6a was abolished. In contrast, inhibition of 
PARG by  ADP-HPD and RBPI-4 was independent of the presence of detergent. When all three 
compounds were tested in the standard 2 h assay with the standard buffer containing 0.1% Triton 
X-100, no inhibition with 6a was observed, while consistent inhibition with ADP-HPD and 
RBPI-4 was observed (Figure 2.15B).
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Figure 2.15. A) Inhibition of PARG-mediated 32P-PAR degradation by 6a, ADP-HPD, or RBPI-4 in the absence or 
presence of Triton X-100 under conditions described by Jacobsen group, assessed by Dr. Kathy Partlow; B) 
Inhibition of PARG-mediated 32P-PAR degradation by 6a, ADP-HPD, or RBPI-4 under standard 2 h assay 
conditions, with standard buffer containing Triton X-100.
 The observation of inhibition of both PARP and PARG along with the sensitivity  to 
detergent strongly suggests that salicylanilide 6a is not a specific PARG inhibitor, nor a selective 
dual PARP/PARG inhibitor, but an aggregator.48  During the TRAP screening and compound 
selection process, the assay used to assess PARG inhibition by  high concentrations of compound 
was conducted in buffer lacking detergent, which could have eliminated many false positives 
during the initial stages of lead discovery. Interestingly, the PARG assay for TRAP screening was 
conducted with 0.1 µg/µL bovine serum albumin, which should have bound non-specifically  to 
any aggregates, though it may have only served to eliminate weak aggregators. Additionally, this 
report and our subsequent evaluation of the salicylanilides drives home the importance of 
carefully choosing screening conditions and running appropriate counter-screens when 
conducting an in vitro inhibitor discovery campaign.
2.4.2 Evaluation for ARH3 inhibition
 As further evidence of enzyme specificity, the RBPIs were also found not to inhibit ARH3 
(Figure 2.16), an enzyme with weak PAR-hydrolysis activity.49,50  While ARH3 is much more 
efficient at deacetylation of O-acetyl-ADP-ribose, its ability to also hydrolyze PAR suggests that 
it may  play  a role in cellular PAR catabolism, although how significant of a role is still under 
investigation. For a PARG inhibitor to be a useful tool compound (or drug candidate) in the study 
of PARG, it should inhibit PARG selectively  over ARH3, otherwise any observed effects could 
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be attributed to either increased PAR or O-acetyl-ADP-ribose levels. In contrast to the RBPIs, 
ADP-HPD is a reasonably potent inhibitor of ARH3 with an IC50 of 14.3 µM. 
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s.e.m.
This high degree of selectivity is unique among known PARG inhibitors, making the RBPIs an 
extremely useful tool for probing the activity of PARG. 
2.5 Co-crystal of PARG and RBPI-3
 The past four years have resulted in the report  of 20 different PARG crystal structures, 
ranging from the initial report of a bacterial PARG, followed by mouse, rat, and human PARGs 
either with or without various ligands, in addition to enzymes with point mutations at the 
catalytic glutamate residues. This section will provide an overview of the key findings from each 
reported species of PARG crystal structure, followed by a detailed analysis of the PARG/RBPI-3 
co-crystal.
2.5.1 Literature structures of PARG
  The first reported PARG crystal structure was that of a bacterial enzyme with PAR 
hydrolase activity identified in the Thermomonospora curvata bacteria.51 This structure revealed 
that PARG is structurally very similar to the already  characterized macrodomain family, a class 
of ADP-ribose-binding proteins. The feature which distinguishes PARG is the presence of an 
extra catalytic loop inserted in the ADP-ribose binding pocket (orange, Figure 2.17A). This 
catalytic loop  contains the previously-identified PARG consensus sequence, GGG-X6-8-QEE,52 
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containing the two glutamic acids which are responsible for catalytic activity. When co-
crystallized with ADP-ribose (black, Figure 2.17B), the ligand is bound in the “n” position, with 
the ribose positioned adjacent to the catalytic glutamate residues. The diphosphate and adenine 
were bound in a similar fashion to other macrodomains, with a diphosphate-binding loop  (blue, 
Figure 2.17A and B) providing a number of hydrogen-bond partners for the phosphate groups, 
and the adenosine group buried in a deep pocket.
 With the publication of the canonical protozoan Tetrahymena thermophila24 and the 
mammalian Rattus norvegicus26 crystal structures, the origins of specificity  for the adenosine 
base and a role for the tyrosine residue, which was previously-determined to be critical, were 
revealed. Both structures reveal that π-stacking with a eukaryotyically-conserved phenylalanine 
residue (yellow, Figure 2.17C) and hydrogen bonds with an isoleucine and glutamine residue are 
important factors for adenine recognition and binding. These structures and subsequent 
eukaryotic PARG structures have emphasized the importance of an additional binding site loop, 
containing a conserved tyrosine residue. This loop, which is sometimes referred to as a “tyrosine 
clasp”, contains the conserved sequence of YTGYA. The key tyrosine, (Try791, pink, Figure 
2.17C and D) is involved in a hydrogen-bonding network which is in contact with the adenosine 
3’ hydroxyl and the adjacent phosphate group, in addition to edge π-stacking with the adenine. 
Unlike the bacterial structure, the 2’ OH of the adenosine is solvent-exposed in both T. 
thermophila and R. norvegicus PARGs, providing space for further ADP-ribose units, and thus 
theoretical endoglycohydrolase activity. Unfortunately, neither report experimentally 
demonstrated the capacity for such activity  with either enzyme. Although T. thermophila lacks an 
obvious REG/MTS segment, this portion is clearly defined in the R. norvegicus structure. The 
function of this stretch of protein is an overall stabilization of the binding pocket. Specifically, 
the REG/MTS domain travels along the outer surface of the enzyme, making specific contacts 
that allow it to stabilize helix alpha7, which participates in adenine base recognition, and the 
tyrosine clasp. The R. norvegicus structure also provided information on how the enzyme 
accommodates substrate binding, as a 180˚ rotation of the dihedral angles of Phe898 upon ADP-
HPD binding (Figure 2.17D) was observed when compared with the apo structure.
48
  
  
Figure 2.17.  A) T. curvata PARG (apo); B) T. curvata PARG bound to ADP-ribose (black), Glu114 and Glu115 in 
orange; C) R. norvegicus PARG (apo), Tyr791 in pink and Phe898  in bright yellow; D) R. norvegicus PARG bound 
to ADP-HPD (black), Tyr791 in pink and Phe898  in bright yellow. Proteins are colored as follows: alpha-helices 
(purple), beta sheets (green), diphosphate macrodomain loop (bright blue), catalytic consensus sequence (orange), 
and tyrosine clasp (pink).
 Late in 2012, Astra Zeneca revealed the results of their considerable efforts to crystallize 
human PARG with the publication of four crystal structures, one apo and three with different 
ligands.27 Surprisingly, the authors noted a high degree of structural similarity for a key 200 
amino acid stretch between all crystallized PARGs, from bacterial to human. Although the 
sequence identity in this section is very  low, the three-dimensional structure is highly conserved. 
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Human PARG was found to be very similar to rat PARG, existing as a macrodomain with a 
PARG catalytic loop and a tyrosine clasp. Although they  obtained high resolution structures and 
identified two tightly-bound water molecules at the catalytic site, they was not  able to suggest 
whether PARG uses an inverting or retaining mechanism, just that it was likely that one of these 
two water molecules was activated for attack at the oxocarbenium and each would result in either 
retention or inversion of the original stereochemistry. The conserved phenylalanine seen in all 
PARGs, from bacteria to human, displayed distinct behavior in these human PARG structures. 
This residue partially blocks the binding site in the apo structure, and can be modeled in two 
conformations, indicating greater flexibility than in other PARGs.
 In 2014, an extensive study of mouse PARG (Mus musculus, Figure 2.18) was reported 
by the Poirier and Xu groups.25 Here they demonstrated that mutation of either catalytic 
glutamate to a glutamine does not significantly alter the catalytic pocket shape and allows for 
some residual enzymatic activity. Conversely, mutation of either catalytic glutamate to an 
asparagine residue causes drastic conformational changes in the PARG-specific loop and results 
in a complete loss in activity.
 
Figure 2.18.  M. musculus PARG E748Q bound to iso-ADP-ribose (on left, light blue, ball-and-stick). Protein is 
colored as follows: alpha-helices (purple), beta sheets (green), diphosphate macrodomain loop (bright blue), 
catalytic consensus sequence (orange), and tyrosine clasp (pink).
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In addition, through their efforts to co-crystallize iso-ADP-ribose with a catalytically inactive 
mutant, they identified an iso-ADP-ribose binding site on the opposite side of the protein from 
the catalytic pocket  (Figure 2.18), which they hypothesized might be responsible for the 
observed processivity of PARG in the degradation of long but not short PAR polymers.53  In 
addition, they could remove the N-terminal exon4+5 region from PARG, rendering the enzyme 
inactive, and exogenously add in expressed exon4+5 to restore activity  in a dose-dependent 
manner. This provides good evidence that docking and dislodging of this N-terminal portion 
from its hydrophobic channel may  be a mechanism for PARG regulation under physiological 
conditions.
2.5.2 RBPI binding mode vs ADP-HPD binding mode
 To elucidate how the RBPIs interact with the enzyme, we initiated a collaboration with 
Prof. Ivan Ahel at  Oxford University  and sent him a small selection of RBPIs to try in co-
crystallization experiments. In addition, the Ahel group sent samples of T. curvata and T. 
thermophila PARGs, which we used to determine the activity  of the RBPIs using the radiometric 
PARG assay. The potency of RBPI-3 was determined against T. curvata (3.3 µM) and T. 
thermophila (5.8 µM) PARG and was found to be very similar to its potency  against bovine 
PARG (5.8 µM) (Figure 2.19).
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Figure 2.19. IC50 curves of RBPI-3 against T. curvata (left, 5 nM) and T. thermophila (right, 50 nM) PARGs 
assessed using the standard 32P-PAR degradation assay.
The Ahel group was able to obtain a crystal structure of RBPI-3 bound to a canonical PARG 
from Tetrahymena thermophila (left, Figure 2.20), as well as a structure of the same enzyme 
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bound to ADP-ribose (right, Figure 2.20). Inspection of the RBPI-3/PARG structure indicates 
that the inhibitor mainly  binds in the n-position, occupying roughly the same space as the 
adenosine and the 5’ phosphate group, with the benzyl group  extending past the adenosine region 
into a shallow area of the protein surface. The benzyl group was disordered in the crystal and as 
such its preferred conformation has not yet been determined. Since the benzyl group has free 
rotation around the nitrogen-carbon bond, this group could potentially adopt a variety of 
conformation depending on its substitution pattern, which may explain why the SAR on this ring 
is so flexible. Inspection of the site and virtual manipulation of the benzyl group do not reveal 
any clear pi-stacking or halogen-bonding partners in the protein structure, thus the preference for 
ortho halogen substitution is still unexplained.
 The apparent role of the rhodanine ring is to enforce a planar conformation of the core and 
position the propionic acid into the phosphate binding area. Similarly to the pyrophosphate, 
which forms multiple hydrogen bonds with main chain atoms, the carboxylic acid forms three 
hydrogen bonds with main chain atoms at Lys365 and Gln 254, and an additional hydrogen bond 
with a crystallographically-defined water molecule. The importance of these interactions is 
underscored by the observed requirement for a polar group in the SAR. We envision that a 
negatively charged tetrazole group would be able to make similar contacts at this position.
 In contrast with the structure of ADP-ribose/PARG, the conserved Phe398 residue in the 
PARG/RBPI-3 structure moves into the adenosine binding region to allow for π-stacking with 
the rhodanine-isatin core and Tyr296 (orange residues, Figure 2.20). Interestingly, Tyr296 was 
identified in photo-crosslinking studies with 8-azido-ADP-HPD as important for binding of that 
inhibitor.30 This residue adjustment and the creation of a π-stacking system may explain why the 
rhodanine-isatin core is able to bind well, as the planar rhodanine-isatin core and the aromatic π-
system of the isatin would both need to be present for this type of interaction. This is consistent 
with the observed SAR where disruption of this planar ring system results in a significant loss in 
activity. 
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Figure 2.20. Structure of RBPI-3 (left) and ADP-ribose (right) bound to T. thermophila PARG. Ligands are in dark 
green and residues are in grey; Tyr296 and Phe398 are highlighted in orange; the protein molecular surface is shown 
in light blue; key water residues are indicated by blue spheres.
 Further, the new Phe398 position induces a change in the shape and location of the 
adenine-binding pocket, with most of this pocket occupied by the aromatic ring of the isatin and 
the 5-substituent extending further into the pocket. Here, the disadvantages of 7-substitution, 
which was explored in the first generation RBPI libraries, become evident as the addition of 
steric bulk at that position would result in a direct clash with the protein surface. Thus in 
retrospect it is not surprising that such 7-substituted compounds had low-to-no activity. 
Intriguingly, the 5-chloro substituent of RBPI-3 does not fill this adenine pocket, and viewing 
the structure from “behind” RBPI-3 reveals that the adenine pocket is rather large and mostly 
unoccupied by the ligand (Figure 2.21). Additionally, since most of the residues comprising this 
pocket are normally involved in binding adenine, they are mainly  polar side-chains, opening up 
the possibility  for engineering new hydrogen bond interactions within this site. The size of this 
pocket also explains why a variety of substituents, from halogens to N-acetyl amines, were 
tolerated at this position of the isatin.
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Y293 K365 
F398 
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Figure 2.21. Adenine pocket in RBPI-3/PARG co-crystal as viewed from inside the enzyme. Protein residues are 
shown in grey, protein molecular surface is shown in blue and RBPI-3 is shown in green.
 Through this collaboration, a new inhibitor binding mode was discovered using the RBPIs 
and this new binding mode may be responsible for the difference in duration of inhibition 
observed between ADP-HPD and the RBPIs. Even more significantly, this structure now allows 
for structure-based design of new PARG inhibitors based on the RBPI binding mode, as distinct 
from the ADP-ribose/ADP-HPD binding mode. A more detailed analysis of the ADP-ribose/
ADP-HPD binding mode is provided in chapter 3.
2.6 Value of RBPIs in future work
 The development of the RBPIs has demonstrated that selective and specific inhibition of 
PARG with a small, non-substrate- or non-product-like molecule is possible, and further, that 
such a compound can competitively inhibit PARG. Through the RBPI-3/PARG co-crystal, a new 
binding mode was revealed, yielding insight  into another way in which the adenosine binding 
pocket may be accessed. This is especially  important due to the highly specific nature of the 
diphosphate binding channel and the relatively exposed and small binding pocket near the active 
glutamate residues. Unfortunately, the low solubility and high lipophilicity of the RBPIs 
prevents them from efficiently  entering whole cells and inducing a build-up of PAR, as would be 
expected with a cell-permeable PARG inhibitor. Due to the limitations of the RBPIs, a structure-
based approach is especially attractive for the development of new truly drug-like inhibitors. 
Hopefully  the information gleaned from the SAR and structural information will allow for the 
development of specific small-molecule PARG inhibitors with greater potency and clear activity 
in whole cells.
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2.8 Materials and Methods
General Materials
Acetonitrile (Fisher, HPLC grade), and methanol (Fisher, low water) were dried by percolation 
through two columns packed with neutral alumina under a positive pressure of nitrogen. All 
other solvents were obtained from Fisher Scientific and were used without further purification. 
All H2O used was either deionized or purified through a MilliQ purification system. 
 
Silica gel for chromatography was performed on EMD Biosciences silica gel 60 (230-400 mesh). 
Thin-layer chromatography plates (Merck, 245 nm fluorescent  indicator) were visualized by UV 
and stained with potassium permanganate (KMnO4), iodine (I2), or ninhydrin.   
All NMR experiments were acquired in the Varian-Oxford Instrument Center for Excellence in 
NMR Spectroscopy (VOICE) laboratory at the University  of Illinois at Urbana-Champaign. 
NMR experiments were recorded in CDCl3, CD3OD, or DMSO-d6 on Varian Unity 500 MHz 
spectrometers.  Chemical shift, δ (ppm); coupling constant, J (Hz); multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet, m = multiplet); and integration are reported. High-
resolution mass spectral data were recorded on a Micromass Q-T of Ultima hybrid quadrupole/
time-of-flight ESI mass spectrometer at  the University  of Illinois at Urbana-Champaign Mass 
Spectrometry Laboratory.
32P-β-NAD+ (ARP 0141, 800 Ci/mmol, 5 mCi/mL) was purchased from American Radiolabeled 
Chemicals, Inc. and stored at -20 °C. Calf thymus activated DNA (D4522, CAS 91080-16-9) was 
purchased from Sigma-Aldrich, diluted in H2O, the concentration was determined per 
manufacturer’s instructions and stored at -20 °C. PARG buffer (10, 4680-096-02), PARG 
(4680-096-01) and PARP (4668-100-01) were purchased from Trevigen and stored at -80˚C. 
Congo Red was purchased from Sigma-Aldrich (CAS 573-58-0).  ADP-HPD was purchased 
from Calbiochem (118415) and stored as a 1 mM solution in H2O at -20 ˚C.
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Mouse embryonic fibroblasts (MEFs) and B16F10 (mouse melanoma cells) were cultured in 
Dulbecco’s modified Eagle medium (DMEM) containing 4.5 g/L glucose and supplemented with 
10% (v/v) fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 1mM sodium 
pyruvate, 100 U/ml penicillin (Cellgro, Manassas, VA), 100 µg/mL streptomycin, and 100 IU/
mL penicillin (Cellgro, Manassas, VA). HeLa (human cervical carcinoma cells), MCF-7 (human 
breast cancer cells), U937 (human lymphoma cells), and A549 (human lung cancer cells) were 
grown in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Gemini Bio-Products, 
West Sacramento, CA), 100 U/ml penicillin (Cellgro, Manassas, VA), and 100 µg/mL 
streptomycin (Cellgro, Manassas, VA). All cells were maintained in a humidified atmosphere 
with 95% air and 5% CO2. 
Synthesis of 32P-PAR 
In a 2.0-mL tube, PAR synthesis buffer (final concentrations 100 mM  Tris-HCl (pH 8.0), 10 mM 
MgCl2, 8 mM DTT, 10% v/v glycerol, 1 mM unlabeled β-NAD+, 23 µg of calf thymus activated 
DNA) was prepared from concentrated stocks. To the solution was added 75 µCi of 32P β-NAD+, 
and water to a final volume of 900 µL. Lastly, 100% ethanol (90 µL) was added dropwise, and 
the solution heated at 30 °C for 5 min. 20 U of PARP-1 was added, and was incubated at 30 °C 
for 30 min. Upon completion, the reaction was quenched and 100 µL of 3 M sodium acetate (pH 
5.2) and 700 µL of isopropanol were added. The sample was incubated at 0 ˚C for 30 min, and 
then PAR was pelleted by centrifugation at  14,100xg at 4 °C for 10 min. The pellet was washed 
twice with cold 80% (v/v) ethanol in H2O with centrifugation between each wash (14,000xg at 4 
°C for 10 min). The pellet was re-suspended in 800 µL of H2O and stored at -20 °C. 
Radiometric PARG TLC Assay 
Compounds were diluted from 10 mM stock solutions in DMSO (or 1 mM stocks in H2O for 
ADP-HPD) to the specified concentrations. First, 10X PARG buffer was diluted to 2X 
concentration. Next, bovine PARG was diluted to 0.025 ng/µL (from a 1 µg/mL solution of 
PARG) in 2X PARG buffer. To a 4.5 µL aliquot of this PARG solution was added 0.5 µL of 
compound (16X in DMSO). Control samples were prepared with 0.5 µL DMSO in the presence 
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and absence of PARG enzyme. The solution was incubated at room temperature for 10 min. 
Next, 32P-PAR (3 µL) was added to each solution with mixing and the samples were incubated at 
37 °C for 2 h. Samples were quenched either by  heating at 90 °C for 2 min or by the addition of 
1 µL 1% SDS with mixing. Then 1.3 µL of each sample was spotted twice on a TLC plate. The 
plate was developed twice in 70:30 iPrOH:0.2% NH4OH (aq), allowing for the TLC plate to dry 
completely between each run. Once dry, the TLC plate was wrapped in clear plastic wrap, and 
placed in Storage Phosphor Screen (Amersham Biosciences, Sunnydale, CA) overnight, and the 
screen was imaged on a Storm Imager (GE Life Sciences, Piscataway, NJ). Intact 32P-PAR was 
analyzed by densitometry using ImageJ (NIH, Bethesda, MD), and the mean intensity of each 
spot was used to calculate percent PARG inhibition as compared to the control lacking PARG 
enzyme. 
IC50 curves: Increasing concentrations of compound were tested. The data were plotted as 
compound concentration versus percent PARG inhibition, and fitted to a logistic-dose response 
curve using Table Curve (SYSTAT Software, Richmond, CA). The data were generated in 
triplicate, and IC50 values are reported as the average of three separate experiments along with 
standard deviation. 
Addition of detergent: 32P-PAR degradation was assessed as described above except using 
phosphate buffer (final concentrations of 50 mM  KH2PO4, 50 mM KCl, 10 mM  ß-
mercaptoethanol, pH = 7.5) supplemented with a final concentration of 0.1% Triton X-100 as 
indicated.  
ARH3 Activity: 32P-PAR degradation was assessed in Trevigen PARG buffer as described above 
except with a final concentration of 10 µg/mL ARH3 and 4 mM MgCl2. When directly 
comparing PARG and ARH3 activity  and inhibition (as in Figure 5), PARG activity was assessed 
in the presence of 4 mM MgCl2. 
T. curvata and T. thermophila Activity: To determine the appropriate concentration of each 
enzyme to employ, each enzyme was tested at 5, 50, and 500 nM under standard assay conditions 
in phosphate buffer with 0.1% Triton X-100. 32P-PAR degradation was monitored over 60 
minutes. For IC50 determination assays, T. curvata PARG was employed at a final concentration 
of 5 nM and T. thermophila PARG was employed at 50 nM. 
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Activity in cellular lysate: Generation of cellular lysate – Cells were lysed at  0 ˚C in 1X 
Trevigen PARG buffer and centrifuged at 4 ˚C to remove cell debris. Protein content was 
determined by BCA assay  (Pierce, Rockford, IL). Lysate was diluted in 1X Trevigen PARG 
buffer to the desired concentration (final lysate concentrations: MEF – 1.5 µg; HeLa – 1.5 µg; 
U937 – 2.5 µg; MCF7 – 1.5 µg; B16F10 – 3.0 µg; A549 – 1.5 µg) and treated with either vehicle 
or compound. Then 3.0 µL 32P-PAR was added with mixing and the samples were incubated at 
37 ˚C for various amounts of time (0 – 60 min). The reaction was quenched by the addition of 
1.0 µL 1% SDS with mixing, then the samples were applied to a TLC plate, eluted and analyzed 
as described above. Intact 32P-PAR was analyzed by  densitometry  using ImageJ (NIH, Bethesda, 
MD) as before and graphed as percent intact PAR by normalizing the 0 min time-point as 100% 
intact PAR.
Radiometric PARP-1 Inhibition Assay 
Compounds were diluted from 10 mM  stock solutions in DMSO to the specified concentrations. 
Control samples were prepared with DMSO in the presence and absence of PARG. To 90 µL of 
Trevigen PARG buffer containing compound, calf thymus activated DNA (5 µg), NAD+ (500 
µM), 32P-NAD+ (1 µCi), and DTT (200 µM), 10 µL containing PARP-1 enzyme (1 U) was added 
with mixing (all amounts are final concentrations). The solution was incubated at room 
temperature for 30 min. Next, 175 µL iPrOH and 25 µL 3 M  NaOAc was added and the samples 
were incubated at 0 °C for 30 min. After centrifugation at 4 ˚C (10 min, 14.1 g), the liquid was 
removed and 100 µL of 80% EtOH was added. After an additional centrifugation at 4 ˚C, the 
liquid was removed again. The pellet was suspended in 5 µL of Trevigen PARG buffer. Next 1.5 
µL of each sample was spotted twice on a cellulose PEI TLC plate. The plate was developed in 
100% MeOH, allowed to dry, then developed in 0.9 M  AcOH 0.3 M LiCl (aq). Once dry, the 
lower spots were cut out, the solid phase was removed from the backing and placed in 2 mL of 
scintillation fluid. Intact 32P-PAR was quantified by scintillation counting (Beckman LS6500) 
and the mean cpm for each sample was used to calculate percent PARP inhibition as compared to 
the control lacking PARP enzyme. 
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General Procedure for N-alkylation of Isatins
N
O
R
O
X
R'
R'
NH
O
R
O
KI, K2CO3
MeCN, rt
A round-bottom flask was charged with isatin substrate (1.0 equiv.) potassium carbonate (2.0 
equiv.) and acetonitrile (0.1 M) and stirred for 30 minutes. A solution of benzyl halide (1.0 
equiv.) and potassium iodide (0.1 equiv.) in acetonitrile (0.1 M) was added dropwise to the 
reaction mixture. The flask was capped and the reaction was stirred at ambient temperature for 
20 hours.  Solvent was removed in vacuo yielding a solid which was taken up in chloroform and 
filtered, rinsing with large amounts of chloroform to ensure complete dissolution of product. The 
filtrate was concentrated in vacuo yielding a brightly colored solid. The solid was further purified 
by the repeated addition of small volumes of methanol, sonication of the resulting mixtures, and 
removal of the supernatent. Residual solvent was removed in vacuo to give the final brightly 
colored solid. 
General Procedure for Knoevenagel Condensation
N
O
O
R
NaOAc
AcOH, ↑↓
N
O
R
S
N
S
OFG R'
50-95%
R'SN
S
OFG
A round-bottom flask was charged with rhodanine-containing substrate (1.0 equiv.), isatin-
containing substrate (1.0 equiv.), sodium acetate (10.0 equiv.) and acetic acid (0.2 M). The flask 
was fitted with a water-cooled reflux condenser and lowered into a pre-heated oil bath at 105-110 
°C. The reaction was heated to reflux for 12-16 hours and then allowed to cool to ambient 
temperature. The mixture was diluted with deionized H2O and filtered. The solids were rinsed 
with additional deionized H2O then allowed to dry on the filter paper and further dried in vacuo. 
No further purification was done unless otherwise noted.
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1-(2-fluorobenzyl)indoline-2,3-dione (2-42)
2-42 was prepared from isatin and 2-fluorobenzyl bromide as described above. Product was an 
orange powder (208.1 mg, 0.82 mmol, 82%).
1H-NMR (d6-DMSO, 500 MHz): δ 5.00 (ts 2H, 9), 6.90 (d, 1H, J = 8 Hz, 11), 7.11 (m, 3H, 4, 12, 
14), 7.31 (m, 1H, 13), 7.37 (td, 1H, J = 7.8, 1, Hz, 6), 7.54 (td, 1H, J = 7.8, 1.5 Hz, 5) 7.62 (dd, 
1H, J = 7, 0.5, 7). 
13C-NMR (d6-DMSO, 125 MHz): δ 37.6 (9), 110.9, (d, J=3.8 Hz, 7), 116.0 (d, J = 22 Hz, 14), 
118.0 (3), 122.0 (d, J = 14 Hz, 10), 124.1 (4), 125.0 (d, J = 3.8 Hz, 13), 125.5 (5), 130.1 (d, J = 
2.8 Hz, 12), 130.2 (d, J = 8.3 Hz, 11), 138.6 (6), 150.7 (8), 158.6 (1), 160.9 (d, J = 244.5 Hz, 15), 
183.1 (2).
HRMS (ESI) calcd (M+H)+: 256.0774, found: 256.0771
5-chloro-1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)indoline-2,3-dione (2-43)
2-43 was prepared from 5-chloroisatin and 6-chloropiperonyl chloride as described above.  
Product was an orange powder (222.0 mg, 0.63 mmol, 63%).
1H-NMR (d6-DMSO, 500 MHz): δ 4.80 (s, 1H, 6), 6.03 (s, 2H, 4), 6.81 (d, 1H, J = 8.5 Hz, 3), 
7.13 (d, 2H, J = 6 Hz, 5, 7), 7.62 (dd, 1H, J = 8.5, 2.5 Hz, 2), 7.65 (d, 1H, J = 2 Hz, 1).
13C-NMR (d6-DMSO, 125 MHz): δ 41.8, 102.8, 108.8, 110.5, 113.1, 120.5, 124.1, 124.6, 125.9, 
128.3, 137.3, 147.7, 148.7, 149.1, 159.1, 182.3.
HRMS (ESI) calcd (M+H)+: 349.987, found: 349.9990. 
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5-chloro-1-(2-fluoro-6-(trifluoromethyl)benzyl)indoline-2,3-dione (2-44)
2-44 was prepared from 5-chloroisatin and 2-chloro-6-(trifluoromethyl)benzyl bromide as 
described above.  Product was an orange powder (92.3 mg, 0.26 mmol, 26%).
1H-NMR (CDCl3, 500 MHz): δ 4.20 (s, 1H, 9), 6.61 (d, 1H, J = 8.5 Hz, 7), 7.27 (t, 1H, J = 9.5 
Hz, 14), 7.41 (dd, 1H, J = 8.5, 2, 6), 7.49 (m, 1H,  13), 7.59 (m, 2H, 12, 4).
13C-NMR (d6-DMSO, 125 MHz): δ 37.0, 113.2, 119.6, 120.6, 121.2 (d, J = 22 Hz, 12), 121.6 (d, 
J = 15 Hz, 10), 123.3, 124.1 (q, J = 44 Hz, 16), 124.9, 128.3, 131.5 (d, J = 9 Hz, 14), 138.0, 
150.0, 158.4, 162.1 (d, J = 247 Hz, 15), 182.4. 
HRMS (ESI) calcd (M+H)+: 358.0258, found: 358.0253. 
5-bromo-1-(2,6-dichlorobenzyl)indoline-2,3-dione (2-3)
2-3 was prepared from 5-bromoisatin and 2,6-dichlorobenzyl bromide as described above.  
Product was an orange powder (2.419 g, 6.3 mmol, 63%).
1H-NMR (CDCl3, 500 MHz): δ 5.25 (s, 2H, 4), 6.65 (d, 1H, J = 8.5 Hz, 3), 7.27 (t, 1H, J = 7 Hz, 
6), 7.39 (d, 2H, J = 8 Hz, 5), 7.56 (dd, 1H, J = 9, 2.5 Hz, 2), 7.71 (d, 1H, J = 2 Hz, 1). 
13C-NMR (CDCl3, 125 MHz): δ 40.5, 113.1, 116.9, 119.3, 128.4, 128.9, 129.4, 130.7, 136.5, 
140.8, 149.3, 157.3, 182.0.
HRMS (ESI) calcd (M+H)+: 383.9194, found: 383.9201. 
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5-chloro-1-(2,6-dichlorobenzyl)indoline-2,3-dione (2-7)
2-7 was prepared from 5-chloroisatin and 2,6-dichlorobenzyl bromide as described above.  
Product was an orange powder (774 g, 2.3 mmol, 76%).
1H-NMR (CDCl3, 500 MHz): δ 5.26 (s, 2H, 4), 6.69 (d, 1H, J = 8.5 Hz, 3), 7.28 (t, 1H, J = 8 Hz, 
6), 7.39 (d, 2H, J = 8 Hz, 5), 7.41 (dd, 1H, J = 8.5, 2 Hz, 2), 7.58 (d, 1H, J = 2.5 Hz, 1). 
HRMS (ESI) calcd (M+H)+: 339.9699, found: 339.9702.
5-bromo-1-(2,6-difluorobenzyl)indoline-2,3-dione (2-45)
2-45 was prepared from 5-bromoisatin and 2,6-difluorobenzyl bromide as described above. 
Product was an orange powder (265.5 mg, 0.75 mmol, 75%).
1H-NMR (d6-DMSO, 500 MHz): δ 4.93 (s, 2H, 9), 7.10 (m, 3H, 7, 12), 7.43 (tt, 1H, J = 6.8, 8.2 
Hz, 13), 7.70 (d, 1H, J = 2 Hz, 4), 7.84 (dd, 1H, J = 8.5, 2 Hz, 6).
13C-NMR (d6-DMSO, 125 MHz): δ 32.9 (9), 111.5 (t, J = 18 Hz, 10), 112.5 (dd, J = 20, 5 Hz, 
12), 113.3 (7), 115.8 (5), 120.1 (3), 127.5 (4), 131.5 (t, J = 10 Hz, 13), 140.6 (6), 149.9 (8), 158.1 
(2), 161.7 (dd, J = 247, 8 Hz, 11), 182.3 (1).
HRMS (ESI) calcd (M+H)+: 351.9785, found: 351.9780.
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5-chloro-1-(2-chloro-6-fluorobenzyl)indoline-2,3-dione (2-46)
2-46 was prepared from 5-chloroisatin and 2-chloro-6-fluorobenzyl bromide as described above. 
Product was an orange powder (159.9 mg, 0.50 mmol, 50%).
1H-NMR (CDCl3, 500 MHz): δ 5.12 (s, 2H, 9), 6.79 (d, 1H, J = 8.5 Hz, 7), 7.05 (t, 1H, J = 8 Hz, 
13), 7.24-7.32 (m, 2H, 12, 14), 7.44 (dd, 1H, J = 8.5, 2 Hz, 6), 7.56 (d, 1H, J = 2.5 Hz, 4).
13C-NMR (d6-DMSO, 125 MHz): δ 36.9 (d, J = 3 Hz, 9), 113.1, 114.5, 115.6 (d, J = 22 Hz, 14), 
119.7 (4), 121.0 (d, J = 16 Hz, 10), 124.9 (6), 126.6 (d, J = 3 Hz, 12), 128.3, 131.6 (d, J = 10 Hz, 
13), 135.1 (d, J = 6 Hz, 11), 137.9 (5), 149.8 (8), 158.3 (2), 162.1 (d, J = 248 Hz, 15), 182.4 (1).
HRMS (ESI) calcd (M+H)+: 323.9994, found: 323.9994. 
5-chloro-1-(6-chloro-2-fluoro-3-methoxybenzyl)indoline-2,3-dione (2-47)
2-47 was prepared from 5-chloroisatin and 2-chloro-6-fluoro-5-methoxybenzyl bromide as 
described above. Purified via silica gel chromatography (5 - 20% acetone in hexanes). Product 
was an orange powder (86.6 mg, 0.24 mmol, 24%).
1H-NMR (CDCl3, 500 MHz): δ 3.89 (s, 3H, 7), 5.12 (s, 2H, 4), 6.79 (d, 1H, J = 8.5 Hz, 3), 6.93 
(t, 1H, J = 8.5 Hz, 6), 7.18 (dd, 1H, J = 9, 1.5 Hz, 5), 7.45 (dd, 1H, J = 8.5, 2 Hz, 2), 7.57 (d, J = 
2 Hz, 1).
13C-NMR (d6-DMSO, 125 MHz): δ 37.2, 57.0, 113.1, 115.1, 119.6, 121.3 (d, J = 14 Hz), 124.9, 
125.0, 125.9 (d, J = 4 Hz), 128.4, 138.0, 147.3 (d, J = 10 Hz), 149.8, 151.6 (d, J = 249 Hz), 
158.2, 182.4.
HRMS (ESI) calcd (M+H)+: 354.0100, found: 354.0102.
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5-chloro-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzyl)indoline-2,3-dione (2-48)
2-48 was prepared from 5-chloroisatin and 2,3,5,6-tetrafluoro-4-trifluoromethylbenzyl bromide 
as described above. Product was an orange powder (345.3 mg, 0.84 mmol, 84%).
1H-NMR (CDCl3, 500 MHz): δ 5.10 (s, 2H, 9), 6.87 (d, 1H, J = 8.5 Hz, 7), 7.59 (dd, 1H, J = 8, 
1.5 Hz, 6), 7.64 (s, 1H, 4). 
HRMS (ESI) calcd (M+H)+ : 411.9975, found: 411.9984.
N-(1-(2,6-dichlorobenzyl)-2,3-dioxoindolin-5-yl)acetamide (2-34)
2-34 was prepared from 5-acetamidoisatin (prepared according to: Besson et al. Bioorg. Med. 
Chem. 2006, 14, 6434-43) and 2,6-dichlorobenzyl bromide as described above. Product was a 
red solid (17.4 mg, 0.085 mmol, 46%).
1H-NMR (CDCl3, 500 MHz): δ 2.65 (s, 3H, 7), 5.31 (s, 2H, 4), 6.71 (d, 1H, J = 8 Hz, 3), 7.10 (t, 
1H, J = 8 Hz, 6), 7.38 (d, 2H, J - 8 Hz, 5), 7.58 (d, 1H, J = 2 Hz, 1), 7.74 (dd, 1H, J = 2, 8 Hz, 2).
5-azido-1-(2,6-dichlorobenzyl)indoline-2,3-dione (2-30)
2-30 was prepared from 5-azidoisatin and 2,6-dichlorobenzyl bromide as described above. 
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Product was a red solid (210  mg, 0.61 mmol, 82%).
1H-NMR (CDCl3, 500 MHz): δ 5.24 (s, 2H, 9), 6.73 (d, 1H, J = 8.5 Hz, 7), 7.09 (dd, 1H, J = 8.5, 
2.5 Hz, 6), 7.27 - 7.29 (m, 2H, 4, 13), 7.38 (d, 2H, J = 8 Hz, 12). 
13C-NMR (CDCl3, 125 MHz): δ 40.5, 112.7, 115.8, 119.0, 128.5, 129.1, 129.4, 130.7, 136.5, 
136.7, 147.4, 157.6, 182.4.
HRMS (ESI) calcd (M+H)+: 347.0103, found: 347.0097.
(Z)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-(2,6-dichlorophenethyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (RBPI-6)
RBPI-6 was prepared from 2,6-dichlorophenethyl iodide (Bo, Y. et al. Bioor. Med. Chem. 2005, 
15, 5211-5217) and 13 as described above. Product was a red powder (60.0 mg, 0.11 mmol, 
76%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.24 (t, 2H, J = 6.5 Hz, 2), 3.33 (t, 2H, J = 7.5 Hz, 7), 4.07 (t, 
2H, J = 7, 6), 4.40 (t, 2H, J = 7 Hz, 1), 7.03 (d, 1H, J = 8.5 Hz, 5), 7.27 (t, 1H, J = 8.5 Hz, 9), 
7.41 (d, 2H, J = 8.5 Hz, 8), 7.53 (dd, 1H, J = 2, 8.5, 4), 8.8 (d, 1H, J = 2, 3)
HRMS (ESI) calcd (M+H)+: 564.9842, found: 564.9852
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(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-2-oxo-1-(2,3,5,6-tetrafluoro-4-
(trifluoromethyl)benzyl)indolin-3-ylidene)-2-thioxothiazolidin-4-one (2-39)
2-39 was prepared from 2-15 and 2-48 as described above. Product was a red powder (60.2 mg, 
0.096 mmol, 74%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.30 (t, 2H, J = 7 Hz, 2), 4.40 (t, 2H, J = 7 Hz, 3), 5.25 (s, 
2H, 15), 7.26 (d, 1H, J = 8.5, 13), 7.61 (dd, 1H, J = 8, 1.5, 12), 8.86 (d, 1H, J = 1.5, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 21.5 (2), 33.9, (15), 42.6 (3), 108.7 (20), 111.9 (9), 119.9 
(16), 121.4 (13), 122.4 (19), 122.8 (10), 127.6 (12), 127.8 (6), 132.9 (11), 135.0 (14), 143.3 (7), 
143.9 (17), 146.0 (18), 154.1 (1), 167.0 (5), 167.3 (8), 197.1 (4).
HRMS (ESI) calcd (M+H)+: 622.9962, found: 622.9969
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-azido-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (28)
2-31 was prepared from 2-15 and 2-30 as described above. Product was a red powder (75.7 mg, 
0.14 mmol, 94%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.28 (t, 2H, J = 7 Hz, 2), 4.37 (t, 2H, J = 7 Hz, 3), 5.22 (s, 
2H, 15), 6.94 (d, 1H, J = 9 Hz, 13), 7.22 (dd, 1H, J =10.5, 2 Hz, 12), 7.40 (d, 1H, J = 8 Hz, 19), 
7.51 (d, 2H, J = 7.5 Hz, 18), 8.55 (d, 1H, J = 2 Hz, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 21.5 (2), 41.3, (15), 42.5 (3), 111.6 (13), 118.7 (9), 121.0 
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(10), 123.2 (19), 124.0 (6), 129.8 (18), 130.4 (12), 131.5 (11), 134.6 (16), 134.8 (14), 136.0 (17), 
142.4 (1), 154.0 (7), 166.8 (5), 167.3 (58), 197.5 (4).
HRMS (ESI) calcd (M+H)+: 558.0089, found: 558.0097.
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-bromo-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (RBPI-5)
RBPI-5 was prepared from 2-15 and 2-3 as described above. Product was a red powder (145.3 
mg, 0.24 mmol, 93%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.27 (t, 2H, J = 7.5 Hz, 2), 4.37 (t, 2H, J = 7.5 Hz, 3), 5.26 (s, 
2H, 15), 6.95 (d, 1H, J = 8.5 Hz, 13), 7.42 (t, 1H, J =8.5 Hz, 19), 7.53 (d, 2H, J = 8 Hz, 18), 7.68 
(dd, 1H, J = 8.5, 2 Hz, 12), 9.01 (d, 1H, J = 2.5 Hz, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 22.7 (2), 41.3, (15), 43.6 (3), 112.2 (13), 115.2 (11), 121.8 
(0), 122.4 (19), 129.8 (18), 130.3 (6), 130.4 (10), 131.5 (12), 135.3 (16), 135.5 (14), 136.0 (17), 
144.2 (1), 156.2 (7), 166.7 (5), 167.3 (8), 197.3 (4).
HRMS (ESI) calcd (M+H)+: 596.9211, found: 592.9200.
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (RBPI-5)
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RBPI-5 was prepared from 2-15 and 2-7 as described above. Product was a red powder (160.6 
mg, 0.29 mmol, quant.).
1H-NMR (d6-DMSO, 500 MHz): δ 3.27 (t, 2H, J = 7.5 Hz, 2), 4.40 (t, 2H, J = 7.5 Hz, 3), 5.27 (s, 
2H, 15), 7.01 (d, 1H, J = 8.5 Hz, 13), 7.42 (t, 1H, J = 7.5 Hz, 19), 7.56 (m, 3H, 12, 18), 8.87 (d, 
1H, J = 2 Hz, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 22.0 (2), 41.3, (15), 43.1 (3), 111.9 (13), 121.3 (11), 122.7 
(0), 127.5 (19), 127.6 (6), 129.8 (18), 130.4 (10), 131.5 (12), 132.7 (16), 135.2 (14), 136.0 (17), 
143.9 (1), 155.0 (7), 166.8 (5), 167.3 (8), 197.4 (4).
HRMS (ESI) calcd (M+H)+: 550.9685, found: 550.9683.
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(1-(2-fluorobenzyl)-2-oxoindolin-3-ylidene)-2-
thioxothiazolidin-4-one (2-18)
2-18 was prepared from 2-15 and 2-42 as described above. Product was a red powder (41.2 mg, 
0.088 mmol, 68%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.22 (t, 2H, J = 7 Hz, 2), 4.40 (t, 2H, J = 7.5 Hz, 3), 5.07 (s, 
2H, 15), 7.06 (d, 1H, J = 8 Hz, 13), 7.15 (t, 2H, J = 7.5 Hz, 20, 11), 7.22 (t, 1H, J = 9 Hz, 12), 
7.27 (t, 1H, J = 7.5 Hz, 21), 7.34 (m, 1H, 18), 7.45 (t, 1H, J = 7.5 Hz, 19), 8.80 (d, 1H, J = 8 Hz, 
10).
13C-NMR (d6-DMSO, 125 MHz): δ 21.4 (2), 38.5 (d, J = 4 Hz, 15), 42.5 (3), 111.6 (13), 116.3 
(18), 120.0 (9), 123.1 (d, J = 15 Hz, 16), 123.7 (11), 124.6 (12), 125.4 (6), 125.5 (20), 128.5 (10), 
130.1 (d, J= 5 Hz, 19), 130.6 (d, J = 8 Hz, 21), 132.9 (14), 133.8 (7), 145.1 (1), 160.8 (d, J = 245 
Hz, 17),  167.2 (8), 167.3 (5), 197.8 (4).
HRMS (ESI) calcd (M+H)+: 467.0760, found: 467.0754.
N
O
F
S
N
O
S
NN
N
H
N 1
2
3
4
5
6 7
8
9
10
11 12
13
14
15
16
17 18
19
2021
72
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-(2-fluoro-6-(trifluoromethyl)benzyl)-2-
oxoindolin-3-ylidene)-2-thioxothiazolidin-4-one (2-37)
2-37 was prepared from 2-15 and 2-44 as described above. Product was a brown powder (68.6 
mg, 0.12 mmol, 93%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.19 (t, 2H, J = 7.5 Hz, 2). 4.36 (t, 2H, J = 7.5 Hz, 3), 5.24 (s, 
2H, 15), 7.05 (d, 1H, J = 8.5 Hz, 13), 7.56 (m, 2H, 19, 18), 7.62 (m, 1H, 20), 7.70 (d, 1H, J = 8 
Hz, 12), 8.89 (d, 1H, J = 2 Hz, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 21.8, 37.2, 43.4, 111.7, 121.4, 121.6, 122.3, 122.6, 125.4, 
127.5, 129.8, 131.6, 132.7, 135.2, 138.0, 143.9, 155.8, 161.0, 163.0, 167.1, 172.7, 197.3.
HRMS (ESI) calcd (M+H)+: 569.0244, found: 569.0245.
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-(6-chloro-2-fluoro-3-methoxybenzyl)-2-
oxoindolin-3-ylidene)-2-thioxothiazolidin-4-one (2-36)
2-36 was prepared from 2-15 and 2-47 as described above. Product was a brown powder (44.6 
mg, 0.08 mmol, 72%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.33 (t, 2H, J = 7 Hz, 1). 3.82 (s, 3H, 9), 4.41 (t, 2H, J = 7 
Hz, 2), 5.14 (s, 2H, 6), 7.03 (d, 1H, J = 8.5 Hz, 5), 7.20 (t, 1H, J = 8.5 Hz, 8), 7.30 (d, 1H, J = 9 
Hz, 7), 7.57 (dd, 1H, J = 8.5, 2 Hz, 4), 8.83 (d, 1H, J = 2.5 Hz, 3).
13C-NMR (d6-DMSO, 125 MHz): δ 21.4, 37.4, 42.5, 57.0, 111.8, 115.0, 121.2, 121.3, 122.8, 
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124.8, 125.9, 127.5, 127.6, 132.9, 135.0, 143.8, 147.2, 151.4, 166.7, 167.3, 197.4.
HRMS (ESI) calcd (M+H)+: 565.0086, found: 565.0092.  
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-(2-chloro-6-fluorobenzyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (2-16)
2-16 was prepared from 2-15 and 2-46 as described above. Product was a brown powder (57.2 
mg, 0.11 mmol, 82%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.32 (t, 2H, J = 7 Hz, 1). 4.40 (t, 2H, J = 7 Hz, 2), 5.17 (s, 
2H, 6), 7.06 (d, 1H, J = 8.5 Hz, 5), 7.26 (t, 1H, J = 8.5 Hz, 8), 7.37 - 7.44 (m, 2H, 9, 7), 7.57 (dd, 
1H, J = 8.5, 2.5 Hz, 4), 8.84 (d, 1H, J = 2 Hz, 3).
13C-NMR (d6-DMSO, 125 MHz): δ 21.4, 37.2, 42.4, 111.8, 113.0 (d, J = 17 Hz), 115.6 (d, J = 22 
Hz), 121.1, 122.8, 124.9, 126.6, 127.5 (d, J = 9 Hz), 131.7 (d, J = 10 Hz), 132.9, 134.9, 138.0, 
143.8, 153.9, 162.0 (d, J = 248 Hz), 166.7, 167.3, 197.3
HRMS (ESI) calcd (M+H)+: 534.9981, found: 534.9988. 
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-bromo-1-(2,6-difluorobenzyl)-2-oxoindolin-3-
ylidene)-2-thioxothiazolidin-4-one (2-17)
2-17 was prepared from 2-15 and 2-45 as described above. Product was a brown powder (95.6 
mg, 0.17 mmol, 77%).
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1H-NMR (d6-DMSO, 500 MHz): δ 3.28 (t, 2H, J = 7 Hz, 2). 4.39 (t, 2H, J = 7.5 Hz, 3),  5.11 (s, 
2H, 15), 7.08 (d, 1H, J = 8.5 Hz, 13), 7.13 (t, 2H, J = 8.5 Hz, 18), 7.44 (m, 1H, 19), 7.72 (dd, 1H, 
J = 8.5, 2 Hz, 12), 8.99 (d, 1H, J = 2 Hz, 10).
13C-NMR (d6-DMSO, 125 MHz): δ 21.9 (2), 33.3 (15), 42.9 (3), 111.4 (t, J = 18 Hz, 16), 112.1 
(13), 112.6 (dd, J = 20, 5 Hz, 18), 115.3, (11), 121.6 (9), 122.6 (6), 130.4 (10), 131.6 (t, J = 10 
Hz, 19), 135.2 (12), 135.6 (14), 144.0 (7), 161.6 (dd, J = 247, 8 Hz, 17), 166.6 (5), 167.3 (8), 
197.4 (4).
HRMS (ESI) calcd (M+H)+: 562.9771, found: 562.9764. 
(E)-3-(2-(1H-tetrazol-5-yl)ethyl)-5-(5-chloro-1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-2-
oxoindolin-3-ylidene)-2-thioxothiazolidin-4-one (2-38)
2-38 was prepared from 2-15 and 2-43 as described above. Product was a brown powder (51.4 
mg, 0.09 mmol, 70%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.33 (t, 2H, J = 6.5 Hz, 1). 4.43 (t, 2H, J = 7 Hz, 2),  4.99 (s, 
2H, 5), 6.04 (s, 2H, 8), 6.79 (s, 1H, 7), 7.01 (d, 1H, J = 8.5 Hz, 5), 7.15 (s, 1H, 9), 7.55 (dd, 1H, J 
= 8.5, 2.5 Hz, 4), 8.86 (d, 1H, J = 2 Hz, 3).
13C-NMR (d6-DMSO, 125 MHz): δ 21.4, 42.3, 42.5, 102.9, 108.7, 110.6, 112.2, 121.4, 123.5, 
124.5, 126.0, 127.6, 127.7, 132.9, 134.6, 143.8, 147.7, 148.4, 167.2, 167.4, 197.4.
HRMS (ESI) calcd (M+H)+: 560.9973, found: 560.9969. 
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(E)-3-(5-(5-chloro-2-((2,6-dichlorobenzyl)(methyl)amino)benzylidene)-4-oxo-2-
thioxothiazolidin-3-yl)propanoic acid (2-12)
2-12 was prepared from 2-11 and rhodanine-3-propionic acid as described above. Product was an 
orange solid (65.0 mg, 0.126 mmol, 60%).
1H-NMR (CDCl3, 500 MHz): δ 2.74 (s, 3H, 8). 2.83 (t, 2H, J = 6.5 Hz, 2),  4.40 (s, 2H, 9), 4.42 
(t, 2H, J = 8 Hz, 3), 7.12 (t, 1H, J = 8 Hz, 11), 7.22-7.27 (m 3H, 10, 6), 7.31-7.38 (m, 2H, 5, 7), 
7.92 (s, 1H, 4), 10.18 (s, 1H, 1).
13C-NMR (CDCl3, 125 MHz): δ 31.2, 39.7, 42.9, 55.2, 123.4, 128.7, 128.8, 129.3, 129.5, 130.3, 
131.2, 131.7, 133.0, 137.2, 152.7, 167.4, 175.9, 193.4.
HRMS (ESI) calcd (M+H)+: 514.9824, found: 514.9824.
(E)-N-(3-(3-(2-(1H-tetrazol-5-yl)ethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)-1-(2,6-
dichlorobenzyl)-2-oxoindolin-5-yl)acetamide (2-35)
2-35 was prepared from 2-15 and 2-34 as described above. Product  was a dark purple powder 
(11.8 mg, 0.02 mmol, 50%).
1H-NMR (d6-DMSO, 500 MHz): δ 2.02 (s, 3H, 4),  3.26 (t, 2H, J = 7.5 Hz, 1), 4.37 (t, 2H, J = 
7.5 Hz, 2), 5.20 (s, 2H,  7), 6.82 (d, 1H, J = 8.5 Hz, 6), 7.39 (t, 1H, J = 8 Hz, 9), 7.51 (d, 2H, J = 
8 Hz, 8), 7.73 (d, 1H, J = 8.5 Hz, 5), 8.95 (s, 1H, 3) 10.07 (s, 1H, 10). 
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13C-NMR (d6-DMSO, 125 MHz): δ 21.7, 24.4, 41.2, 42.7, 110.1, 120.0, 120.6, 124.4, 124.8, 
129.8, 130.6, 131.5, 133.2,135.2, 136.0, 140.9, 154.4, 167.0, 167.2, 168.9, 197.9.
HRMS (ESI) calcd (M+H)+: 574.0290, found: 574.0291. 
(E) -3- (5- (5-az ido-1- (2 ,6-d ichlorobenzyl ) -2-oxoindol in-3-y l idene) -4-oxo-2-
thioxothiazolidin-3-yl)propanoic acid (2-32)
2-32 was prepared from 2-30 and rhodanine-3-propionic acid as described above. Product was a 
brown powder (146.1 mg, 0.27 mmol, 94%).
1H-NMR (d6-DMSO, 500 MHz): δ 1 was under H2O peak, 4.22 (t, 2H, J = 7 Hz, 2),  5.25 (s, 2H, 
6), 6.97 (d, 1H, J = 8.5 Hz, 5), 7.25 (d, 1H, J = 7.5 Hz, 4), 7.41 (t, 1H, J = 7.5 Hz, 8), 7.53 (d, 2H, 
J = 8 Hz, 7), 8.70 (s, 1H, 3), 
Note: compound was too insoluble for a 13C-NMR to be collected in any solvent.
HRMS (ESI) calcd (M+H)+: 533.9864, found: 533.9858.  
(E)-3-(5-(5-bromo-1-(2 ,6-dichlorobenzyl) -2-oxoindol in-3-yl idene)-4-oxo-2-
thioxothiazolidin-3-yl)propanenitrile (2-24)
2-24 was prepared from 2-23 and 2-3 as described above. Product was a brown powder (88.8 
mg, 0.16 mmol, 80%).
1H-NMR (d6-DMSO, 500 MHz): δ 2.97 (t, 2H, J = 6.5 Hz, 1), 4.33 (t, 2H, J = 6.5 Hz, 2),  5.25 
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(s, 2H, 6), 6.95 (d, 1H, J = 8.5 Hz, 5), 7.41 (t, 1H, J = 8.5 Hz, 8), 7.53 (d, 2H, J = 8 Hz, 7), 
7.67-7.84 (m, 1H, 4), 9.03 (d, 1H, J = 2 Hz, 3), 
13C-NMR (d6-DMSO, 125 MHz): δ 15.8, 41.3, 112.4, 115.2, 118.9, 121.7, 122.8, 127.7, 129.8, 
130.3, 130.4, 131.5, 135.7, 136.0, 144.3, 166.7, 167.1, 197.3.
HRMS (ESI) calcd (M+H)+: 551.9010, found: 551.8984. 
(E)-3-(4-(5-bromo-1-(2 ,6-dichlorobenzyl) -2-oxoindol in-3-yl idene)-5-oxo-2-
thioxoimidazolidin-1-yl)propanoic acid (2-4)
2-4 was prepared from 2-2 and 2-3 as described above. Product was a purple powder (15.0 mg, 
0.03 mmol, 16%).
1H-NMR (d6-DMSO, 500 MHz): δ 2.63 (t, 2H, J = 7.5 Hz, 1), 4.03 (t, 2H, J = 7.5 Hz, 2),  5.24 
(s, 2H, 6), 6.85 (d, 1H, J = 9 Hz, 5), 7.39 (t, 1H, J = 8 Hz, 8), 7.53 (m, 3H, 4, 7), 9.82 (s, 1H, 3).
HRMS (ESI) calcd (M+H)+: 553.9344, found: 553.9355.
(Z)-3-(5-(5-bromo-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)-N-methylpropanamide (2-29)
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2-29 was prepared from 2-3 and 2-28 as described above. Product was a red/brown solid (328 
mg, 0.56 mmol, 75%).
1H-NMR (d6-DMSO, 500 MHz): δ 2.64 (t, partially obscured by water peak, 2), 3.44 (s, 3H, 1), 
4.27 (t, 2H, 3), 5.25 (s, 2H, 7), 6.96 (d, 1H, J = 8.5 Hz, 6), 7.41 (t, 1H, J = 7.5 Hz, 9), 7.52 (d, 
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2H, J = 8 Hz, 8), 7.67 (d, 1H, J = 6.5 Hz, 5), 9.08 (s, 1H, 4).
(Z)-5-(5-chloro-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-3-(2-(2-methyl-2H-
tetrazol-5-yl)ethyl)-2-thioxothiazolidin-4-one (Me-RBPI-6)
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Me-RBPI-6 was prepared from 2-22 and 2-7 as described above then purified via flash column 
chromatography in 1% methanol in chloroform. Product was a brown solid with very low DMSO 
solubility (3.6 mg, 5%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.37 (t, 2H, J = 7 Hz, 2), 4.30 (s, 3H, 1), 4.60 (t, 2H, J = 7 
Hz, 3),  5.30 (s, 2H, 7), 6.67 (d, 1H, J = 8.5 Hz, 6), 7.27 (m, 2H, 7, 9), 7.37 (d, 2H, J = 8 Hz, 8), 
8.97 (s, 1H, 4).
HRMS (ESI) calcd (M+H)+: 564.9842, found: 564.9844.
Methyl 3-(5-oxo-2-thioxoimidazolidin-1-yl)propanoate (2-2)
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A 10 mL round-bottom flask was charged with isothiocyanatoacetic acid ethyl ester (120 µL, 1.0 
mmol, 1.0 equiv.) and chloroform (3.3 mL) and fitted with an addition funnel.  The addition 
funnel was charged with a solution of β-alanine methyl ester (103 mg, 1.0 mmol, 1.0 equiv.) in 
chloroform (2.5 mL).  The amine solution was added dropwise over 2 minutes, then the reaction 
was allowed to stir at room temperature for 4.5 hours.  The solvent was removed in vacuo and 
the mixture was taken up in HCl (10 M, 3.5 mL) and ethanol (3.5 mL).  The mixture was 
refluxed for 3 hours, then allowed to cool to room temperature.  The reaction was concentrated in 
vacuo, then taken up in deionized water, neutralized with sat. aq. sodium bicarbonate and 
extracted 3x with dichloromethane.  The aqueous layer was then re-acidifed and extracted with 
ethyl acetate, the organic layer was dried over magnesium sulfate, filtered, and concentrated 
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down to a bright yellow solid (34.0 mg, 0.17 mmol, 17%).
1H-NMR (D3O, 500 MHz): δ 2.52 (t, 2H, J = 9.5 Hz, 1), 3.84 (t, 2H, J = 8.5 Hz, 2), 3.97 (s, 2H, 
3), 4.63 (s, 3H, 4).
5-azidoisatin
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A 50 mL round-bottom flask was charged with 5-aminoisatin (84.0 mg, 0.52 mmol, 1.0 equiv, 
prepared according to: Besson et al. Bioorg. Med. Chem. 2006, 14, 6434-43) and 2 N HCl (12 
mL).  The flask was cooled to 0 ˚C and a solution of NaNO2 (39.3 mg, 0.57 mmol, 1.1 equiv.) in 
water (0.5 mL) was added.  The reaction was stirred at 0 ˚C for 30 min, then NaOH and CaCO3 
were added until pH = 9.  Next, a solution of sodium azide (37.0 mg, 0.57 mmol, 1.1. equiv.) in 
water (0.5 mL) was added and the reaction was stirred at 0 ˚C for 40 min.  Ethyl acetate was 
added and the layers were partitioned.  The aqueous phase was extracted 3x with ethyl acetate 
and the combined organics were washed with sat. aqueous sodium chloride.  The organic phase 
was dried over magnesium sulfate and filtered through celite.  The filtrate was concentrated in 
vacuo to yield a red solid (77.4 mg, 0.41 mmol, 79%) which was used without further 
purification. 
1H-NMR (d6-DMSO, 500 MHz): δ 6.94 (d, 1H, J = 8.5 Hz, 3), 7.25 (d, 1H, J = 2.5, 1), 7.34 (dd, 
1H, J = 8.5, 2.5, 2), 11.08 (br s, 1H, NH). 
5-chloro-1-(2,6-dichlorobenzyl)-3-ethynyl-3-hydroxyindolin-2-one (2-8)
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A flame-dried round-bottom flask was charged with 2-7 (50.0 mg, 0.15 mmol, 1 equiv.), fitted 
with a septum and purged with positive nitrogen pressure.  Dry dichloromethane (1 mL) was 
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added via syringe and the solution was cooled to -78 °C.  Ethynyl magnesium bromide (0.5 M 
THF, 320 μL, 1.1 equiv.) was added dropwise.  The reaction was stirred at -78 °C for 30 min, 
then allowed to warm to ambient temperature and stirred for 4 hours.  The reaction was quenched 
by the addition of saturated ammonium chloride (2 mL), the layers were partitioned and the 
aqueous layer was extracted 3x with DCM (5 mL).  The combined organics were washed with 
sat. aqueous sodium chloride and dried over magnesium sulfate.  After filtration through Celite, 
the filtrate was concentrated in vacuo  to provide 9 as a beige solid (50.9 mg, 0.14 mmol, 93%).
1H-NMR (CDCl3, 500 MHz): δ 2.67 (s, 1H, 2), 3.64 (br s, 1H, 3), 5.23 (ABq, 2H, ΔνAB = 64.7 
Hz, JAB = 15.5 Hz, 7), 6.61 (d, 1H, J = 8 Hz, 6), 7.18 (dd, 1H, J = 8, 1 Hz, 5), 7.24 (t, 1H, J = 8.5 
Hz, 9), 7.36 (d, 2H, J = 8, 8), 7.52 (s, 1H, 4). 
13C-NMR (CDCl3, 125 MHz): δ 40.8, 68.8, 75.7, 80.2, 111.3, 125.6, 129.3, 129.5, 129.5, 129.9, 
130.4, 130.8, 136.6, 140.6 , 172.7.
HRMS (ESI) calcd (M+H)+: 365.9855, found: 365.9861.
3-(4-(5-chloro-1-(2,6-dichlorobenzyl)-3-hydroxy-2-oxoindolin-3-yl)-1H-1,2,3-triazol-1-
yl)propanoic acid (2-9)
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A 1-dram vial was charged with 3-azidopropionic acid (18.8 mg, 0.16 mmol, 3.0 equiv.) and 
dichloromethane (0.2 mL).  In a separate vial, 2-8 (20 mg, 0.06 mmol, 1.0 equiv.) was mixed 
with CuSO4 (4.1 mg, 0.02 mmol, 0.3 equiv.) in a 1:1:1 mixture of dichloromethane, ethanol, and 
deionized water (0.6 mL total volume) and this mixture was added to the azide solution.  Sodium 
ascorbate (6.5 mg, 0.03 mmol, 0.6 equiv.) was added to the reaction mixture.  The vial was 
capped and stirred at ambient temperature.  The reaction changed from cloudy yellow to dark 
purple and then to a clear yellow appearance within 10 min.  After 15 min, TLC (5% methanol in 
dichloromethane) showed complete consumption of the starting material.  The reaction was 
transferred to separatory funnel and 4 drops of 2 M HCl were added.  The aqueous mixture was 
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extracted 2x with dichloromethane.  The combined organics were washed with sat. sodium 
chloride, dried over magnesium sulfate and filtered through Celite. The filtrate was concentrated 
in vacuo yielding a light yellow solid which was purified via flash chromatography (5 - 10% 
methanol in dichloromethane) to give the final product as a yellow solid (3.1 mg, 0.007 mmol, 
12%).  
1H-NMR (CDCl3, 500 MHz): δ 2.98 (t, 2H, J = 6.5 Hz, 1), 3.61 (s, 1H, 8), 4.60 (t, 2H, J = 7 Hz, 
2), 5.12 (ABq, 2H, ΔνAB = 64.7 Hz, JAB = 15.5 Hz, 7), 6.80 (d, 1H, J = 8.5 Hz, 6), 7.35 - 7.38 
(m, 1H, 5), 7.39 (t, 1H, J = 8.5 Hz, 9), 7.51 (d, 2H, J = 8 Hz, 8), 8.16 (s, 1H, 4).
HRMS (ESI) calcd (M+H)+: 481.0237, found: 481.0232.
(5-chloro-2-((2,6-dichlorobenzyl)amino)phenyl)methanol (2-49)
Cl OH
NH2 Cl
Cl
Br
Cl OH
NH
Cl
Cl
1
4
3
2
5
6
7
Et3N
MeOH
2-49
A flame-dried 10 mL round-bottom flask under N2(g) was charged with 2-amino-5-chlorobenzyl 
alcohol (307.3 mg, 1.95 mmol, 1.5 equiv.) and 2,6-dichlorobenzyl bromide (311.9 mg, 1.3 mmol, 
1.0 equiv.).  Methanol (6 mL) was added via syringe, followed by triethylamine (0.27 mL, 1.95 
mmol, 1.5 equiv.).  The clear light yellow solution was stirred overnight.  The solution was 
concentrated in vacuo and the resulting residue was taken up in ethyl acetate and 2 M HCl.  The 
layers were partitioned and the aqueous phase was extracted twice with ethyl acetate.   The 
combined organics were washed with sat. sodium chloride, dried over magnesium sulfate, 
filtered through Celite and concentrated in vacuo  to yield an off-white solid (348.9 mg, 85%). 
1H-NMR (CDCl3, 500 MHz): δ 4.57 (s, 2H, 5), 4.58 (s, 2H, 1), 6.83 (d, 1H, J = 8.5 Hz, 4), 7.05 
(d, 1H, J = 2 Hz, 2), 7.17-7.22 (m, 2H, 3, 7), 7.33 (d, 2H, J = 8 Hz, 6).
13C-NMR (CDCl3, 125 MHz): δ 43.9, 64.4, 112.8, 122.0, 126.7, 128.9, 129.0, 129.3, 129.7, 
134.5, 136.4, 145.9. 
HRMS (ESI) calcd (M+H)+: 316.0063, found: 316.0064.
82
5-chloro-2-((2,6-dichlorobenzyl)amino)benzaldehyde (2-10)
Cl OH
NH
Cl
Cl
Cl
O
NH
Cl
Cl
1
4
3
2
5
6
7
MnO2
DCM
2-49 2-10
A 50 mL round-bottom flask was charged with 2-49 (268.4 mg, 0.81 mmol, 1.0 equiv.) and 
purged with N2(g).  Dichloromethane (15 mL) was added via syringe and manganese dioxide 
(1.41 g, 16.2 mmol, 20 equiv.) was added in one portion.  The mixture was stirred at ambient 
temperature for 15 h.  Then, the mixture was filtered though Celite, rinsing with ethyl acetate and 
dichloromethane, and the resulting filtrate was concentrated in vacuo to yield a yellow solid 
(238.9 mg, 94%).  
1H-NMR (CDCl3, 500 MHz): δ 4.70 (d, 2H, J = 6 Hz, 5), 6.95 (d, 2H, J = 9 Hz, 6), 7.22 (t, 1H, J 
= 8.5, 7), 7.34 - 7.44 (m, 2H, 3, 4), 7.44 (d, 1H, J = 7, 2), 9.75 (s, 1H, 1).
5-chloro-2-((2,6-dichlorobenzyl)(methyl)amino)benzaldehyde (2-11)
Cl
O
N
Cl
Cl
1
4
3
2
5
6
7
DMF, 80 ˚C
Cl
O
NH
Cl
Cl
Me8NaH, MeI
2-10 2-11
A flame-dried 15 mL round-bottom flask was charged with 2-10 (238.9 mg, 0.76 mmol, 1.0 
equiv.) and sodium hydride (33.5 mg, 60% in oil, 0.84 mmol, 1.1 equiv.) and purged with N2(g). 
Dimethyl formamide (7 mL) was added via syringe and the mixture was stirred, resulting in a 
dark purple mixture. Methyl iodide (0.23 mL, 3.76 mmol, 4.95 equiv.) was added via syringe, 
which resulted in a light yellow solution. The flask was fitted with a reflux condenser and 
lowered into a pre-heated bath and heated at 80 ˚C for 2.5 h. The reaction was poured into 
deionized water (40 mL) and extracted 3x with ethyl acetate. The combined organics were 
washed 3x with sat. sodium chloride, dried over magnesium sulfate, and filtered through Celite. 
The clear yellow filtrate was concentrated in vacuo to yield a yellow oil which was purified by 
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flash chromatography (3 - 10% ethyl acetate in hexanes). The product was a yellow oil (154.8 
mg, 62%). 
1H-NMR (CDCl3, 500 MHz): δ 3.32 (s, 3H, 8), 4.53 (s, 2H, 5), 7.18 (d, 2H, J = 9 Hz, 6),  7.25 - 
7.33 (m, 2H, 3, 7), 7.48 (d, 1H, J = 8 Hz, 4), 7.75 (d, 1H, J = 2.5 Hz, 2), 10.17 (s, 1H, 1). 
3-(4-oxo-2-thioxothiazolidin-3-yl)propanenitrile (2-23)
NH2 CS2, NaOH;
Br Br
O
SN
O
S
2
3
4 5
6
N N 1
2-23
A 25 mL round-bottom flask was charged with deionized water (6 mL), sodium hydroxide (96 
mg, 2.4 mmol, 2.0 equiv.) and 3-aminopropionitrile (88 µL, 1.2 mmol, 1.0 equiv.).  The mixture 
was stirred vigorously while carbon disulfide (114 µL, 1.8 mmol, 1.5 equiv.) was added 
dropwise , followed by tetrahydrofuran (2.4 mL) in one portion.  The reaction was allowed to stir 
at ambient temperature for 22 hours.  The reaction was concentrated in vacuo, then a solution of 
bromoacetyl bromide (158 µL, 1.8 mmol, 1.5 equiv.) in dichloromethane (1.5 mL) was added in 
one portion.  The reaction was stirred for an additional 24 hours.  The reaction layers were 
partitioned and the aqueous phase was extracted 2x with dichloromethane. The combined 
organics were washed with sat. sodium chloride, dried over magnesium sulfate, then filtered. 
The filtrate was concentrated in vacuo  to a yellow oil (201 mg, 1.1 mmol, 90%).
1H-NMR (CDCl3, 500 MHz): δ 2.81 (t, 2H, J = 7 Hz, 2), 4.06 (s, 2H, 5), 4.30 (t, 2H, J = 7.5 Hz, 
3). 
13C-NMR (CDCl3, 125 MHz): δ 15.7 (2), 35.6 (5), 39.6 (3), 116.5 (1), 173.3 (4), 200.6 (6).
HRMS (ESI) calcd (M+H)+: 208.9819, found: 208.9826.
N-methyl-3-(4-oxo-2-thioxothiazolidin-3-yl)propanamide (2-28)
NH2
CS2, NaOH;
Br Br
O SN
O
S
2
3
4
1
2-28
N
H
O
Me N
H
O
Me
2-27
Compound 2-28 was prepared from 3-amino-N-methylpropanamide in the same manner as 2-23.
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1H-NMR (CDCl3, 500 MHz): δ 1.89 (m, 2H, 2), 3.41 (s, 3H, 1), 3.81 (m, 2H, 3), 4.03 (s, 2H, 4). 
HRMS (ESI) calcd (M+H)+: 241.0081, found: 241.0077.
3-(2-(1H-tetrazol-5-yl)ethyl)-2-thioxothiazolidin-4-one (2-15)
H
N O Ph
O
N
N
N NH
Pd/C
MeOH, rt;
CS2, NaOH;
Br Br
O
SN
O
S
NN
N N
H
1 2
3
4 5
6
2-50 2-15
NH2N
N
N NH
2-14
A 25 mL round-bottom flask under nitrogen was charged with Pd/C (400 mg, equal weight to 
2-50) and 57 (400.0 mg, 1.62 mmol, 1 equiv.). Neat 1,4-cyclohexadiene (0.92 mL, 97 mmol, 6.0 
equiv.) was added via syringe, followed by methanol (6.5 mL, 0.25M). The reaction was stirred 
at ambient temperature for 24 hours, after which the stir bar was removed and the reaction 
solution was filtered through Celite, rinsing with methanol. Solvent was removed from the 
filtrate in vacuo to yield a white crystalline solid (183 mg, 1.62 mmol, quant.) whose 1H-NMR 
spectrum matched the reported values (Yuan, H.; Silverman, R. B. Bioorg. Med. Chem. 2006, 14, 
1331). This intermediate was used within 1 day and was not purified further.  2-14 (457.0 mg, 
4.04 mmol, 1.0 equiv.) was dissolved in deionized water (20 mL, 0.2 M) and NaOH (484.8 mg, 
12.12 mmol, 3.0 equiv.) was added. The mixture was stirred until all solids were dissolved. 
Carbon disulfide (384 µL, 6.06 mmol, 1.5 equiv.) was added dropwise followed by 
tetrahydrofuran (8 mL, 0.5 M) in one portion. The flask was capped and the reaction was stirred 
at ambient temperature for 18 hours. The mixture was subjected to rotary evaporation to remove 
all volatile components – a bleach mixture was placed in the trap to reduce the smell from carbon 
disulfide vapors. To the resulting aqueous solution was added a solution of bromoacetyl bromide 
(532 µL, 6.06 mmol, 1.5 equiv.) in dichloromethane (5 mL, 0.8 M). The reaction was allowed to 
stir at ambient temperature for 2.5 hours, at which time large amounts of white precipitate was 
observed. The precipitate was filtered off and the filtrate was returned to the flask and stirred for 
an additional 14 hours. The reaction mixture was filtered again, yielding more white precipitate. 
The solids were dried in vacuo yielding a white powder (721.4 mg, 3.15 mmol, 78%).
1H-NMR (d6-DMSO, 500 MHz): δ 3.20 (t, 2H, J = 7.5 Hz, 2), 4.19 (t, 2H, J = 7.5 Hz, 3).
13C-NMR (d6-DMSO, 125 MHz): δ 21.2 (3), 36.7 (5), 42.4 (2), 153.7 (1), 174.9 (6), 203.9 (4).
HRMS (ESI) calcd (M+H)+: 230.0170, found: 230.0176.
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Benzyl (2-(1-methyl-1H-tetrazol-5-yl)ethyl)carbamate (2-20) and benzyl (2-(2-methyl-2H-
tetrazol-5-yl)ethyl)carbamate (2-21)
H
N O Ph
O
N
N
N NH
2-50
H
N O
O
N
N
N N Me
H
N O
O
N
N
N N
Me2-20 2-211
2
3
4
5
6
7
acetone, rt
Et3N, MeI
8
9
10
1
2
3
4
5
6
7 8
9
10
A 15 mL round-bottom flask was charged with 2-50 (124 mg, 0.5 mmol, 1.0 equiv) and purged 
with N2(g). Acetone (5 mL, 0.1 M) was added, followed by the addition of triethylamine (139 
µL, 1.0 mmol, 2 equiv.) and methyl iodide (62 µL, 1.0 mmol, 2.0 equiv.). The solution was 
allowed to stir at ambient temperature for 15 hour, upon which time a white solid had 
precipitated out of solution. The reaction mixture was filtered and the filtrate was concentrated in 
vacuo to yield a pale yellow residue. The residue was dissolved in dichloromethane and washed 
1X with dilute NaOH (aq.), dried with sat. sodium chloride and MgSO4, filtered, and 
concentrated in vacuo to yield a clear light yellow oil which was purified by flash 
chromatography (1 - 33% methanol in dichloromethane).  The products were a off-white solids, 
2H-Z (57 mg, 44%) and 1H-Z (43 mg, 33%). Assignment of isomers was based on presence of a 
1D NOE interaction between methyl (1) and methylene (3) in 2-20 and absence of this 
interaction in 2-21.
2-20
1H-NMR (CDCl3, 500 MHz): δ 3.05 (t, 2H, J = 6.5, 3), 3.70 (m, 2H, 4), 3.93 (s, 3H, 1), 5.08 (s, 
2H, 6), 5.62 (br s, 1H, NH), 7.33 (m, 5H, 8, 9, 10).
13C-NMR (CDCl3, 125 MHz): δ 24.0 (3), 33.5 (1), 38.2 (4), 67.1 (6), 128.3 (8), 128.5 (9), 128.8 
(10), 136.5 (7), 153.5 (2), 156.7 (5).
HRMS (ESI) calcd (M+H)+: 262.1304, found: 262.1298.
2-21
1H-NMR (CDCl3, 500 MHz): δ 3.11 (t, 2H, J = 6, 3), 3.67 (m, 2H, 4), 4.31 (s, 3H, 1), 5.1 (s, 2H, 
6), 7.36 (m, 5H, 8, 9, 10).
13C-NMR (CDCl3, 125 MHz): δ 26.3 (3), 39.0 (1), 39.6 (4), 67.0 (6), 124.9 (8), 128.4 (9), 128.8 
(10), 136.7 (7), 156.5 (2), 164.9 (5).
HRMS (ESI) calcd (M+H)+: 262.1304, found: 262.1305.
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3-(2-(2-methyl-2H-tetrazol-5-yl)ethyl)-2-thioxothiazolidin-4-one (2-22)
H
N O
O
N
N
N N
Me 2-21
2
3
4
Pd/C
MeOH, rt;
CS2, NaOH;
Br Br
O
SN
O
S
NN
N NMe
1 2-22
Compound 2-22 was prepared following the same procedure used to prepare 2-15. Product was 
an off-white oil (38 mg, 87%). 
1H-NMR (CD3OD, 500 MHz): δ 3.29 (t, 2H, J = 7.5 Hz, 2), 3.42 (t, 2H, J = 7.5 Hz, 3), 4.0 (s, 
2H, 4), 4.37 (s, 3H, 1).
HRMS (ESI) calcd (M+H)+: 244.0327, found: 244.0336.
3-(5-(5-bromo-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-yl)-4-oxo-2-thioxothiazolidin-3-
yl)propanoic acid (2H-RBPI-2)
N
O
Cl
S
N
O
S
O
HO
Br
Cl
N
O
Cl
S
N
O
S
O
HO
Br
Cl
H
H
LiBH4, pyridine
THF, reflux
1
2 3
4
5
6
7
8 9
10
To a flame-dried 1- mL round bottom flask under N2(g) was added RBPI-2 (50 mg, 0.087 mmol, 
1.0 equiv.), pyridine (0.6 mL), and THF (anhydrous, 0.4 mL). The flask was fitted with a 
jacketed condenser and LiBH4 (0.1 mL, 0.19 mmol, 2.2 equiv., Sigma Aldrich, 2 M in THF) was 
added via syringe. The flask was lowered into a pre-heated oil bath at 65 ˚C and refluxed for 20 
h. The reaction mixture was poured into 2 M HCl (75 mL) and extracted with ethyl acetate. The 
combine organics were dried with saturated sodium chloride, MgSO4, and filtered. The filtrate 
was concentrated in vacuo to yield a yellow residue. The residue was purified via reverse-phase 
column chromatography to yield a pale yellow solid which decomposed upon exposure to air. 
1H-NMR (d6 -DMSO, 500 MHz): δ 4.08 (m, 2H, 2), 4.65 (d, 1H, J = 3.5 Hz, 3), 5.07 (s, 2H, 8), 
5.52 (d, 1H, J = 3.5 Hz, 4), 6.72 (d, 1H, J = 8.5 Hz, 7), 7.30 (t, 1H, J = 8.5 Hz, 10), 7.50 (m, 3H, 
6, 9), 7.76 (s, 1H, 5). Note: 1 protons were under H2O peak and tabulated values reflect those of 
desired product from within a spectra containing starting material as well.
HRMS (ESI) calcd (M+H)+: 572.9112, found: 572.9091. 
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(3aR,5R,6S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d]
[1,3]dioxol-6-yl 3-(4-oxo-2-thioxothiazolidin-3-yl)propanoate (2-25)
O SN
S
OHO
DCC, DMAP
DCM, rt
2-25
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O
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A flame-dried 15 mL round-bottom flask under N2(g) was charged with dichloromethane (1.3 
mL, anhydrous) and isopropylidene-protected glucose (31.7 mg, 0.12 mmol, 1.0 equiv.). Next, 
rhodanine propionic acid (50 mg, 0.24 mmol, 2.0 equiv.) and N,N’-dicyclohexylcarbodiimide 
(DCC, 30.2 mg, 0.15 mmol, 1.2 equiv.) were added, followed by dimethylaminopyridine 
(DMAP, 3.0 mg, 0.02 mmol, 0.2 equiv.). The reactions was allowed to stir at room temperature 
for 2 hours until the glucose starting material was consumed. The reaction was filtered, rinsing 
with dichloromethane, and the filtrate was concentrated in vacuo to yield a yellow residue, which 
was purified via column chromatography (1-3% methanol in dichloromethane) to yield the 
desired product as a colorless foam (43 mg, 79%).
1H-NMR (CDCl3, 500 MHz): δ 1.32 (s, 6H, 1), 1.41 (s, 3H, 1), 1.52 (s, 3H, 1), 2.76 (m, 1H, 7), 
3.98-4.02 (m, 3H, 2, 9), 4.08 (m, 1H, 2), 4.18 (m, 2H, 3, 4), 4.3 (t, 2H, J = 8 Hz, 8), 4.55 (d, 1H, 
J = 3.5 Hz, 10), 5.22 (s, 1H, 6), 5.95 (d, 1H, J = 3.5 Hz, 5).
(3aR,5R,6S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d]
[1,3]dioxol-6-yl 3-((Z)-5-(5-chloro-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)propanoate (2-26)
SN
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2-26 was prepared from 2-25 and 2-7 following general procedure. Product was a flaky brown 
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solid.
1H NMR (DMSO-d6): δ 1.21 (s, 6H), 1.37 (s, 6H), 1.96 (m, 2H), 2.74 (m, 2H), 3.84-4.03 (m, 
2H), 4.26 (d, 3H), 4.37 (d, 1H, J = 3 Hz), 5.07-5.11 (m, 1H), 5.24 (s, 2H), 5.77 (d, 1H), 6.97 (br 
s, 1H), 7.40 (t, 1H, J = 7.5 Hz), 7.48 (d, 2H, J = 8 Hz), 8.31 (s, 1H).
3,5-dichloro-N-(3-chloro-4-(naphthalen-2-yloxy)phenyl)-2-hydroxybenzamide, 6a  
Prepared according to reported procedure: Steffen J. D. et al. J Med Chem 2011, 54, 5403-5413.
1H NMR (DMSO-d6): δ 12.42 (bs, 1H), 10.83 (bs, 1H), 8.07 (s, 2H), 7.99 (d, 1H, J = 9.0 Hz), 
7.93 (d, 1H, J = 8.0 Hz), 7.83 (d, 1H, J = 11.5 Hz), 7.84 (s, 1H), 7.70 (dd, 1H, J = 9.0, 2.5 Hz), 
7.50 (t, 1H, J = 7.5 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.33 (dd, 1H, J = 9.0, 2.0 Hz), 7.29 (d, 1H, J = 
9.0 Hz), 7.26 (d, 1H, J = 2.0 Hz).
HRMS (ESI) calcd (M+H)+ for C23H14Cl3NO3, 458.0118; found, 458.0125.
N
H
Cl
Cl
OH
O O
Cl
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Chapter 3: Efforts Towards New PARG Inhibitor Scaffolds
 Due to the limitations of both ADP-HPD and the RBPIs as PARG inhibitors, we explored 
whether new classes of PARG inhibitors could be discovered using a variety  of computational 
methods.
3.1 Lead hopping searches for ADP-HPD-like compounds 
 We were inspired by a report from the Churchill group1  to use lead hopping to search 
virtual libraries for ADP-HPD-like compounds. The Churchill group  reported the use of 
OpenEye lead hopping software to identify  a potent probe of the signaling molecule NAADP 
(nicotinic acid adenine dinucleotide phosphate). By using NAADP in different low-energy 
conformations as their query molecule and comparing it to the three-dimensional shape and 
electrostatic distribution of compounds from a large virtual library, they were able to identify  a 
small molecule, Ned-19 (Figure 3.1), which specifically  blocks NAADP signaling in a variety  of 
contexts. This approach relies upon the idea that binding of a small molecule to a protein occurs 
due to shape (or volume) complementarity and favorable electrostatic interactions between the 
two binding partners. By identifying compounds with similar shape and electrostatics as a known 
ligand, one should be able to find a compound that binds in a similar manner.
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Figure 3.1. Structures of NAADP and Ned-19.
 Due to the high degree of structural similarity between ADP-ribose/ADP-HPD and 
NAADP, we hypothesized that  a similar strategy could be successful for our purposes. Thus, we 
employed lead hopping searches on a number of different virtual libraries using ADP-HPD as the 
query molecule. From these results, a selection of the top-ranked compounds were obtained and 
tested for PARG inhibition.
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3.1.1 ZINC library
 The ZINC library is a publicly available database of commercially-available small 
molecules developed by the Shoichet lab at the University of California, San Francisco.2,3  The 
ZINC database currently contains over 35 million compounds which can be searched and 
downloaded from the ZINC website according to user-determined parameters. Additionally, pre-
constructed subsets of the ZINC database are available for immediate download and the key 
subset for our purposes is the Drugs Now subset. These compounds have been filtered for drug-
like properties according to Lipinski’s rules (e.g. molecular weight less than 500, polar surface 
area less than 150, etc)4 and for immediate availability  for purchase. At the time of our use, this 
subset contained around 6.2 million compounds, but with continual updating it now contains 7.4 
million compounds.5  This set of compounds was particularly  attractive to us due to its 
commercial availability and its large selection of compounds with the drug-like features that we 
hoped would give us the best chance of finding a drug-like cell-permeable PARG inhibitor.
 Using ADP-HPD as the query molecule and the ZINC Drugs Now virtual library, a series 
of OpenEye programs were used to generate a ranked list  of compounds with shape and 
electrostatics similar to ADP-HPD. In our first search, we followed Churchill’s example and 
represented ADP-HPD with protonated phosphate groups (query A, Figure 3.2) 
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Figure 3.2. Query molecules used for lead hopping searches of virtual libraries for ADP-HPD -like compounds.
First, the program OMEGA6 was used to generate 100 low-energy conformers of each database 
molecule, to ensure a large diversity of structures are considered, and 40 low-energy conformers 
of ADP-HPD, to obtain a good diversity  of query conformations while keeping the search time 
reasonable (Figure 3.3). Next, the program ROCS7  was used to conduct shape comparisons 
between each ADP-HPD conformer and each library conformer, generating a list of the top 2,000 
shape-matched conformers ranked by their shape scores (0 to 1, where 0 is no shape similarity 
and 1 is identical shape). This list  was then taken through the program EON,8  which compared 
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the electrostatics of each of the 2,000 conformers to the electrostatics of the matched ADP-HPD 
conformer.  
ADP-HPD
ZINC 
6.2 million
OMEGA
40 conformations
100 conformations
of each compound
ROCS
matched
conformations
Top 2000 ranked
compounds
EON
Top 100 ranked
compounds
matched
conformations
Figure 3.3. Flow-chart of lead hopping steps and OpenEye programs.
 A list of 200 top compounds was generated, with the compounds ranked according to 
their electrostatics scores (-1 to 1, where 1 is a perfect electrostatics match and -1 is completely 
opposite electrostatics). Based on the electrostatics rankings and their availability  from 
commercial sources, 29 of the top compounds, named the E-series, were ordered (Figure 3.4). 
Since we hoped to identify compounds that not only had a similar shape but also similar charge 
distribution as ADP-HPD, we followed-up  with the electrostatics rankings as these were 
determined on the top shape-matched structures only. Many of the other top compounds were 
either prohibitively expensive or only  available upon requests for their synthesis, thus they were 
not purchased for testing. Inspection of these structures reveals that there are a few sets of similar 
structures, such as E1, E2, E5, E6, E21 and E30, which all contain a common tetrazole-amide 
core with varying cyclic groups on either side, or E8, E9, and E10, which consist of a common 
benzimidazole and oxazole-containing core with varying fluorine and methoxy substitution. 
Additionally, the structures are mostly linear overall as would be expected when searching with a 
linear query such as ADP-HPD, and the compounds contain only positive charges and no formal 
negative charges. The lack of formal negative charges is likely due to the protonated 
representation of the ADP-HPD phosphates in the query structure.
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Figure 3.4. Purchased compounds from ZINC database search with ADP-HPD query A. Each compound is labeled 
with its ranking and ZINC ID number.
 These top compounds were tested initially at  100 µM  for PARG inhibition in vitro 
(Figure 3.5A). A few compounds, E1, E6, and E18, displayed some activity, but upon retesting at 
a range of concentrations none inhibited PARG (Figure 3.5B). Thus, these primary  hits were 
determined to be false positives.
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Figure 3.5. A) Test of E-series compounds PARG inhibition in 32P-PAR degradation assay, compounds used at a 
final concentration of 100 µM; B) Re-test of selected compounds up to 300 µM.
  Next, the same lead hopping search protocol was carried out on the same ZINC Drugs 
Now subset  with query  B (Figure 3.2). We hypothesized that the deprotonated and negatively 
charged phosphates in query B would more faithfully represent the charge distribution of ADP-
HPD and yield better results. The compounds were ranked by electrostatics and 9 compounds 
(named the D-series) were obtained and tested for inhibition of PARG in vitro at  300 and 625 
µM (Figure 3.6). 
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Figure 3.6. Structures of D-series compounds and assessment for in vitro PARG inhibition.
 None of the tested D-series compounds inhibited PARG up  to 625 µM. One explanations 
for the lack of inhibitors found by the initial lead hopping search, is that the database used could 
simply  have not contained a suitable molecule, especially  since most drug-like molecules are 
smaller than ADP-HPD and few contain negative charges. As NAADP is similar to ADP-HPD, 
we hoped that the approach which identified a specific NAADP probe would yield similarly 
successful results when applied towards PARG inhibition. Unfortunately, suitable PARG 
inhibitors were not identified when searching the commercially available ZINC library with this 
technique.
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3.1.2 UIUC HTSF libraries
 Since many  of the compounds contained within in the High Throughput Screening 
Facility  at the University  of Illinois at Champaign-Urbana are not commercially  available, but 
are easily accessible to our lab, we carried out lead hopping searches against all three HTSF 
libraries (Chembridge Microformat, Marvel, and HTSF libraries). For these searches we utilized 
ADP-HPD (query B) as the query  molecule because we believed that more accurately 
representing the charge of the diphosphate was important for identifying compounds most 
similar to ADP-HPD.
3.1.2.1 I-series
 The commercial Chembridge Microformat library, which contains approximately 150,000 
compounds, was searched using the same parameters as before, and the top  30 compounds when 
ranked by electrostatics, named the I-series, were cherry-picked from the HTSF screening plates 
(Figure 3.7). 
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Figure 3.7. Structures of top 30 I-series Chembridge compounds.
Each compound was tested in the in vitro PARG assay  at 300 µM and no inhibition was observed 
(Figure 3.8).
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Figure 3.8. In vitro assessment of top 30 I-series compounds at 300 µM for inhibition of PARG.
 No primary hits were identified using the lead hopping approach on the HTSF 
Microformat Chembridge library.
3.1.2.2 M-series 
 The Marvel library, which consists of over 10,000 synthetic compounds collected from 
the chemistry laboratories at UIUC throughout its history, was also searched using the same 
protocol. Due to the uniqueness of the library, the top 100 compounds when ranked by 
electrostatics were investigated for activity (Table 3.1).
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M"series'
Rank Marvel'Name
Plate'and'
Well'Location
Electrostatics'
Score
M1 M91 1K6 0.592
M2 M1460 4H23 0.579
M3 M784 3B4 0.554
M4 M8446 23B23 0.541
M5 M1449 4M22 0.533
M6 M3432 10L8 0.529
M7 M3448 10L9 0.524
M8 M8449 23 E 23 0.522
M9 M3463 10K10 0.522
M10 M8683 24O14 0.51
M11 M8127 22A22 0.501
M12 M3747 11G5 0.498
M13 M1626 5N10 0.489
M14 M1953 6E 8 0.489
M15 M331 1M21 0.485
M16 M3439 10C9 0.481
M17 M4079 12I17 0.48
M18 M8978 25F10 0.474
M19 M8946 25F8 0.472
M20 M3562 10O16 0.466
M21 M4703 13C19 0.458
M22 M100 1D7 0.458
M23 M1430 4J21 0.458
M24 M821 3G6 0.457
M25 M3712 11D3 0.457
M26 M1428 4H21 0.456
M27 M1250 3P23 0.456
M28 M7634 21F18 0.453
M29 M1826 5F23 0.451
M30 M8067 23B16 0.443
M31 M3146 10N6 0.442
M32 M8065 23P15 0.441
M33 M3462 10J10 0.432
M34 M7829 22I7 0.43
M35 M7510 21J10 0.429
M36 M3861 11I12 0.428
M37 M4457 13M3 0.46
M38 M245 1F16 0.428
M39 M87 1G6 0.425
M40 M3504 10D13 0.424
M41 M3433 10G9 0.423
M42 M604 2N15 0.423
M43 M4009 12C13 0.42
M44 M4743 13K21 0.419
M45 M8348 23P16 0.417
M46 M3754 11N5 0.415
M47 M1285 4C3 0.411
M48 M4464 13A4 0.41
M49 M7606 21J16 0.406
M50 M2963 9G2 0.404
M"series'
Rank Marvel'Name
Plate'and'
Well'Location
Electrostatics'
Score
M51 M1625 5M10 0.402
M52 M8069 23D16 0.398
M53 M7533 21A12 0.395
M54 M34 1B3 0.394
M55 M8066 23A16 0.393
M56 M3743 11C5 0.389
M57 M8537 24M5 0.389
M58 M4635 13O14 0.387
M59 M7165 20A12 0.381
M60 M3566 10B17 0.38
M61 M3513 10M13 0.378
M62 M4505 13M6 0.377
M63 M3559 10K16 0.377
M64 M4555 13O9 0.368
M65 M3447 10K9 0.365
M66 M3755 11O5 0.364
M67 M4781 14A1 0.363
M68 M1629 5A11 0.361
M69 M1975 6K9 0.358
M70 M3507 10G13 0.352
M71 M3101 10A4 0.351
M72 M3563 10O16 0.35
M73 M4768 13D23 0.35
M74 M7164 20P11 0.349
M75 M956 3O14 0.346
M76 M86 1F6 0.345
M77 M4474 13N4 0.337
M78 M8351 23C17 0.334
M79 M8489 24M2 0.334
M80 M7589 21I15 0.327
M81 M3163 10O7 0.326
M82 M3708 11P2 0.321
M83 M8687 24C15 0.319
M84 M8340 23H16 0.315
M85 M4823 6F18 0.313
M86 M6553 18M19 0.308
M87 M63 1O4 0.298
M88 M955 3N14 0.287
M89 M4739 13G21 0.28
M90 M8148 22F23 0.279
M91 M3080 10L2 0.272
M92 M805 3G5 0.269
M93 M8975 25C10 0.261
M94 M6034 17N22 0.259
M95 M4811 14O2 0.258
M96 M6510 18B17 0.258
M97 M3749 11I5 0.257
M98 M1024 4B11 0.249
M99 M7792 22D5 0.243
M100 M5289 15M8 0.242
Table 3.1. Top 100 M-series compounds ranked by electrostatics.
 The electrostatics scores for the top  100 compounds were all positive and ranged from a 
modest 0.242 to a fairly  good 0.592 (Table 3.1). These compounds were then tested at 300 µM or 
625 µM for PARG inhibition (Figure 3.9 and 3.10). 
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Figure 3.9. 32P-PARG assay of M1-M36 at 300 µM and M37-M54 at 625 µM
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Figure 3.10. 32P-PARG assay of M55-M100 at 625 µM.
Fourteen compounds were identified as primary hits, M12, M21, M27, M29, M37, M43, M48, 
M52, M63, M71, M73, M74, M77 and M85 (Figure 3.11). A number of these primary hit 
compounds had been reported previously in the literature and some had been tested for biological 
activity. Compound M85 is aurintricarboxylic acid and is known to polymerize in water, forming 
a stable free radical that inhibits protein-nucleic acid interactions, and it has been shown to be a 
potent inhibitor of the AIF-DNA interaction,9  as well as ribonuclease and topoisomerase II 
through this mechanism.10 Due to our desire to eliminate promiscuous inhibitors and concentrate 
only on those compounds which may inhibit PARG specifically, we did not further investigate 
the activity of M85. Compound M12 is a known fabric dye called Mordant Brown 33. M21 is a 
heme breakdown product  called billirubin, which is also known to have antioxidant properties.11 
M63 was reported to be a moderately potent HIV zinc finger inhibitor12  while M71 was reported 
to be a weak inhibitor of AMP deaminase13 and has also been used as a dye.14 
 Two of the primary hits were first reported by groups at UIUC. M37 was reported by the 
lab of Roger Adams in 193015  and was later determined to be a weak inhibitor of HIV 
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integrase.16  M29 is the natural product spectomycin A1 and was isolated by the Rhinehart group, 
who determined that similar natural products had antiviral and antibacterial activity.17 
Additionally, M73 is folic acid, a water soluble vitamin and M43 is gossypolonic acid, the acid 
version of the known pro-apoptotic aldehyde compound gossypol. In general, M-series primary 
hits were rich in aryl groups and carboxylic acids, with some compounds containing multiples of 
each.
O
ONO2
NO2
O
O
O2N NO2
O2N NO2
M37
OH
OH
MeO O
HO
HO
MeMe
OH
MeOH
Me Me
OO
M43
OO
O2N
O2N
O2N
O2N
NO2
NO2
O
O
M48
O
tBu
O
N
H
O
O
M52
SS
NH2O
O
H2N
O
O
HIV zinc finger inhibitor
S OO
O
OH
N
H M71
dye, AMP deaminase inhibitor
OH
N
N N
N N
H
O
N
H
O
O
OO
H2N M73
OH
O
O
O
OHO
M74
O
O
O
O
O2N
NO2
NO2
O2N
NO2
NO2
M77
OH
O
O
O
O
O
O
O OH
M85
S
O
O ONNO2N
OH
H2N NH2
M12
O
NH HN
HN
NH
O
Me
Me
O
O
O
O
Me
Me
M21
OO
M27
OMe O
OH
Me
O2C
OMe
OH
M29
Billirubin Spectomycin A1Mordant Brown 33
Gossypolonic acidHIV Integrase inhibitor
Folic Acid
M63
Aurintricarboxylic acid
Figure 3.11. Structures of primary hit M-series compounds.
The solid stocks of compounds M12, M21, M27, and M29 were obtained from the Marvel 
Storeroom in Noyes Laboratory, fresh DMSO solutions were prepared and each compound was 
tested at a range of concentrations up to 625 µM (Figure 3.12). 
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Figure 3.12. Dose-response assessment of M12, M21, M27, and M29 in 32P-PAR assay.
 Only M12 and M27 displayed dose-dependent inhibition of PARG, although neither was 
able to inhibit below 200 µM. Next, these two compounds were tested directly for their 
detergent-dependence by using either 0% or 0.1% Triton X-100 in phosphate buffer within the 
standard 32P-PAR assay (Figure 3.13). Detergent-dependent inhibition is a sign of aggregation, 
where compounds form large structures which can non-specifically  adsorb to proteins and inhibit 
enzymes.18 This type of aggregation is somewhat sensitive to changes in buffer salts and normal 
variation between samples, which can also lead to inconsistent inhibition (lack of normal dose-
response).19
M12 M12 M27M27
100 200 300 100 200 300 100 200 300 100 200 30050 50 50 50
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DMSO
µM cmpd
DMSO
32P-PAR
ADP
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Figure 3.13. Assessment of detergent-dependent inhibition of PARG by M12 and M27.
 Only M12 displayed detergent-independent inhibition of PARG, but the change in 
potency of M12 between assays (50 vs 200 µM as lowest inhibitory  concentration in Figures 
3.12 and 3.13 respectively) was concerning. Additionally, the non-dose-dependent inhibition by 
M27 in either buffer suggested that it was not a specific inhibitor. Thus, M12 was tested for 
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inhibition of ß-lactamase, an unrelated enzyme whose inhibition can be used as a measure of 
promiscuity. When tested for inhibition of ß-lactamase in the presence and absence of detergent, 
M12 displayed inhibition only  in its absence (Figure 3.14), indicating that it readily forms 
aggregates and that these can non-specifically inhibit enzymes. Congo Red, a known aggregator, 
was included as a control and displays very robust aggregation, with persistent  inhibition at 100 
µM (Figure 3.14).
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Figure 3.14. Inhibition of ß-lactamase by M12 and aggregator control compound Congo Red with and without 
Triton X-100 detergent.
 Since compounds M37-M100 were initially  assessed at 625 µM, we carried out another 
analysis of these primary hits from this set of compounds at lower concentrations. Additional 
DMSO stocks of compounds M37, M43, M48, M52, M63, M71, M74, and M77 were obtained 
from the HTSF and each was assessed at 100 and 300 µM for PARG inhibition in vitro (Figure 
3.15).
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Figure 3.15. Assessment of 9 M-series primary hit compounds in 32P-PAR assay.
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Two compounds, M63 and M73 displayed inhibition at 100 µM, and each was tested for 
detergent-dependence in the in vitro 32P-PAR assay (Figure 3.16). 
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M63 M73
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0% Triton-X 0.1% Triton-X
-PARG +PARG+PARG -PARG +PARG
DMSO
32P-PAR
ADP
-ribose
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Figure 3.16. Detergent-dependence of M63 and M73 in 32P-PAR assay.
Neither compound was able to inhibit PARG in the presence of detergent nor did they show 
consistent inhibition, indicating that their inhibition of PARG was not selective and may have 
been due to the formation of aggregates. Thus, no promising lead compounds were identified 
from a lead hopping search of the Marvel library.
3.1.2.3 H-series 
 The HTSF library consists of approximately 4,700 compounds submitted by synthetic 
laboratories at UIUC and other universities such as Massachusetts Institute of Technology, 
University  of Pittsburgh, and University of Texas at Austin. A lead hopping search of this library 
was carried out using the same previously-described settings, employing ADP-HPD (query B) as 
the query molecule. The top compounds were ranked by their electrostatics scores and the top 
100 compounds from this list  (Table 3.2) were cherry-picked and tested at 625 µM for inhibition 
of PARG (Figure 3.17 and 3.18). 
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H"series'
Rank HTSF'Name
Plate'and'
Well'Location
Electrostatics'
Score
H1 H3143 10G11 0.539
H2 H632 2H22 0.533
H3 H4284 14P5 0.53
H4 H208 1P15 0.514
H5 H2892 9L15 0.509
H6 H2867 9C14 0.492
H7 H3122 10B10 0.492
H8 H3119 10O9 0.49
H9 H3103 10O8 0.484
H10 H1203 4C18 0.484
H11 H3146 10J11 0.482
H12 H1207 4J17 0.482
H13 H197 1E15 0.473
H14 H3136 10P10 0.473
H15 H3140 10D11 0.471
H16 H3817 12M16 0.465
H17 H198 1F15 0.464
H18 H2693 9E3 0.463
H19 H433 2A10 0.458
H20 H3135 10O10 0.456
H21 H3748 12H12 0.452
H22 H199 1G15 0.447
H23 H61 1M6 0.447
H24 H435 2C10 0.446
H25 H4437 14I15 0.446
H26 H1211 4K18 0.443
H27 H3943 13K4 0.443
H28 H1688 6H8 0.442
H29 H4431 14C15 0.44
H30 H4411 14O13 0.439
H31 H4302 14B7 0.438
H32 H4323 14G8 0.437
H33 H628 2D22 0.436
H34 H2777 9H8 0.435
H35 H3120 10P9 0.435
H36 H627 2C22 0.434
H37 H3906 12F22 0.434
H38 H196 1D15 0.433
H39 H437 2E10 0.433
H40 H4214 13J21 0.432
H41 H3138 10B11 0.431
H42 H436 2D10 0.427
H43 H4327 14K8 0.427
H44 H629 2E22 0.425
H45 H428 2L9 0.425
H46 H294 1F21 0.425
H47 H594 2B20 0.42
H48 H402 2B9 0.419
H49 H596 2D20 0.418
H50 H620 2L21 0.417
H"series'
Rank HTSF'Name
Plate'and'
Well'Location
Electrostatics'
Score
H51 H597 2E20 0.416
H52 H3104 10P8 0.415
H53 H2776 9I8 0.414
H54 H416 2P8 0.413
H55 H595 2C20 0.408
H56 H3144 10H11 0.406
H57 H2800 9P9 0.405
H58 H3823 12C17 0.405
H59 H1482 5J15 0.403
H60 H4295 14K6 0.398
H61 H4441 14M15 0.397
H62 H4240 14D3 0.394
H63 H440 2H10 0.394
H64 H443 2K10 0.394
H65 H593 2A20 0.389
H66 H601 2I20 0.387
H67 H3145 10I11 0.387
H68 H4304 14D7 0.386
H69 H244 1D18 0.386
H70 H4435 14G15 0.385
H71 H442 2J10 0.385
H72 H4439 14K15 0.385
H73 H429 2M9 0.385
H74 H4403 14G13 0.382
H75 H3118 10N9 0.382
H76 H1971 12H17 0.382
H77 H2801 9A10 0.381
H78 H2803 9C10 0.381
H79 H430 2N9 0.381
H80 H4373 14I11 0.379
H81 H4533 14I21 0.378
H82 H4379 14O11 0.376
H83 H556 2L17 0.376
H84 H4473 14M17 0.375
H85 H4306 14F7 0.373
H86 H431 2O9 0.373
H87 H438 2F10 0.373
H88 H4252 14P3 0.372
H89 H441 2I10 0.371
H90 H4280 14L5 0.37
H91 H603 2K20 0.369
H92 H444 2L10 0.368
H93 H4537 14M21 0.368
H94 H439 2G10 0.367
H95 H551 2G17 0.367
H96 H618 2J21 0.367
H97 H4574 15B4 0.366
H98 H4588 15P4 0.364
H99 H2410 15N13 0.362
H100 H2799 9O9 0.358
Table 3.2. Ranking, locations, and electrostatic scores of top 100 H-series compounds
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Figure 3.17. Test of H1-H48 at 625 µM in 32P-PAR degradation assay.
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Figure 3.18. Test of H49-H100 at 625 µM in 32P-PAR degradation assay.
Only 7 compounds displayed at least partial inhibition of PARG at 625 µM (Figure 3.19). Out of 
the seven primary hit compounds identified, some could be quickly eliminated from 
consideration based on prior experience with them within our laboratory. 
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Figure 3.19. Primary hit compounds from compounds identified from HTSF library.
Compound H2 was synthesized during structure-activity  relationship studies of a potent 
apoptosis-inducing compound known as 4150, in which the carboxylic acids are replaced by 
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aldehydes.20  Since H2 is very structurally similar to 4150 and has low-micromolar activity 
against cancer cells, it  likely induces cell death in a manner similar to 4150, and thus it was not 
investigated further. Compounds H33, H47, H49, and H51 are all RBPI-type compounds, which 
were discussed in Chapter 2 and thus were not further considered here. H69 was initially 
synthesized in our lab during efforts towards developing inhibitors of vPARP, although this 
specific analog did not display any  activity  in PARP assays.21  H69 and H95 were both retested at 
100 and 300 µM for PARG inhibition (Figure 3.20).
H69 H95
300 100 300100
-PARG +PARG+PARG
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Figure 3.20. Assessment of H69 and H95 at 100 and 300 µM in the 32P-PAR degradation assay.
Since both H69 and H95 behaved similarly at lower concentrations, displaying partial inhibition 
at 100 µM and full inhibition at 300 µM, we carried out two tests of specificity. The first was 
inhibition of ß-lactamase, in which H95 was shown to have significant detergent-dependent 
activity (Figure 3.21). Given the dye-like structure of this molecule, this result is not surprising.  
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Figure 3.21. Inhibition of ß-lactamase enzymatic activity by H69, H95, and known aggregator Congo Red.
Next, H69 was assessed for detergent-dependent inhibition of PARG, and in this assay H69 
displayed significant detergent-dependence, as well as a lack of dose-response in the absence of 
detergent (Figure 3.22). 
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Figure 3.22. 32P-PAR degradation assay for PARG inhibition in the presence and absence of detergent.
 Although a number of potentially promising primary hit compounds were identified from 
lead hopping searches of all three in-house compound libraries, none of them were able to pass 
tests for consistent dose-dependent inhibition, detergent-independence, and specificity for PARG 
over unrelated enzymes.
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3.1.3 Broad Institute ChemBank library
 The Broad Institute has a unique screening collection containing 229,000 compounds and 
the virtual form of this library  is open to the public.22  Thus, this library was searched using the 
same lead hopping search settings, with ADP-HPD (query B) as the query molecule. Out of the 
top 110 compounds (named the CB-series), when ranked by electrostatics, 35 could be purchased 
from the Broad Institute as concentrated stocks in DMSO (Table 3.3).
CB#series(
Rank
ChemBank(
Number
Electrostatics(
Score
CB1 3212939 0.594
CB3 3630382 0.545
CB9 3629990 0.525
CB14 1868767 0.519
CB17 3044420 0.512
CB22 1740749 0.488
CB28 1663793 0.479
CB30 1624 0.478
CB39 3036611 0.455
CB44 1243149 0.451
CB46 3629180 0.446
CB49 3629732 0.443
CB51 3632943 0.440
CB53 3629525 0.439
CB57 1556837 0.429
CB61 3064830 0.421
CB63 3063528 0.415
CB64 1614161 0.414
CB#series(
Rank
ChemBank(
Number
Electrostatics(
Score
CB73 1000097 0.382
CB74 3558351 0.381
CB75 3213852 0.377
CB76 3633038 0.376
CB78 3035643 0.368
CB79 3023688 0.365
CB80 3031115 0.364
CB81 3031443 0.356
CB83 3121566 0.342
CB88 3632160 0.331
CB89 3210637 0.329
CB92 3030008 0.329
CB101 3040464 0.299
CB102 3628825 0.298
CB106 72 0.285
CB107 3119700 0.284
CB109 3625956 0.265
Table 3.3. Ranking, ChemBank numbers, and electrostatics scores for all 35 purchasable CB-series compounds.
Since the DMSO stocks were at varying concentrations, each compound was tested at the highest 
concentration possible by employing the stock solution directly  in the in vitro PARG assay. All 
35 compounds were tested in the 32P-PAR assay for inhibition of PARG (Figure 3.23) at 
concentrations ranging from 600 - 800 µM.
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Figure 3.23. Assessment of high concentrations of top-ranked CB-series compounds in 32P-PAR degradation assay.
 Five compounds were identified as primary hits: CB64, CB14, CB79, CB89, and CB107 
(Figure 3.24). Each primary hit compound was re-tested at 100 and 300 µM (Figure 3.24).
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Figure 3.24. Structures of five primary hit CB-series compounds and their assessment at 100 and 300 µM in the 32P-
PAR degradation PARG inhibition assay.
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Only CB79 and CB107 displayed any inhibition at these concentrations, with CB107 being the 
most potent of the two. Next, both compounds were assessed in phosphate buffer in the presence 
and absence of 0.1% Triton X-100 detergent (Figure 3.25).
CB79 CB107
200 400 200 400
CB79 CB107
200 400 200 400
0% Triton X-100 0.1% Triton X-100
-PARG +PARG+PARG -PARG +PARG
DMSO
32P-PAR
ADP
-ribose
µM cmpd
DMSO
Figure 3.25. Assessment of PARG inhibition by CB79 and CB107 in the presence and absence of detergent in the 
32P-PAR degradation assay.
Here we observed that CB79’s activity  was very sensitive to the addition of detergent, indicating 
that it is probably an aggregator and inhibits PARG through a non-specific mechanism. In 
contrast, CB107 maintained most of its activity  in the presence of detergent, and the decreased 
inhibition at 200 µM  can be attributed to the small boost in enzymatic efficiency caused by  the 
detergent. However, the structure of CB107 makes it  unattractive for further investigation as an 
in vivo PARG inhibitor. The dual carboxylic acid nature lowers the ability for the compound to 
permeate the cell membrane and the exocyclic olefin between the furan and 4-oxothiazole is 
potentially reactive. Reactivity is a particular concern as cells can have high concentrations of 
thiols which readily react  through conjugate addition to olefins such as the one found in CB107. 
Thus, we decided not to further pursue CB107 any further as a potential PARG inhibitor.
3.1.4 Assessment of lead hopping approach
 The failure of lead hopping with ADP-HPD to provide any attractive compounds as new 
lead PARG inhibitors may be due to a number of factors. In comparison to many published lead 
hopping efforts, ADP-HPD is a difficult query, as it is large, linear, and contains many formal 
charges, which are difficult  to match using most compound libraries. Additionally, without 
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knowing the bound conformation of ADP-HPD, a collection of 40 low-energy conformations 
were used as the query. The bound conformation of ADP-HPD may or may not have been 
represented in this collection of conformers, or there could have been few compounds that 
matched well with the most relevant conformer. Most publications that compare the performance 
of lead hopping programs measure success by enrichment of active compounds into the top 2-5% 
of the ranked list. When starting with libraries that contain 6,200,000 compounds, purchasing 
and testing even the top 2% of this library (124,000 compounds) is implausible. Thus, even if the 
search performed well by current standards, it may not have performed well enough for active 
compounds to be detected by our limited ability to test compounds experimentally due to the low 
throughput nature of the assay.
3.2 Pyrophosphate mimics of ADP-HPD
 Since the main feature preventing wider use of ADP-HPD is the cell-impermeable 
diphosphate group, we explored whether the use of any known phosphate mimics within the 
ADP-HPD framework could provide a cell-permeable ADP-HPD-like molecule. Due to the 
variety of phosphate mimics available, including perfluoroaryls, sulfonamides, squaric acids, and 
many others,23  we used lead hopping searches to determine which functional groups best 
approximate a diphosphate within the context of the ADP-HPD structure. 
3.2.1 Virtual library of diphosphate replacements
 To this end, a small virtual library was created in which different phosphate replacements 
were substituted for the diphosphate in ADP-HPD (Figure 3.26). The structures of the phosphate 
replacement groups varies from straightforward structures such as sulfonamides and carboxylic 
acids to less intuitive groups such as the squaric acids. These functional groups were chosen 
based on their successful use as mono-phosphate replacements and the feasibility of adapting 
them for internal positions. Spacer length and functional group location were varied to allow for 
different orientations of the key  portion of the phosphate replacement. Included in this library 
were 15 ADP-HPD derivatives with aliphatic linkers between the adenosine and the pyrrolidine, 
previously prepared by Dr. Amanda Nottbohm, which are known to be inactive against PARG.24 
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Figure 3.26. Virtual library of ADP-HPD-like structures. Box encloses compounds previously synthesized and 
determined to be inactive against PARG by Dr. Amanda Nottbohm.
 To determine which ADP-HPD analogs should be synthesized and tested for PARG 
inhibition, a lead hopping search was undertaken using this library  (named the C-series). Here 
OMEGA was used to generate up to 100 conformers of each library compound and 40 
conformers of ADP-HPD either with or without protonated phosphates (query A and query B). 
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Next, ROCS was used to compare the three-dimensional shapes and volumes of the query 
conformers and the library conformers. All of the results from ROCS were input into EON and 
the matched conformers were ranked by comparison of electrostatics. 
 Comparing the number of known inactive compounds in the top ten molecules as ranked 
by their combination score, the differences in query molecules are clear. Query A, returned 7 
known inactive compounds in the top  10, while query B, which better represents the charge of 
the phosphates, returned no known inactive compounds (Table 3.4). Thus we chose to pursue a 
well-ranked compound from the query B search results.
           Query B                                                  Query A
 
Rank Name EON*Score
1 C24 0.713
2 C15 0.695
3 C22 0.355
4 C5 0.272
5 C8 0.262
6 C4 0.259
7 C23 0.246
8 C11 0.236
9 C7 0.221
10 C1 0.217
Rank Name EON*Score
1 C25 0.557
2 C27 0.509
3 C9 0.498
4 C30 0.492
5 C35 0.429
6 C32 0.427
7 C21 0.35
8 C1 0.3
9 C16 0.287
10 C36 0.281
Table 3.4. EON ranking of top C-series compounds using ADP-HPD query B or query A.
3.2.2 Synthesis of bis-sulfonamide ADP-HPD
 A three-dimensional overlay  of ADP-HPD and C5 show how closely  sulfonamide groups 
approximate the position of the phosphate groups (Figure 3.27).  
Figure 3.27. Left - 3D overlay of ADP-HPD query B and C5; Right - structure of C5.
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The high degree of overlap with ADP-HPD suggested that C5 might be able to interact in a 
similar manner with PARG. Due to this and its high degree of synthetic feasibility, ADP-HPD 
analog C5 was pursued for synthesis first. The 4-hydroxyl on the pyrrolidine was omitted in this 
initial synthesis as the preparation of enantiopure (2R,3R,4S)-2-(hydroxymethyl)pyrrolidine-3,4-
diol is time-intensive and low yielding.25,26  Removal of the 3-hydroxyl of ADP-HPD results in a 
3-fold loss in potency, and the monohydroxy analog (ADP-HPM) inhibits the catalytic fragment 
of PARG with an IC50 of 3.07 µM.27  Retrosynthetically, C5-H can be constructed by bringing 
together methanedisulfonyl dichloride with protected adenosine and pyrrolidine fragments 
bearing primary  amines, and each fragment can be accessed from an inexpensive commercial 
compound (Figure 3.28)
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Figure 3.28. Retrosynthetic analysis of C5-H.
Preparation of the pyrrolidine amine intermediate was initiated with the conversion of 4-
hydroxyproline to the fully  protected alcohol via the previously reported methyl ester 
formation,28  TBS protection, and sodium borohydride-mediated reduction steps in a high yield 
over 3 steps (Scheme 3.1). Mesylation of the free primary  alcohol allowed for substitution with 
an azide group, which was subsequently reduced to the free primary amine via transfer 
hydrogenation to yield intermediate 3.3 in good yield (Scheme 3.1).
117
NTBSO
NH2
BOC
N
TBSO
N3
BOC
N
TBSO
OH
BOC
N
TBSO
OMe
BOC OH
N
HO
OH
O
1) SOCl2, MeOH;
BOC2O, Et3N
2) TBSCl, imid
NaBH4, CaCl2
MsCl, Et3N,
NBu4N3 Pd(OH)2/C
68%99%
92% (3 steps)
3.2 3.3
3.1
Scheme 3.1. Synthesis of pyrrolidine intermediate 3.3.
Preparation of the adenosine amine intermediate followed a similar sequence as that for 3.3. The 
primary alcohol was converted to the azide via substitution and the primary amine 3.5 was 
accessed via transfer hydrogenation (Scheme 3.2).
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Scheme 3.2. Synthesis of intermediate 3.5.
Both protected intermediates were brought together with methanedisulfonyl dichloride in THF to 
give a low yield of the protected compound (3.6, Scheme 3.3). Removal of the protecting groups 
using TFA gave C5-H as a colorless solid.
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Scheme 3.3. Synthesis of C5-H from 3.3 and 3.5.
With this phosphate-replacement-containing ADP-HPD analog in hand, we assessed the ability 
of C5-H to inhibit PARG in vitro.
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3.2.3 Evaluation of C5-H for PARG inhibition
 The inhibitory activity of C5-H was assessed using the 32P-PAR degradation assay in 
phosphate buffer, with added 0.1% Triton X-100 detergent to prevent aggregation-based 
inhibition. Additionally, since ADP-HPD has significant activity against ARH3, this enzyme was 
also tested at the same time to investigate whether an ADP-HPD analog with a phosphate 
replacement also inhibits ARH3 (Figure 3.29).
-PARG +PARG -ARH3 +ARH3
DMSO DMSO[C5-H] (µM) [C5-H] (µM)
1 25 50 100 500 1 25 50 100 500
ADP-ribose
32P-PAR
Figure 3.29. Evaluation of C5-H activity against PARG and ARH3 in 32P-PAR degradation assay.
Even when employed at very  high concentrations (500 µM), C5-H did not prevent  the PARG- or 
ARH3-mediated degradation of 32P-PAR during a one hour incubation. 
3.2.4 Feasibility of pyrophosphate replacement
 The lack of PARG inhibition by C5-H, which is very structurally similar to ADP-HPD, at 
high concentrations calls into question the ability  of any phosphate-replacement-containing 
ADP-HPD analog to effectively inhibit PARG. Previous work had indicated that non-polar 
neutral linkers were not sufficient to replace the phosphate of ADP-HPD,29 but  the complete lack 
of activity  with polar and phosphate-like sulfonamide groups was surprising. We had based this 
investigation on the hypothesis that the ability to form hydrogen bonds with PARG was the key 
function of the phosphates during binding. Though it  was never published in peer-reviewed 
journal, the Jacobson group reported the assessment of a bisphosphonate analog of ADP-HPD in 
a graduate thesis,30 where they refer to this compound as ADP(Me)-HPD (Figure 3.30).  
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Figure 3.30. Structure of bisphosphonate ADP(Me)-HPD reported by the Jacobson group.
When they measured PARG inhibition using the 32P-PAR degradation assay, the Jacobson group 
observed no inhibition with up to 1 mM of ADP(Me)-HPD. This 1000-fold drop in potency upon 
the replacement of the central phosphate oxygen with a carbon indicates that the phosphates 
function as more than just hydrogen bonding partners.
 Insight into the strong requirement for an intact pyrophosphate in ADP-HPD for 
inhibition can be gleaned from structural studies of PARG with various ligands. Some structural 
biology  groups have suggested that in the enzymatic PARG reaction, the oxocarbenium formed 
after elimination of the (n-1) adenosine hydroxyl is stabilized by  its proximity to the negative 
charge of the distal phosphate group and that  enforcing this conformational association between 
the two groups is key to the activity of PARG (Figure 3.31A).31,32 
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Figure 3.31. A) Stabilization of the enzymatic intermediate oxocarbenium by ionic interactions B) binding of ADP-
HPD utilizes the same stabilizing ionic interaction.
In a similar manner, the stabilization provided by binding of ADP-HPD is likely  due to the strong 
ionic interaction between the positively charged pyrrolidinium and the negatively  charged 
phosphate (Figure 3.31B). The loss of affinity upon weakening or elimination of this ionic 
interaction, by employing a bisphosphonate or a bis-sulfonamide, is consistent with this model.
 Additionally, a role for the diphosphate in the dynamic movements required for initial 
binding of substrate was hypothesized based on attempts to crystallize human PARG with 
smaller substrate-like fragments. Scientists at Astra Zeneca noted: “structures of hPARG26 in 
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complex with adenine containing fragments suggested an intact diphosphate moiety was required 
to achieve complete closure of the phosphate binding loop and thus formation of the ribose’’/
HPD binding site.”31 Given the many experimental observations that an intact diphosphate is 
required for ADP-HPD inhibition and the structural studies suggesting that an ionic interaction 
is critical for high affinity binding, it is unlikely  that further modifications to the pyrophosphate 
of ADP-HPD will yield a potent yet cell-permeable PARG inhibitor. 
3.3 High-throughput docking screens for RBPI-like compounds
 With the continued lack of success from ADP-HPD-focused efforts and the advent of the 
first crystal structures of PARG in the literature, we turned our attention towards using the RBPI/
PARG structure as a launching point for the discovery of new PARG inhibitor scaffolds. 
Specifically, upon receiving the PARG/RBPI-3 structure from the Ahel laboratory,33  we were 
able to utilize structural information on the enzyme-inhibitor interaction to inform our 
computational searches and virtual screens.
3.3.1 UIUC HTSF library with OpenEye FRED
 We first  ran a docking screen of all in-house compound libraries (Marvel, HTSF, and 
Microformat) using the T. thermophila PARG/RBPI-3 protein as the receptor. The docking was 
carried out using OpenEye software, specifically OMEGA for library preparation and FRED34 
for docking. To improve the quality  of docking and utilize information from both the protein 
structure and the RBPI-3 pose, the virtual screen was performed in high-resolution utilizing the 
HYBRID mode of FRED. These settings are described and their performance compared to more 
standard settings in a paper published by OpenEye in 2011.35 Briefly, the HYBRID mode scores 
docked poses of library molecules based not only on how well they complement and bind to the 
protein but also on how well they align with and mimic the pose of the crystallized ligand, or 
RBPI-3 in this case. High-resolution refers to the number of conformers of each ligand searched, 
with 1,000 conformers per ligand referred to as high-resolution, the rotational step size between 
poses during exhaustive searching, with 1.0 A at high-resolution versus of 1.5 at default, and the 
number of poses optimized, with 1,000 poses at high-resolution versus 100 at default settings. 
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When compared to other commonly-used docking programs, FRED HR-HYBRID was often the 
best or second-best performing program.
 The Marvel, HTSF, and Microformat libraries were combined into a single file which was 
processed by OMEGA to generate 1,000 conformers per ligand. Next, a receptor was generated 
using the T. thermophila PARG structure, in which the outer contour of the RBPI-3 pocket was 
decreased from its default size. Then, the ligand conformers were docked into the protein pocket 
using FRED HYBRID in high-resolution mode. When compared with the results from the 
previously  described lead hopping search of the same libraries (see section 3.1), none of the top 
1000 ranked compounds from this docking run were the same as the top  100 compounds 
identified by lead hopping searches. Most of the top compounds were from the Chembridge 
Microformat library, but one HTSF library compound was present in this list.
 The top  100 compounds (named the FI-series, Table 3.5) were cherry-picked from the 
HTSF compound plates and tested for inhibition of PARG at 625 µM in the 32P-PAR degradation 
assay (Figure 3.32).
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FI-series 
rank
Compound 
Name
Plate and Well 
Location
FI1 20862 216H06
FI2 3897 163F18
FI3 26244 236B07
FI4 57736 15O12
FI5 134891 422G06
FI6 111898 374G11
FI7 100466 361I05
FI8 29124 250H17
FI9 135909 425I12
FI10 6576 178H03
FI11 119572 411N03
FI12 133172 417A08
FI13 142330 445N12
FI14 18051 215L07
FI15 148247 464F03
FI16 1813 162A05
FI17 130307 406L16
FI18 1842 162J13
FI19 133156 417I12
FI20 22309 225C13
FI21 29317 246J13
FI22 141420 442B08
FI23 132938 416 E 10
FI24 39719 103L15
FI25 H551
FI26 133890 419O08
FI27 2324 162 E 20
FI28 38112 101G22
FI29 138414 433M10
FI30 136551 427N04
FI31 3620 169H06
FI32 31189 248K16
FI33 57343 14H15
FI34 13298 197D10
FI35 29571 246A06
FI36 131926 415D06
FI37 25717 235C07
FI38 65514 65N22
FI39 136699 428G13
FI40 2336 162M22
FI41 100620 270 E 11
FI42 113755 316 E 19
FI43 130376 406L20
FI44 128468 300B06
FI45 136621 427L14
FI46 144010 450D06
FI47 115150 378 E 20
FI48 107753 367L06
FI49 31207 248P06
FI50 29421 243M14
FI-series 
rank
Compound 
Name
Plate and Well 
Location
FI51 128021 405C10
FI52 123969 391G04
FI53 17296 207C18
FI54 137486 430O12
FI55 42200 105L22
FI56 33598 97J10
FI57 138045 432L11
FI58 106769 367M19
FI59 133326 417K13
FI60 126197 394F08
FI61 124608 392H09
FI62 25198 228N22
FI63 131964 415H13
FI64 24832 230B04
FI65 115605 291F21
FI66 131726 412H16
FI67 99913 359 E 14
FI68 118484 382M07
FI69 118390 382B03
FI70 129114 400K05
FI71 62768 55G12
FI72 129669 301F18
FI73 18019 215F05
FI74 149904 469L21
FI75 2328 162M20
FI76 134455 421M11
FI77 139460 436J06
FI78 128024 405I10
FI79 31220 248J10
FI80 125418 325N21
FI81 129153 302H06
FI82 132728 416C03
FI83 123785 391D03
FI84 116806 292J22
FI85 24596 230P21
FI86 25058 231P16
FI87 131433 301D06
FI88 124353 323D20
FI89 126331 397K15
FI90 24956 231B04
FI91 117056 380N22
FI92 125726 325A12
FI93 28677 242A14
FI94 101487 286H11
FI95 37283 149H10
FI96 37175 101M19
FI97 34909 99L07
FI98 140807 441 E 06
FI99 146548 458J22
FI100 143528 449O08
Table 3.5. Rank, library number, and plate/well location of top 100 compounds identified through FRED HR-
HYBRID docking.
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Figure 3.32. Assessment of top 100 FI-series compounds at 625 µM in the 32P-PAR assay.
Only three compounds, FI4, FI25, and FI58 displayed inhibition of PARG at 625 µM. One 
compound, labelled FI25, is the same as a primary hit compound previously identified in the H-
series (see section 3.1.2) as H95 and was shown to be an aggregator. The remaining two primary 
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hit compounds were further tested for inhibition of PARG at lower concentrations in the presence 
and absence of detergent (Figure 3.33). 
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Figure 3.33. Assessment of FI4 and FI58 at 100 and 300 µM in the presence or absence of detergent.
Both primary hit compounds were rendered inactive by the addition of detergent to the assay 
buffer, indicating that they both relied upon a non-specific aggregation-based inhibition mode. 
Thus, neither compound was further pursued as a PARG inhibitor. In future docking studies we 
chose to use Schrödinger software due to its increased flexibility  when setting parameters at 
various stages.
3.3.2 ZINC library and Schrödinger Glide docking, with 2D and 3D similarity 
 In order to further utilize the PARG/RBPI-3 complex crystal structure, we carried out a 
virtual docking screen of the ZINC Drugs Now subset. Because docking all 6.2 million 
compounds in this subset would take an extremely  long time, we carried out two parallel filtering 
steps prior to docking (Figure 3.34). 
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Figure 3.34. Workflow for virtual screen of ZINC drugs now subset.
The first was 2D similarity  searching, in which an ECFP_2 description, a type of molecular 
fingerprint based on atom connectivity, was generated for RBPI-3 and all compounds in the 
ZINC Drugs Now subset. The ECFP_2 fingerprints were then compared to that of RBPI-3 and 
assigned a Tanimoto score for how well they overlapped and the 6,000 top-ranked compounds 
were retained. The second was 3D similarity  searching, which entailed using OMEGA and 
ROCS to generate library conformers and then compare the volumes of each conformer to the 
crystal structure conformation of RBPI-3. The 6,000 top-ranked compounds from the 3D filter 
were also retained and combined with the top 6,000 from the 2D filter for docking. 
 Next, the compounds were docked in the T. thermophila PARG structure using the Virtual 
Screening Workflow in the program Glide.36  The first step  of this workflow is to dock all of the 
compounds using the High-Throughput Virtual Screening (HTVS) mode, which is designed to 
quickly dock large numbers of ligands but  samples fewer conformations per ligand. We allowed 
the top  20% of ligands to advance from HTVS mode docking to the next docking step using 
Standard Precision (SP) mode. This is the default mode of Glide and is designed to deal with 
most types of ligands. We allowed the top 20% of ligands to advance from SP mode docking to 
the final docking step  with Extra-Precision (XP) mode. This mode is significantly  slower than 
either HTVS or SP, but is much better at discriminating between ligands of different binding 
affinity.
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! From the output  of this library, the top-ranked compounds were grouped into compound 
classes and one or two representative compounds from each class were ordered. In total, 14 
compounds were ordered and tested for inhibition of PARG at 625 µM (Figure 3.35).
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Figure 3.35. Structures and assessment for in vitro PARG inhibition of 14 compounds identified through 2D and 3D 
similarity filtering followed by high throughput docking. 
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Only one compound, 3D4, inhibited PARG and, as before, this compound was tested for 
detergent-dependence (Figure 3.36).
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Figure 3.36. Assessment of 3D4 in the presence and absence of detergent.
3D4 displayed high levels of detergent dependence, indicating that it was not  a specific inhibitor 
of PARG but instead inhibited through an aggregation-based mode. As before, a virtual screen of 
the ZINC Drugs Now subset yielded no promising leads.
3.3.3 Schrödinger BROOD core-replacement and Glide docking
 Another strategy for lead hopping is the use of fragment libraries to replace a portion of 
the existing inhibitor structure, which is the fragment hopping technique described in Chapter 1 
(see section 1.1). In the case of the RBPIs, the most problematic portion of the molecules in 
terms of solubility and potential reactivity is the rhodanine-isatin core (Figure 3.37). 
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Figure 3.37. Core hopping strategy for new PARG inhibitors. Core of RBPI-3 to be replaced highlighted in blue and 
representative new core shown on right.
Thus, two programs were employed to carry out the virtual replacement of this core with 
structures from fragment libraries, OpenEye’s BROOD37  and Schrödinger’s Core Hopping.38 
Each program includes a large fragment library (BROOD 600,000 and Schrödinger 160,000) 
specifically curated to contain a variety  of structures with a range of attachment points. When 
evaluating new fragments, each program ensures that the orientation of the carboxylic acid and 
benzyl side chains is similar to that of the RBPI and that the overall fragment shape is similar to 
that of the rhodanine-isatin core. After suitable core-replacement analogs were generated by each 
program, the analogs were docked into the RBPI-binding pocket of T. thermophila PARG 
(Figure 3.38) and ranked according to their docking scores.
9,000
RBPI analogs
Glide VSW
Top 375 cmpd
candidates
600,000 
fragment library
BROODCore Hopping
160,000 
fragment library
Figure 3.38. Workflow for virtual core hopping approach.
 The top-ranked virtual analogs generated by  this approach were analyzed in three ways. 
First their water solubility was predicted using QikProp,39  then they  were visually inspected for 
their binding pose within the RBPI pocket, and last they were assessed for synthetic feasibility. 
Solubility predictions are important  as the benzyl group is very  lipophillic and the planar nature 
of the rhoadnine-isatin core will cause the software to favor other very planar fragments, which 
may lead to very insoluble compounds. Out of the CH-series compounds predicted to be soluble, 
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approximately a fourth had undesirable docking poses in which the carboxylic acid and benzyl 
groups were in drastically  different positions than the RBPI-3 pose or there was significant bulk 
outside of the RBPI-3-occupied space. The remaining top-ranked compounds with good 
predicted solubility and good poses were analyzed for synthetic feasibility (Figure 3.39). 
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Figure 3.39. Candidate virtual compounds from core-hopping approach.
 Unfortunately, none of the proposed compounds could be accessed in fewer than 10 
steps, resulting in a large potential synthetic overhead for preparation of more than one 
compound from this list. Given the rates of success of docking studies in the literature and in our 
experience, we would ideally  prepare many compounds from this list, but this was not reasonable 
based on our analysis. Instead, we chose to pursue an alternative docking-based strategy that 
relies more upon our structure-activity knowledge of the RBPIs.
3.3.4 Assessment of docking approach
 Our overall lack of success with the docking approaches described in this section is 
attributable to both the limitations of current docking methods to accurately separate real ligands 
from non-binding library compounds, the limitations of commercial compound libraries, and the 
limited amount of structural information about PARG ligand binding.
 The catch-22 of many  computational techniques, including docking and lead hopping is 
that these techniques work best when they  can utilize structural information from multiple tight-
binding ligands targeting the same pocket, but the more that such information becomes available, 
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the lower the transformative power of these techniques is. Despite significant optimization of the 
docking and scoring protocol of Glide using active RBPIs within the Schrodinger decoy library, 
this method still did not yield any validated active compounds. Ideally, optimization is carried 
out using active compounds that are structurally distinct from those that yielded the receptor 
structure, but in our case, no such distinct active compounds exist. Further, even though the 
active RBPIs used in the optimization library were structurally similar analogs of RBPI-3, the 
best docking results achieved still ranked some decoy ligands above some of the known active 
compounds. This further demonstrates the current limitations of docking to identify active 
compounds.
 Analyses by our group40  and others41,42  have shown that the diversity and molecular 
complexity of commercial compound libraries is very  low. In addition, due to the heavy use of 
combinatorial chemistry, these libraries also tend to consist of easy-to-synthesize linear 
compounds over more complex and difficult-to-synthesize structures. 43  Although the RBPIs are 
overall linear, the rhodanine-isatin ring structure along with the orientation of the side-chains is, 
surprisingly, considerably different than most library  compounds, as evidenced by  the 3D 
similarity search results. Core hopping techniques are an attempt to address this issue, as they 
allow certain features of the query  molecule, such as side chains, to remain constant. But in our 
investigation, the trade-off of compound accessibility  for molecules more similar to our query 
required by core-replacement unfortunately proved not to be useful. This is a risk in any core-
replacement endeavor and is not unique to this specific circumstance. 
 The underlying assumption of all high-throughput screens, that  a reasonably active 
compound exists within the library, is not a guarantee, and this fact must be considered each time 
a screen fails to identify a real hit. Of course, this is precisely the reason that  large libraries are 
utilized, though the addition of more compounds can lead to more false positives and a need to 
test more of the highest-ranked compounds. Additionally, most compounds in the RBPI series 
were only somewhat active, with IC50 values for PARG inhibition in the low micromolar range. 
Since successful docking campaigns usually result in a lead-like, and thus lower potency, 
compound,44  starting with a mid-potency  compound such as RBPI-3 may have reduced the 
potential potency of any compounds found with this method. 
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 One major disadvantage we faced in this pursuit was the limited structural information 
available to us. Most PARG crystal structures were solved with either ADP-ribose or ADP-HPD 
as the ligand, and thus display  a binding mode and pocket shape very different from that of the 
RBPI-3/PARG structure. This restricted us to only one crystal structure for docking efforts. Only 
through the use of the rigid receptor docking method can thousands of compounds be docked in a 
reasonable timeframe. Ideally, use of a rigid receptor can be mitigated by  using a matrix of 
receptors, where all compounds are docked into a collection of receptors originating from co-
crystals of a variety of tight-binding but distinct  ligands. Unfortunately, in our case, only one 
structure with a drug-like compound (RBPI-3) was available, so matrix docking could not be 
carried out. Thus, our docking results do not take into account the dynamic nature of ligand-
protein binding nor do they account for variations in the binding pocket which might have been 
revealed by crystal structures with other drug-like ligands.
  Experimentally, a number of primary hits were identified, but these were quickly 
eliminated based on prior literature reports or simple secondary  assays. Although this may give 
the impression that primary hits were dismissed quickly, the progression of experiments was 
carefully  chosen to only  allow truly specific PARG inhibitors to advance to more advanced 
experiments, while minimizing the amount of time spent evaluating false positives. Indeed, we 
hoped to eliminate compounds earlier in the process rather than later, which allowed us to 
explore a wide variety of approaches to the search for PARG inhibitors.
 Given the difficulties with docking and lead hopping methods outlined above and in 
section 3.1.4, experimental screening methods may be viewed much more favorably as a method 
for identifying new PARG inhibitors. In the case of PARG activity, a number of challenges in the 
development of high-throughput assays remain (see section 2.1.3). However, as each of these 
challenges are addressed through new techniques and tools, high-throughput screening will 
become a more and more attractive and feasible approach. Similarly, there will likely be an 
increasing number of PARG crystal structures with different ligands, which would address some 
of the challenges of docking approaches. Overall, both theoretically- or experimentally-based 
screening approaches should become easier and more robust in the future. 
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3.4 Rational design of virtual library
 To capitalize on our extensive knowledge of RBPI SAR, binding mode, and activity, we 
created a rationally-designed core-replacement library and assessed the resulting compounds by 
docking.
3.4.1 Motivation and library design
 The failure of unbiased screening methods, with or without the benefit  of three-
dimensional structural information, guided the decision to initiate a rational-design based 
approach. In addition, while virtual screens did produce some initial candidates with decent 
shape complementarity, there is an overall a lack of existing compounds which can adopt the 
unique shape of the RBPI ring system as well as contained a negative charge at one extremity. 
Even in the fragment libraries used in the core-hopping approach there was a surprising dearth of 
fragments that reasonably approximated the shape of the rhodanine-isatin core. 
 Through traditional SAR studies and thorough inspection of the RBPI-3/PARG co-
crystal, we conceived of a number of requirements for new rationally-designed inhibitor 
scaffolds:
1) a polar anionic end group
2) an appended benzyl/aryl ring
3) a mostly planar “L-shaped” internal ring system
4) appropriately-placed substituents on the internal ring system
The first two requirements could be accomplished by  retaining the proprionic acid chain and the 
dichlorobenzyl side chain, while the last two could be accomplished by deliberately modifying 
the internal ring system. Using these requirements, a two-round system of compound design and 
docking was used to generate new candidate virtual inhibitors (Figure 3.40). 
Ranked
Scaffolds
Synthesis and 
testing
Initial Library
115 cmpds
Glide VSW Library Expansion Glide VSW
Expanded
Library
Figure 3.40. Two-round design and docking approach to rational design of new candidate inhibitors.
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3.4.2 Two-round Glide docking
 A 115-compound virtual library was constructed by systematically altering the RBPI-3 
structure (Figure 3.41). The first step in library  design was to replace the isatin with an indole. 
Indoles are found in many approved drugs and in general have better solubility properties than 
isatins.45 A 5-chloro substituent was added to the indole to maintain the favorable pocket-filling 
interaction identified in the RBPI-3/PARG crystal structure. Since an indole cannot be easily 
connected with a rhodanine and the rhodanine ring poses other challenges, it  was replaced with 
other heterocycles. All possible pentacycles were virtually  appended via a single bond to the 3-
position of the indole, and the relative 1,3-substitution pattern of the pentacycle was maintained 
by appending the propionic acid chain to the heterocycle. The 2,6-dichlorobenzyl group was 
appended to the indole nitrogen. In another series of compounds within this library, the RBPI-3 
core was kept intact  and a wide variety  of polar functional groups and small rings were appended 
to the 5-position of the isatin. This series was used to assess what types of structures fit in the 
empty pocket near the 5-position as well as which may participate in favorable hydrogen-
bonding interactions. At this point, no consideration was given to synthetic feasibility.
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! The first round of Glide VSW docking revealed that only 18 compounds had docking 
scores worse than RBPI-3 and 6 compounds docked incorrectly with the benzyl group in the 
isatin/indole spot, so these structures were not included in the next iteration of the library. The 32 
top-ranked indole-heterocycle cores and 51 top-ranked 5-substituent were combinatorially 
combined (Figure 3.42), yielding a 1,725-member expanded library. Included in this library are 
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succinimide-containing analogs of some compounds, to probe the ability  of this substitution to 
provide increased binding affinity as compared to a carboxylic acid.
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Figure 3.42. General structures of expanded library combinatorial compounds. X, Y = heteroatoms (O, N, S); FG = 
functional group or small heterocycle.
This library was then docked with Glide VSW and the top-ranked compounds were assessed for 
their synthetic feasibility. The 1,2,3-triazole/indole core (RD10) was identified as a synthetically-
feasible core that had good docking scores and docked poses which closely mimicked that of 
RBPI-3.
3.4.3 Synthesis of and evaluation of top triazole core structure
 Four 1,2,3-triazole/indole-core molecules were targeted for synthesis. Retrosynthetically, 
the core could be accessed from an azide and alkyne through a 3+2 “click” cycloaddition 
reaction, and each of the click reaction partners could be prepared from commercially available 
materials. Substitution of the primary bromide of 3-bromoproprionate methyl ester and N-(2-
bromoethyl)-succinimide with azide provided the corresponding alkyl azide products 3.7 and 3.8 
(Scheme 3.4). The alkyne reaction partners were both prepared from 5-bromoindole. Alkylation 
with either methyl iodide or 2,6-dichlorobenzyl bromide under basic conditions provided the 
corresponding N-alkyl indole, which could be iodinated to give the corresponding 3-iodoindole 
compounds in good to excellent yields (3.9 and 3.12, Scheme 3.4).
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Scheme 3.4. Synthesis of intermediates for triazole-series compounds.
 Next, the 3+2 copper-catalyzed cycloaddition of the azide and alkyne was completed to 
yield three different final compounds, 10MBS, 10BBS, and 10BBA-OMe. This last compound 
was soponified to yield the free acid, 10BBA (Scheme 3.5).
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Each final compound was tested for its ability to inhibit PARG in vitro using the 32P-PAR 
degradation assay  at 100, 300, and 625 µM (Figure 3.43). Only 10BBA displayed any activity, 
with partial inhibition of PARG at 625 µM.
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Figure 3.43. Assessment of triazole-indole series compounds for inhibition of PARG in vitro.
This weak hit compound was tested at  a larger range of concentrations and its IC50 was estimated 
to be 1.1 mM (Figure 3.44) in phosphate buffer containing 0.1% Triton X-100. This low level of 
potency in spite of a very  good docking score and pose, may be due to the inability  of this 
method of docking to account for movements of the protein.
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Figure 3.44. Dose-response of 10BBA for PARG inhibition, graph is a quantification of the data on the left.
Since docking methods which allow significant receptor flexibility are prohibitively time-
consuming, our docking protocol did not  take into account how the protein moves to 
accommodate an RBPI or database molecule. As we know from the co-crystal structures, some 
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IC50 = 1.1 mM
rearrangement of the substrate pocket is required to bind RBPI-3, the ease of this rearrangement 
could significantly affect binding affinity. While 10BBA is much less potent than we had hoped, 
this scaffold may still be a decent starting point for further optimization. Qualitatively, we 
observed that 10BBA is more soluble than the RBPIs, and its structure is generally  more drug-
like than the RBPIs.
3.5 Future directions for lead compound
 Although rational design of RBPI analogs with different cores has so far only yielded the 
weak inhibitor 10BBA, there are a few reasons to predict  that this lead may further be improved 
through optimization. In the RBPI SAR, we found that the negatively charged carboxylic acid or 
tetrazole was required for activity, and in a similar fashion we found that 10BBA-OMe is 
inactive up to 1250 µM (Figure 3.45). This suggests that 10BBA may  bind to PARG in a pose 
similar to that of RBPI-3, with the negative charge of the carboxylic acid forming similar 
hydrogen bonds. To confirm the binding location of 10BBA, a fluorophore-tagged RBPI could 
be used in a fluorescence polarization assay to determine if 10BBA competes for the RBPI 
binding pocket.
+PARG
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Figure 3.45. Assessment of 10BBA-OMe for inhibition of PARG at high concentrations.
 Additionally, the only 5-substituents which have been tested experimentally with the 
triazole-indole core are bromines. Preparation of a small number of 10BBA analogs with polar 
groups, such as those identified as beneficial by docking studies, will either produce more potent 
inhibitors by introducing a favorable increase in shape complementarity and forming additional 
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hydrogen bonds, or demonstrate that filling this pocket is not a viable strategy for increasing 
potency. In particular, a 5-ethylamine substituent can be accessed in a fairly  straightforward 
manner using a sp2-sp3 Suzuki-Miyaura coupling to yield the carboxybenzyl-protected amine 
(Scheme 3.6).46
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Scheme 3.6. General synthesis of 5-ethylaminoindoles via Suzuki-Miyaura coupling.
Just as exploring halogen substitution patterns resulted in a significant increase in RBPI potency, 
similar changes could increase the potency of 10BBA. There are a large number of 
commercially-available benzyl and indole building blocks which could be used to quickly  build 
differentially-substituted analogs to explore the structure-activity  relationship. Exploration of the 
linker lengths between the core and the carboxylic acid or the aryl group could also help in the 
optimization of this compound. If such an optimization effort  could provide a 10- or 20-fold 
improvement in potency, a potent and cell permeable PARG inhibitor may be developed.
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3.7 Materials and Methods
General Materials
 Acetonitrile (Fisher, HPLC grade), dimethylformamide (Fisher, HPLC grade), and 
methanol (Fisher, low water) were dried by percolation through two columns packed with neutral 
alumina under a positive pressure of nitrogen. All other solvents were obtained from Fisher 
Scientific and were used without further purification. All H2O used was either deionized or 
purified through a MilliQ purification system. 
 
! Silica gel for chromatography was performed on EMD Biosciences silica gel 60 (230-400 
mesh).  Thin-layer chromatography plates (Merck, 245 nm fluorescent  indicator) were visualized 
by UV and stained with potassium permanganate (KMnO4), or iodine (I2).   
! All NMR experiments were acquired in the Varian-Oxford Instrument Center for 
Excellence in NMR Spectroscopy (VOICE) laboratory at the University of Illinois at Urbana-
Champaign. NMR experiments were recorded in CDCl3 or CD3OD on Varian Unity  500 MHz 
spectrometers.  Chemical shift, δ (ppm); coupling constant, J (Hz); multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet, m = multiplet); and integration are reported. High-
resolution mass spectral data were recorded on a Micromass Q-T of Ultima hybrid quadrupole/
time-of-flight ESI mass spectrometer at  the University  of Illinois at Urbana-Champaign Mass 
Spectrometry Laboratory.
 32P-β-NAD+ (ARP 0141, 800 Ci/mmol, 5 mCi/mL) was purchased from American 
Radiolabeled Chemicals, Inc. and stored at  -20 °C. Calf thymus activated DNA (D4522, CAS 
91080-16-9) was purchased from Sigma-Aldrich, diluted in H2O, the concentration was 
determined per manufacturer’s instructions and stored at -20 °C. PARG buffer (10, 4680-096-02, 
contains 0.1% detergent), PARG (4680-096-01) and PARP (4668-100-01) were purchased from 
Trevigen and stored at -80˚C. Congo Red was purchased from Sigma-Aldrich (CAS 573-58-0). 
ADP-HPD was purchased from Calbiochem (118415) and stored as a 1 mM solution in H2O at 
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-20 ˚C. ARH3 enzyme was expressed and purified by  Dr. Kathryn Partlow. The ARH3 plasmid 
was provided by Dr. Hening Lin and was expressed in Rosetta 2 (DE3) cells, and the enzyme 
was purified by affinity to a Ni-NTA matrix. ß-lactamase enzyme was purchased from Sigma and 
the substrate, CENTA, was purchased from CalBioChem (cat. # 219475). Commercial 
compounds identified through computational methods were obtained in 1-2 mg quantities from 
Chembridge, ChemDiv, Interbioscreen, or Enamine.
Synthesis of 32P-PAR 
 In a 2.0-mL tube, PAR synthesis buffer (final concentrations 100 mM  Tris-HCl (pH 8.0), 
10 mM MgCl2, 8 mM  DTT, 10% v/v glycerol, 1 mM unlabeled β-NAD+, 23 µg of calf thymus 
activated DNA) was prepared from concentrated stocks. To the solution was added 75 µCi of 32P 
β-NAD+, and water to a final volume of 900 µL. Lastly, 100% ethanol (90 µL) was added 
dropwise, and the solution heated at 30 °C for 5 min. 20 U of PARP-1 was added, and was 
incubated at 30 °C for 30 min. Upon completion, the reaction was quenched and 100 µL of 3 M 
sodium acetate (pH 5.2) and 700 µL of isopropanol were added. The sample was incubated at 0 
˚C for 30 min, and then PAR was pelleted by centrifugation at 14,100xg at 4 °C for 10 min. The 
pellet was washed twice with cold 80% (v/v) ethanol in H2O with centrifugation between each 
wash (14,000xg at 4 °C for 10 min). The pellet was re-suspended in 800 µL of H2O and stored at 
-20 °C. 
Radiometric PARG TLC Assay 
! Compounds were diluted from 10 mM stock solutions in DMSO (or 1 mM stocks in H2O 
for ADP-HPD) to the specified concentrations. First, 10X PARG buffer was diluted to 2X 
concentration. Next, bovine PARG was diluted to 0.025 ng/µL (from a 1 µg/mL solution of 
PARG) in 2X PARG buffer. To a 4.5 µL aliquot of this PARG solution was added 0.5 µL of 
compound (16X in DMSO). Control samples were prepared with 0.5 µL DMSO in the presence 
and absence of PARG enzyme. The solution was incubated at room temperature for 10 min. 
Next, 32P-PAR (3 µL) was added to each solution with mixing and the samples were incubated at 
37 °C for 1 h. Samples were quenched either by  heating at 90 °C for 2 min or by the addition of 
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1 µL 1% SDS with mixing. Then 1.3 µL of each sample was spotted twice on a TLC plate. The 
plate was developed in 70:30 iPrOH:0.2% NH4OH (aq), and the TLC plate was allowed to dry. 
Once dry, the TLC plate was wrapped in clear plastic wrap, and placed in Storage Phosphor 
Screen (Amersham Biosciences, Sunnydale, CA) overnight, and the screen was imaged on a 
Storm Imager (GE Life Sciences, Piscataway, NJ). Intact  32P-PAR was analyzed by densitometry 
using ImageJ (NIH, Bethesda, MD), and the mean intensity  of each spot was used to calculate 
percent PARG inhibition as compared to the control lacking PARG enzyme. 
IC50 curves: Increasing concentrations of compound were tested. The data were plotted as 
compound concentration versus percent PARG inhibition, and fitted to a logistic-dose response 
curve using Table Curve (SYSTAT Software, Richmond, CA). 
Addition of detergent: 32P-PAR degradation was assessed as described above except using 
phosphate buffer (final concentrations of 50 mM  KH2PO4, 50 mM KCl, 10 mM  ß-
mercaptoethanol, pH = 7.5) supplemented with a final concentration of 0.1% Triton X-100 as 
indicated.  
ARH3 Activity: 32P-PAR degradation was assessed in Trevigen PARG buffer as described above 
except with a final concentration of 10 µg/mL ARH3 and 4 mM MgCl2. When directly 
comparing PARG and ARH3 activity and inhibition, PARG activity was assessed in the presence 
of 4 mM MgCl2. 
ß-Lactamase Activity Assay
 In a 96-well plate, added 2.0 µL of 50X compound in DMSO, followed by  98 µL of 
buffer containing ß-lactamase enzyme (5 U/mL enzyme, 50 mM potassium phosphate, 25 mM 
potassium chloride). The plate was incubated at 37 ˚C for 30 minutes. Next, added 10 µL of a 2 
mM solution of enzyme substrate CENTA to each well. Absorbance was immediately read at  405 
nm at 30 second intervals for 30 minutes on a SpectraMax Plus plate reader. Absorbance was 
plotted vs. time and the initial slope of each curve was used to calculate percent activity or 
inhibition, which were normalized to vehicle controls with and without enzyme.
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Computations
All computations were performed on either a MacBook Pro with a 2.26 GHz Intel Core 2 Duo 
Processor or a Triton cluster running Linux RHEL5 x86_64. When necessary, jobs were run with 
distributed processing, via a parallel virtual machine software system. 
Virtual Libraries
 The ZINC Drugs Now, ChemBank, Marvel, Chembridge Microformat, and HTSF 
libraries were downloaded in SMILES format from the source website. In this format the 
structure and stereochemistry of each compound is represented by a single line of text, followed 
by the identifying number or name on the same line. Visual inspection of the library in this 
format as well as any  simple editing was done using TextEdit (v. 1.7.1) or MacVim (v. 7.3.39). 
To allow ligand preparation programs to recognize these files, libraries were saved from MacVim 
and the extension “.smi” was manually added to the file name.
 The first designed library of 115 compounds (section 3.4) was constructed by drawing 
structures in ChemDraw Ultra (v. 12.0.3), copying as SMILES, and pasting the SMILES string 
into a text document. The second designed library of over 1,700 compounds was constructed in 
Excel for Mac (2011, 14.0.0) by  writing a SMILES string for the new fragment (e.g. a furan 
instead of a pyrrole in a series of indole-core compounds) and this fragment string was inserted 
into existing SMILES strings using the Find and Replace function. The resulting structures were 
randomly spot-check by copying the new SMILES string and pasting as SMILES into a 
ChemDraw document, and visually inspecting the 2D structure. 
 Depending on the downstream use, the SMILES format libraries were converted into 3D 
formats using OpenEye’s OMEGA or Schrodinger’s LigPrep. Both of these programs also adjust 
ionization states to physiological pH and place the ligand in at  least one low-energy 
conformation.
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Pharmacophore Searching
OMEGA settings: 
OMEGA jobs were submitted to the SCS cluster using a script written by Mike Hallock. Input 
file format was filename.smi and output file format was set to filename.oeb.gz. All options were 
left at default settings except for the following:
 maxconfs = 100
 rms = 0.4
Log files were used to assess the overall success of the job and report files were used to assess 
the number of conformers generated per input ligand.
ROCS settings:
ROCS jobs were submitted to the SCS cluster using a script written by Mike Hallock. OMEGA 
output files were used as ROCS input files in the .oeb.gz format and output file format was set to 
filename_hits_1.sdf. All options were left at default settings except for the following:
 besthits = 2000
 shapeonly = true
 maxconfs = 3
 rankby = ShapeTanimoto
 mcquery = true
Log files were used to assess the overall success of the job, such as overall computing time and 
number of failed molecules. Report files contained the 2,000 top-ranked compounds listed in 
order by  ShapeTanimoto score with their matched query conformer and scores by various 
similarity metrics.
EON settings:
EON jobs were submitted to the scs cluster using a script written by Mike Hallock. ROCS output 
files were used as EON input files in the .sdf format and output file format was set to 
filename_hits.sdf. For most searches, an array of 40 EON runs was carried out, one for each 
ADP-HPD query conformer. All options were left at default settings except for the following:
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 rankby = ET_pb
 besthits = 500
Log files were used to assess the overall success of the job, such as overall computing time and 
number of failed molecules. Report files contained the 500 top-ranked compounds listed in order 
by electrostatics score with their scores by various similarity metrics, including shape tanimoto 
and combination scores. After combining results from arrayed EON runs, the ranked list of top 
compounds was assigned a name consisting of a letter to identify the run, such as CB for 
ChemBank or E for electrostatics, and a number corresponding to its electrostatics rank.
Core Replacement
BROOD settings:
 OpenEye’s BROOD program was run using vBROOD, a graphical user interface for the 
program. The fragment library  provided by OpenEye was used with the crystallized 
conformation of RBPI-3, replacing the rhodanine-isatin system as the query. Default settings 
were used for all options. Searches were performed using all three criteria (Shape&Color, 
Shape&Electrostatics, and Link Geometry). Output  files were generated in both the .csb list 
format and the .oeb.gz file format.
Core-Hopping settings:
 The Core Hopping program was run from the Maestro interface in the “ligand-based” 
mode. The fragment library file provided by Schrodinger with the filename 
core_library_2011.2.sqlite was used as the input fragment database. The structure of RBPI-3 was 
input and the rhodanine-isatin system was chosen for replaceent. The following restrictions were 
employed:
 10 < heavy atoms < 40
 minimum of 2 H-bond acceptors
 minimum 2 N or O atoms
A total of 71,449 structures were generated and placed in an output file in the .maegz format.
148
2D Similarity
Canvas settings:
 The ZINC Drugs Now subset was divided into 7 SMILES files with roughly equal 
numbers of compounds per file. Each file was uploaded into Canvas and ECFP_2 fingerprints 
were generated for each compound. Next, a similarity screen was conducted within Canvas, 
using the ECFP_2 fingerprint of RBPI-3 as the query  and Tanimoto coefficient as scoring 
function. From the top 7,000 compounds, all the rhodanine-containing compounds were removed 
through the use of a substructure search. Next, the top 6,000 structures were exported as a .csv 
file and the top 6,000 structures from all 7 jobs were combined, re-ranked according to Tanimoto 
scoring, and the top 6,000 of those re-ranked compounds were carried forward. 
Pharmacokinetic Properties:
QikProp settings:
 The Glide VSW output file (.maegz format) was opened in Maestro and the QikProp 
function was utilized using default settings. Output files were written in the .maegz and the .csv 
file formats.
Docking
FRED HR-HYBRID settings:
 FRED jobs were submitted to the scs cluster using a script written by Mike Hallock. The 
receptor was prepared using the fred_receptor program with the RBPI-3/PARG crystal structure 
downloaded from the Protein Databank (4EPQ, .pdb format). The RBPI-3 binding pocket was 
identified as the receptor location, leaving all settings as the defaults except for decreasing the 
outer contour size to 1418 Å3 (under Shape mode). The receptor format was set to 
filename.oeb.gz. Ligand conformers were prepared in OMEGA with the following settings:
 maxconfs = 1000
 rms = 0.333
All FRED options were left at default except for the following:
 exhaustive_scoring = cgo
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 num_poses = 1000
 rstep = 1.0
 tstep = 1.0
 chemgauss 3 = true
 opt = chemgauss3
 pose_select_weight_oechemscore = 0
 pose_select_weight_plp = 0
 pose_select_weight_chemgauss3 = 0
Results were output into a text  file with compounds ranked by  their docking score and a .oeb.gz 
file with compounds in their docked poses. The docked poses were visualized with the VIDA 
program. The ranked list of top compounds was assigned a name consisting of the letters “FI” for 
“FRED In-House” and a number corresponding to its rank by docking score. ChemFinder along 
with the original name/number of the compound was used to obtain the plate and well location of 
the compound within the HTSF plate collection.
Glide VSW settings:
 LigPrep  input files were either in SMILES or SDF format and output files were in 
the .maegz file format. Ligands were prepared using the LigPrep function found in Schrodinger’s 
Maestro program using the following settings:
 pH = 7 ± 1
 epik = true
Receptors were prepared using Protein Wizard with 4EPQ PARG structure as the input, utilizing 
the following settings:
 change selenomethionines to methionines
 fill in missing side chains with Prime
 keep all waters after analysis (or deleted all waters)
 generate ionization states for pH = 7 ± 1
The prepared proteins (filename_impref_ref_.mae) were then used to generate two receptor grids 
in the Glide Grid Generation function of Maestro, with the following settings:
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 receptor scaling = 0.95
 allow rotation of Tyr293, Tyr296, and Cys368
The Virtual Screening Workflow (VSW) jobs were prepared in Maestro and submitted to the scs 
cluster using the command line. Ligands were input in the .maegz format and both receptors (one 
with crystallographic waters and one without) were input in the grid_filename.zip format. All 
options were left as default values except for the following:
 forcefield = OPLS2005
 use Epik state penalties
 scale ligands = 0.8
 partial charge cutoff = 0.15
 dock flexibly
 penalize non-planar amide bonds
 perform post-docking minimzation
 generate up to 1 pose per compound state
 Keep 20% of all states after HTVS (for rational design library keep 100%)
 Keep 20% of all good scoring states after SP (for rational design library keep 100%)
 Keep 100% of all best scoring states after XP
 no MM-GBSA post-processing
Glide VSW results were written as docked poses in the filename_FINAL_DOCK_OUT.mae and 
as a list with associated docking scores as filename_XP_OUT_1.csv. The ranked list  of top 
compounds was assigned a name consisting of the letters “CH” for “Core Hopping” and a 
number corresponding to its rank by docking score. Alternatively, the notation “2D” or “3D”, to 
indicate which filtering run it was identified by, was used in conjunction with a number 
corresponding to the compound’s rank by docking score. The names of the rationally designed 
compounds were assigned upon their creation (before ligand preparation or docking) and were 
not changed after docking.
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Synthetic Methods
(2S,4R)-tert-butyl 2-(azidomethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-
carboxylate (3.2)
N
TBSO
N3
BOCMsCl, Et3N,
NBu4N3
99%
3.1 3.2
N
TBSO
OH
BOC
A 10 mL round-bottom flask was charged with 3.1 (300 mg, 0.9 mmol, 1.0 equiv.) and purged 
with N2(g). Next, dichloromethane (0.5 mL) was added and the flask was cooled to 0 ˚C. 
Triethylamine (0.3 mL, 2.19 mmol, 2.4 equiv.) was added followed by dropwise addition of 
methanesulfonyl chloride (84 µL, 1.09 mmol, 1.2 equiv.). The reaction was stirred in an ice bath 
for 18 hours, during which time the ice bath was allowed to melt and reach ambient temperature. 
The reaction was diluted with ethyl acetate and water, and the layers were partitioned. The 
organic layer was washed with 1 M HCl, sat. sodium bicarbonate, and sat. sodium chloride. Next 
it was dried over MgSO4, filtered, and concentrated down to a yellow oil (intermediate mesylate 
compound). This oil was transferred to a 25 mL round-bottom flask, purged with N2(g), then 
acetonitrile (0.3 mL) and tetrabutylammonium azide (335 mg, 1.18 mmol. 1.3 equiv.) were 
added. The flask was fitted with a reflux condenser and lowered into a pre-heated oil bath at 60 
˚C and refluxed for 2.5 hours. The reaction was diluted with ethyl acetate and water and the 
organic layer was washed with sat. sodium chloride. Next it was dried over MgSO4, filtered, and 
concentrated down to a yellow oil (319.5 mg, 99%).
1H-NMR (CDCl3, 500 MHz): δ 0.06 (s, 6H), 0.87 (s, 9H), 1.56 (s, 9H), 1.95 (br s, 1H), 2.04 (br 
s, 1H), 3.29 (m, 1H), 3.38 (s, 1H), 3.5-4.2 (m, 3H), 4.37 (t, 1H, J = 4 Hz).
HRMS (ESI) calcd (M+H)+: 357.2322, found: 357.2324.
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(2S,4R)-tert-butyl 2-(aminomethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-
carboxylate (3.3)
3.3
N
TBSO
NH2
BOC
N
TBSO
N3
BOC
Pd(OH)2/C
68%3.2
A 15 mL round-bottom flask was charged with 3.2 (40 mg, 0.112 mmol, 1.0 equiv.) and 
palladium(II) hydroxide (15.8 mg, 0.022 mmol, 0.2 equiv.) and purged with N2(g). Next, 1,4-
cyclohexadione (100 µL, 1.01 mmol, 9.0 equiv.) was added, after 1 minute of stirring, methanol 
(0.6 mL) was added. The flask was fitted with a reflux condenser and lowered into a pre-heated 
oil bath at 65 ˚C and the reaction was refluxed for 2 hours. The reaction was cooled to room 
temperature and filtered through Celite, rinsing with methanol. The filtrate was concentrated 
down to a colorless oil, which was purified via silica gel chromatography in 1-10% methanol in 
dichloromethane with 1% triethylamine. Product was a yellow oil (25.0 mg, 68%) 
1H-NMR (CDCl3, 500 MHz): δ 0.07 (s, 6H), 0.88 (s, 9H), 1.37 (s, 9H), 1.55-1.97 (m, 1H), 2.86 
(br s, 2H), 3.34-3.50 (m, 1H), 3.55 (m, 1H), 3.90 (br s, 1H), 3.99 (br s, 1H), 4.35 (s, 1H).
HRMS (ESI) calcd (M+H)+: 331.2417, found: 331.2416.
9-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)-9H-purin-6-amine (3.4)
O
NN3
N
N N
NH2
O O
O
NHO
N
N N
NH2
O O
DPPA, DBU, 
NaN3, 15-crown-5
92%
3.4
A 25 mL flask was charged with 2’,3’-O-isopropylideneadenosine (614.6 mg, 2.0 mmol, 1.0 
equiv.) and purged with N2(g). Next, 1,4-dioxane (7 mL) was added via syringe, follow by 
dropwise addition of diphenyl phosphoryl azide (DPPA, 0.86 mL, 4.0 mmol, 2.0 equiv.) and 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.9 mL, 6.0 mmol, 3.0 equiv.). The mixture was stirred 
at ambient temperature for 16 hours, after which the mixture appears brown and opaque. Sodium 
azide (650.1 mg, 10 mmol, 5.0 equiv.) and 15-crown-5 (4 µL, 0.02 mmol, 0.01 equiv.) were 
added, the flask was fitted with a condenser and lowered into a pre-heated oil bath at 100 ˚C. The 
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reaction was refluxed for 4 hours, after which it was allowed to cool to room temperature, then 
diluted with dichloromethane, filtered, and the filtrate was concentrated down to a red oil. 
Purification was accomplished via silica gel chromatography in 50-100% ethyl acetate in 
petroleum ether. The product was a yellow oil (611 mg, 92%).
1H-NMR (CDCl3, 500 MHz): δ 1.41 (s, 3H), 1.63 (s, 3H), 3.60 (m, 2H), 4.40 (m, 1H), 5.08 (dd, 
1H, J = 3.5, 6.5 Hz), 5.47 (dd, 1H, J = 2, 6 Hz), 6.12 (s, 1H), 7.93 (s, 1H), 8.37 (s, 1H).
HRMS (ESI) calcd (M+H)+: 333.1424, found: 333.1423.
9-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)-9H-purin-6-amine (3.5)
3.5
O
NH2N
N
N N
NH2
O O
O
NN3
N
N N
NH2
O O
Pd(OH)2/C
62%
3.4
A 15 mL round-bottom flask was charged with 3.4 (200 mg, 6mmol, 1.0 equiv.) and 
palladium(II) hydroxide (84.5 mg, 0.12 mmol, 0.2 equiv.) and purged with N2(g). Next, 1,4-
cyclohexadione (510 µL, 5.4 mmol, 9.0 equiv.) was added, after 1 minute of stirring, methanol 
(1.2 mL) was added. The flask was fitted with a reflux condenser and lowered into a pre-heated 
oil bath at 65 ˚C and the reaction was refluxed for 2 hours. The reaction was cooled to room 
temperature and filtered through Celite, rinsing with methanol. The filtrate was concentrated 
down to a colorless oil, which was taken up in a water/chloroform/dichloromethane mixture, 
acidfied with 1M HCl, and extracted with water. The aqueous layer was basified with 2M NaOH, 
then extracted twice with chloroform/dichloromethane, which was dried with sat. sodium 
chloride, MgSO4, filtered and concentrated down to a foamy solid (114.8 mg, 62%).
1H-NMR (CD3OD, 500 MHz): δ 1.38 (s, 3H), 1.60 (s, 3H), 2.77 (q, 1H, J = 7.5 Hz), 2.94 (d, 1H, 
J = 5.5 Hz), 4.25 (m, 1H), 5.03 (dd, 1H, J = 3, 6 Hz), 5.47 (dd, 1H, J = 3, 6.5 Hz), 6.16 (d, 1H, J 
= 3.5), 8.22 (s, 1H), 8.28 (s, 1H).
HRMS (ESI) calcd (M+H)+: 307.1519, found: 307.1516.
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3.5
N
TBSO
NH2
BOC
Cl S S Cl
O
O
O
O
N
O
N
H
S S N
H
O
O
O
O
O
NH2N
N
N N
NH2
O O
O N
N
N N
NH2
O O
THF, 0 ˚C to rt
12%3.3 3.5
OO
Si 3.6
A 25 mL round-bottom flask was charged with 3.3 (30.8 mg, 0.093 mmol, 1.5 equiv.) and 3.5 
(28.5 mg, 0.093 mmol, 1.5 equiv.) and purged with N2(g) and added anhydrous tetrahydrofuran 
(2 mL). The flask was cooled to 0 ˚C. In a separate flask under N2(g), a solution of 
methanedisulfonyl dichloride (1.3 µL, 0.062 mmol, 1.0 equiv.) in tetrahydrofuran (1 mL) was 
prepared and this mixture was slowly added to the reaction flask dropwise. The reaction was 
stirred at 0 ˚C for 4.5 hours, then concentrated down to a yellow residue which was purified via 
silica gel chromatography in 1-10% methanol in dichloromethane to yield a white residue (9.0 
mg, 12%).
1H-NMR (CD3OD, 500 MHz): δ 0.05 (s, 6H), 0.86 (s, 9H), 1.38 (s, 3H), 1.46 (s, 9H), 1.63 (s, 
3H), 1.79 (br s, 1H), 2.01 (br s, 1H), 3.22-3.62 (m, 5H), 4.14 (br s, 1H), 4.32 (br s, 1H), 4.53 (s, 
2H), 5.10 (s, 1H), 5.31 (s, 1H), 5.82 (d, 2H, J = 4.5 Hz), 7.78 (s, 1H), 8.36 (s, 1H), 9.54 (br s, 
1H).
HRMS (ESI) calcd (M+H)+: 777.3095, found: 777.3098.
C5-H
80%TFA (aq);
50 min
85%
H
N
HO
N
H
S S N
H
O
O
O
O
O N
N
N N
NH2
HO OHC5-H
N
TBSO
N
H
S S N
H
O
O
O
O
BOC
O N
N
N N
NH2
O O3.6
A 4 mL vial was charged with 3.6 (8 mg, 0.01 mmol, 1.0 equiv.) and water (0.2 mL), followed by 
the addition of trifluoroacetic acid (0.8 mL). The reaction was stirred at room temperature for 50 
minutes, then concentrated under vacuum to remove solvent and reagents. Product was a 
colorless residue (4.4 mg, 85%)
1H-NMR (CD3OD, 500 MHz): δ 1.89 (ddd, 1H, J = 4.5, 11, 14 Hz), 2.17 (dd, 1H, J = 5, 15 Hz), 
3.25 (d, 1H, 10.5 Hz), 3.45 (m, 1H), 3.56 (d, 2H, J = 4), 3.59 (d, 1H, J = 4.5 Hz), 4.02 (m, 1H), 
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4.26 (q, 1H, J = 4 Hz), 4.36 (dd, 1H, J = 3.5, 5 Hz), 4.57 (m, 1H), 4.80 (t, 1H, J = 5.5), 4.97 (s, 
2H), 5.97 (d, 1H, J = 6 Hz), 8.44 (s, 1H), 8.47 (s, 1H).
HRMS (ESI) calcd (M+H)+: 523.1293, found: 523.1295.
1-(2-azidoethyl)pyrrolidine-2,5-dione (3.8)
N
O
O
Br
N
O
O
N3NaN3
DMF, rt,
48h
97% 3.8
A 25 mL round-bottom flask was charged with N-(2-bromoethyl)succinimide (412 mg, 2.0 
mmol, 1.0 equiv.) and sodium azide (260 mg, 4.0 mmol, 2.0 equiv.), purged with N2(g) and 
anhydrous dimethylformamide (6 mL) was added.  The reaction was allowed to stir at room 
temperature for 23 hours. The reaction mixture was diluted with ethyl acetate and water, 
extracted 3x with ethyl acetate, then the combined organics were extracted 3x with sat. sodium 
chloride (aq.). The organic layer was dried over magnesium sulfate, filtered, and concentrated 
down to a off-white solid (325.8.0 mg, 1.94 mmol, 97%).
1H-NMR (CDCl3, 500 MHz): δ 2.77 (s, 4H), 3.52 (t, 2H, J = 5.5 Hz), 3.75 (t, 2H, J = 5.5 Hz). 
5-bromo-3-iodo-1-methyl-1H-indole (3.9)
N
Br
Me
N
Br
Me
II2, KOH
DMF, rt, ON
quant.
3.9
A 25 mL round bottom flask was charged with 5-bromo-1-methyl-1H-indole (84 mg, 0.4 mmol, 
1.0 equiv.), dimethylformamide (2 mL), and potassium hydroxide (84.1 mg, 1.5 mmol, 3.75 
equiv.). Next, iodine (203 mg, 0.8 mmol, 2.0 equiv.) was added, the flask was capped and stirred 
at room temperature for 14 hours. The reaction was diluted with ethyl acetate, water, and sodium 
sulfite (aq.). The aqueous layer was extracted twice with ethyl acetate, the combined organics 
were dried over magnesium sulfate, filtered, and concentrated down to a yellow oil (144.5 mg, 
quantitative yield).
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1H-NMR (CDCl3, 500 MHz): δ 3.80 (s, 3H), 7.18 (d, 1H, J = 8.5 Hz), 7.27 (s, 1H), 7.25 (dd, 1H, 
J = 2, 8.5 Hz) 7.59 (d, 1H, J = 2 Hz).
HRMS (ESI) calcd (M+H)+: 335.8885, found: 335.8878.
5-bromo-3-ethynyl-1-methyl-1H-indole (3.10)
N
Br
Me
I
N
Br
Me
TMS
80%
PdCl2(PPh3)2
Et3N, CuI
THF, rt, 1h;
TBAF, 30m
3.9 3.10
A 4 mL vial was charged with 3.9 (20 mg, 0.06 mmol, 1.0 equiv.), PdCl2(PPh3)2 (0.8 mg, 0.001 
mmol, 0.02 equiv.), and copper(I) iodide (0.4 mg, 0.002 mmol, 0.02 equiv.) and purged with 
N2(g). Next THF (0.3 mL) was added, followed by  trimethylsilylacetylene (13 µL, 0.09 mmol, 
1.5 equiv.) and triethylamine (17 µL, 0.12 mmol, 2.0 equiv.). The reaction was stirred at room 
temperature for 1 hour, after which the reaction was black in color. Tetrabutylammonium floride 
(TBAF, 90 µL, 0.09 mmol, 1.5 equiv.) was added and the reaction was further stirred for 45 
minutes. The reaction was diluted with ethyl acetate and water, extracted 3x with ethyl acetate 
and the combined organics were extracted 3x with sat. sodium chloride (aq.). The organic layer 
was dried over magnesium sulfate, filtered, and concentrated down to a yellow oil which 
solidified upon further drying under vacuum (11.2 mg, 80%).
1H-NMR (CDCl3, 500 MHz): δ 3.22 (s, 1H), 3.79 (s, 3H), 7.20 (d, 1H, J = 8.5 Hz), 7.30 (s, 1H), 
7.36 (dd, 1H, J = 2, 8.5 Hz), 7.88 (d, 1H, J = 2 Hz).
HRMS (ESI) calcd (M+H)+: 233.9918, found: 233.9928.
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1-(2-(4-(5-bromo-1-methyl-1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)ethyl)pyrrolidine-2,5-dione 
(10MBS)
N
O
O
N3
10 mol% Cu(OAc)2 
0.2 equiv NaAsc
MeCN, 60 ˚C, ON
N
NN
N
O
O
N
Br
Me
94%
10MBS
N
Br
Me
3.10
3.8
A 4 mL vial was charged with 3.10 (7.3 mg, 0.03 mmol, 1.0 equiv.), 3.8 (5.24 mg, 0.03 mmol, 
1.0 equiv.), copper(II) acetate (0.57 mg, 0.003 mmol, 0.1 equiv.), and sodium ascorbate (1.2 mg, 
0.006 mmol, 0.2 equiv.) and acetonitrile (0.2 mL) was added. The reaction was heated at 60 ˚C 
overnight. The mixture was purified by silica gel column chromatography in 1-5% methanol in 
ethyl acetate to yield 10MBS as a white solid (11.3 mg, 94%).
1H-NMR (CDCl3, 500 MHz): δ 2.69 (s, 4H), 3.89 (s, 3H), 4.02 (t, 2H, J = 6 Hz), 4.69 (t, 2H, J = 
6 Hz), 7.35 (dd, 1H, J = 1.5, 8.5 Hz), 7.39 (d, 1H, J = 8.5 Hz), 8.09 (d, 1H, J = 1.5 Hz), 8.30 (s, 
1H).
HRMS (ESI) calcd (M+H)+: 402.0566, found: 402.0559.
5-bromo-1-(2,6-dichlorobenzyl)-1H-indole (3.11)
HN
Br
N
Br
Cl
Cl
CsCO3
MeCN, rt, ON
Cl
Cl
Br
quant.
3.11
A 100 mL round-bottom flask was charged with 5-bromo-1H-indole (120 mg, 0.61 mmol, 1.0 
equiv.), 2,6-dichlorobenzyl bromide (147 mg, 0.61 mmol, 1.0 equiv.) and cesium(II) carbonate 
(298 mg, 0.92 mmol, 1.5 equiv.), purged with N2(g) and anhydrous acetonitrile (20 mL) was 
added. The reaction was stirred at ambient temperature for 20 hours. Solvent was removed in 
vacuo, then the residue was redissolved in ethyl acetate and water. The aqueous layer was 
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extracted 3x with ethyl acetate, the combined organics were dried with sat. sodium chloride (aq.), 
MgSO4, filtered, and concentrated down to an off-white solid (233 mg, quantitative yield).
1H-NMR (CDCl3, 500 MHz): δ 5.52 (s, 2H), 6.42 (d, 1H, J = 3 Hz), 6.97 (d, 1H, J = 3 Hz), 7.28 
(t, 1H, J = 8.5 Hz), 7.32 (dd, 1H, J = 2, 9 Hz), 7.41 (d, 3H, J = 8 Hz), 7.75 (d, 1H, J = 2 Hz).
5-bromo-1-(2,6-dichlorobenzyl)-3-iodo-1H-indole (3.12)
N
Br
Cl
Cl
N
Br
Cl
Cl
II2, KOH
DMF, rt, ON
95% 3.123.11
A 25 mL round bottom flask was charged with 3.11 (100 mg, 0.28 mmol, 1.0 equiv.), anhydrous 
dimethylformamide (1 mL), and potassium hydroxide (59.3 mg, 1.06 mmol, 3.75 equiv.). Next, 
iodine (142 mg, 0.56 mmol, 2.0 equiv.) was added, the flask was capped and stirred at room 
temperature for 5.5 hours. The reaction was diluted with ethyl acetate, water, and sodium sulfite 
(aq.). The aqueous layer was extracted twice with ethyl acetate, the combined organics were 
dried over magnesium sulfate, filtered, and concentrated down to a yellow solid (127.6 mg, 
95%).
1H-NMR (CDCl3, 500 MHz): δ 5.52 (s, 2H), 7.02 (s, 1H), 7.31 (d, 1H, J = 7.5 Hz), 7.38 - 7.43 
(m, 4H), 7.58 (d, 1H, J = 1.5 Hz).
HRMS (ESI) calcd (M+H)+: 479.8418, found: 479.8406.
5-bromo-1-(2,6-dichlorobenzyl)-3-ethynyl-1H-indole (3.13)
N
Br
Cl
Cl
I
N
Br
Cl
Cl
PdCl2(PPh3)2
Et3N, CuI
THF, rt, 1h;
TBAF, 30m
95%
TMS
3.12 3.13
A 4 mL vial was charged with 3.12 (30 mg, 0.062 mmol, 1.0 equiv.), PdCl2(PPh3)2 (0.9 mg, 
0.001 mmol, 0.02 equiv.), and copper(I) iodide (0.5 mg, 0.002 mmol, 0.04 equiv.) and purged 
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with N2(g). Next THF (0.3 mL) was added, followed by trimethylsilylacetylene (13.2 µL, 0.094 
mmol, 1.5 equiv.) and triethylamine (17.3 µL, 0.12 mmol, 2.0 equiv.). The reaction was stirred at 
room temperature for 1 hour, after which the reaction was black in color. Tetrabutylammonium 
floride (TBAF, 90 µL, 0.09 mmol, 1.5 equiv.) was added and the reaction was further stirred for 
1 hour. The reaction was concentrated under vacuum and then purified via silica gel 
chromatography in 5-30% ethyl acetate in hexanes, yielding a yellow solid (22.4 mg, 95%).
1H-NMR (CDCl3, 500 MHz): δ 3.19 (s, 1H), 5.50 (s, 2H), 7.18 (s, 1H), 7.31 (d, 1H, J = 7.5 Hz), 
7.40-7.43 (m, 4H), 7.87 (s, 1H).
HRMS (ESI) calcd (M+H)+: 377.9452, found: 377.9457.
1-(2-(4-(5-bromo-1-(2,6-dichlorobenzyl)-1H-indol-3-yl)-1H-1,2,3-triazol-1-
yl)ethyl)pyrrolidine-2,5-dione (10BBS)
N
Br
Cl
Cl
N
NN
N
O
O
N
Br
Cl
Cl
10 mol% Cu(OAc)2, 
0.2 equiv NaAsc
MeCN, 60 ˚C, 6 h
N
O
O
N3
45%
10BBS3.13
3.8
A 4 mL vial was charged with 3.13 (11 mg, 0.03 mmol, 1.0 equiv.), 3.8 (4.9 mg, 0.03 mmol, 1.0 
equiv.), sodium ascorbate (1.2 mg, 0.006 mmol, 0.2 equiv.), copper(II) acetate (0.54 mg, 0.003 
mmol, 0.1 equiv.), and acetonitrile (150 µL). The vial was capped with a teflon cap and heated at 
60 ˚C for 7 hours. The product mixture was filtered through a small silica plug with ethyl acetate 
and the filtrate was purified via silica gel chromatography in 0-2% methanol in ethyl acetate to 
yield a colorless residue (7.41 mg, 45%).
1H-NMR (CDCl3, 500 MHz): δ 2.70 (s, 4H), 4.03 (t, 2H, J = 5.5 Hz), 4.66 (t, 2H, J = 5.5 Hz), 
5.55 (s, 2H), 7.31 (m, 2H), 7.40-7.46 (m, 4H), 7.78 (s, 1H), 8.05 (s, 1H).
HRMS (ESI) calcd (M+H)+: 546.0099, found: 546.0110.
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methyl 3-(4-(5-bromo-1-(2,6-dichlorobenzyl)-1H-indol-3-yl)-1H-1,2,3-triazol-1-
yl)propanoate (10BBA-OMe)
N
Br
Cl
Cl
N
NN
OMe
O
N3 OMe
O
63% 10BBA-OMe
10 mol% Cu(OAc)2, 
0.2 equiv NaAsc
MeCN, 60 ˚C, 6 h
N
Br
Cl
Cl
3.13
3.7
A 4 mL vial was charged with 3.13 (10 mg, 0.026 mmol, 1.0 equiv.), 3.7 (7.7 mg, 0.026 mmol, 
1.0 equiv.), sodium ascorbate (1.0 mg, 0.005 mmol, 0.2 equiv.), copper(II) acetate (0.4 mg, 
0.0026 mmol, 0.1 equiv.), and acetonitrile (100 µL). The vial was capped with a teflon cap and 
heated at 60 ˚C for 6 hours. The product mixture was purified via silica gel chromatography in 
30-100% methanol in ethyl acetate to yield a colorless residue (8.3 mg, 63%).
1H-NMR (CDCl3, 500 MHz): δ 3.03 (t, 2H, J = 6.5 Hz), 3.73 (s, 3H), 4.73 (t, 2H, J = 6 Hz), 5.56 
(s, 2H), 7.31 (m, 2H), 7.40-7.46 (m, 4H), 7.81 (s, 1H), 8.06 (s, 1H).
HRMS (ESI) calcd (M+H)+: 506.9990, found: 506.9991.
3-(4-(5-bromo-1-(2,6-dichlorobenzyl)-1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)propanoic acid 
(10BBA)
LiOH
THF, rt, 30 min
N
Br
Cl
Cl
N
NN
OH
O
99%
N
Br
Cl
Cl
N
NN
OMe
O
10BBA-OMe 10BBA
A 4 mL vial was charged with 10BBA-OMe (5.0 mg, 0.01 mmol, 1.0 equiv.), THF (200 µL), 
water (100 µL), and lithium hydroxide (0.6 mg, 0.015 mmol, 1.5 equiv.) and the mixture was 
stirred vigorously at ambient temperature for 30 minutes. The reaction was diluted with ethyl 
acetate and water, the aqueous layer was acidified with 1M HCl and extracted 3x with ethyl 
acetate. The combined organics were dried with sat. sodium chloride (aq.), MgSO4, filtered, and 
concentrated down to a white solid (4.8 mg, 99%).
1H-NMR (CD3OD, 500 MHz): δ 3.02 (t, 2H, J = 7 Hz), 4.72 (t, 2H, J = 7 Hz), 5.67 (s, 2H), 7.40 
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(dd, 1H, J = 2, 7 Hz), 7.43 (m, 2H), 7.54 (d, 2H, J = 8 Hz), 7.59 (d, 1H, J = 8.5 Hz), 8.11 (d, 1H, 
J = 2 Hz), 8.26 (s, 1H).
HRMS (ESI) calcd (M+H)+: 492.9834, found: 492.9835.
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Chapter 4: Phenotype-Based Screening for Discovery of 1257 and Determination of its 
Mode of Action
Portions are reprinted with permission from Granger, B. A.; Jewett, I. T.; Butler, J. D.; Hua, B.; 
Knezevic, C. E.; Parkinson, E. I.; Hergenrother, P. J.; Martin, S. F. Synthesis of (±)-actinophyllic 
acid and analogs: applications of cascade reactions and diverted total synthesis. J. Am. Chem. 
Soc. 2013, 135, 12984-12986.
4.1 High-throughput screen and initial results
 Previous screens of the HTSF and Marvel compound libraries have led to the discovery 
of a number of interesting and promising anticancer compounds, including the 
triphenylmethylamides1 and dexoynyboquinone.2 Since the HTSF library  is constantly expanding 
and incorporating new compounds from numerous synthetic labs, a screen of recently submitted 
HTSF library compounds for anticancer activity was conducted. The work described in section 
4.1 was conducted in conjunction with Elizabeth Parkinson.
4.1.1 Screen protocol and results
 Due to recent reports on the ability of cultured breast cancer cell lines to faithfully 
represent specific subtypes of actual patient tumors,3  a screen in three different breast  cancer cell 
lines was conducted. The hypothesis was that  by using cell lines representative of different types 
of breast cancer, anticancer agents that are selective for certain subtypes over others could be 
identified. Such compounds would be interesting because they  could have predictable efficacy 
against tumors and the selective nature would suggest  that the differences between subtypes is 
important for the compound’s mechanism of action. Of course, compounds that are effective 
against a broad set of cancer cell lines would also be interesting, and would be identified by this 
type of screen. The three cell lines screened were Hs578t, a triple-negative cell line 
representative of the basal subtype, MCF-7, an ER-positive cell line representative of the luminal 
A subtype, and HCC1954, an ER-negative cell line representative of the basal subtype. Each of 
these cell lines falls within broad subtypes of basal, luminal or Erbb2, but they  were also 
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determined to each be representative of a different well-defined subtype of breast  cancer through 
pathway analysis of their gene expression data.3
 A brief protocol for the screen is as follows: the screen was conducted in 384-well plates, 
with a total volume of 50 µL in each well.  First, 40 µL of media was distributed to all wells, 100 
nL of screening compound was pin-transferred into the media, then 10 µL of a 200,000 cells/mL 
suspension of cells was added to each well (2,000 cells/well). Plates were sealed with a gas-
permeable seal and incubated at 37 ˚C for 48 hours. Next, alamar blue was added to each plate, 
which was resealed and incubated for 4-6 hours, and the fluorescence of each well was read. 
Depending on the concentration of the compound plates, the final concentration of compound 
ranged from 2 - 20 µM.
 Initially, viability  was assessed using sulforhodamine B (SRB) dye, using a protocol 
adapted from the commonly  used protocol for 96-well plates.4  While good results could be 
obtained with SRB, significant over-dyeing of wells was often encountered, which could not be 
eliminated by  optimization of the type of plate, washing steps, or plating methods. Thus, viability 
was assessed in the bulk of the screen by alamar blue. In this assay the dye resazurin is converted 
to a fluorescent compound resofurin within the reducing environment of a live cell.5 In addition 
to providing very consistent results, the alamar blue protocol is operationally  simpler, in that dye 
is added at  the desired timepoint and viability is assessed by  reading the fluorescence after a few 
hours. No washing is required, whereas SRB has two washing steps. Additionally, alamar blue 
solutions can be made in-house, by simply dissolving the inexpensive dye resazurin in sterile 
PBS at  440 µM, at the cost of less than a penny  per milliliter. Edge effects, where significantly 
more signal than expected was measured in the outer wells, were accounted for by preparing an 
untreated control plate in parallel with treatment plates, and applying a correction factor derived 
from the control plate to the final data.
 Overall, more than 6,000 compounds were screened, with the majority originating from 
Prof. Kozmin’s lab at  the University  of Chicago (~4,000 compounds screened at 2 µM). The 
remaining compounds were from plates 15-19 of the HTSF submitted library (~2,000 
compounds screened at 20 µM) and early Complexity-to-Diversity  compound collections (~200 
compounds screened at 10 µM). From these efforts, 26 primary  hits were identified. Upon testing 
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the dose-response activity of these compounds in various cell lines, some primary hits were 
revealed to be false positives (no cell death up to 100 µM), while others had weak (IC50 between 
20 and 100 µM) or good (IC50 below 20 µM) anticancer activity (Figure 4.1).
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Figure 4.1. Structures of primary hit compounds organized by potency in follow-up dose-response assays for 
cytotoxicity. Labels indicate library of origin (first line) and compound identifier or well location (second line). 
Screening was performed with Elizabeth Parkinson.
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! The primary hits with good anticancer activity were further assessed to determine their 
activity. One of the Complexity-to-Diversity  (CtD) compounds prepared by Rob Hicklin, 
RH2_1_255C had been reported previously  in the literature, and has significant phototoxicity in 
mice.6  The compound GA4 was already under investigation for its anticancer activity.7 
Compound 1202 contains a reactive α,ß-unsaturated carbonyl whose electrophilic reactivity is 
undesirable as it could result in non-specific reactions with proteins. Further, compound 1223 is 
extremely flat, suggesting that  it may act  via DNA intercalation. The most attractive compound 
in the group was 1227, which was prepared by Prof. Martin’s laboratory at the University of 
Texas at Austin. Thus, the activity  of 1227 was investigated further as it has potent anticancer 
activity without any apparent liabilities. Although compounds that selectively affected certain 
subgroups were originally sought, none of the validated hit  compounds had any differential 
activity between various breast cancer cell lines. 
4.1.2 Activity of 1227 and analogs
 The activity  of 1227 was assessed in a small panel of cell lines to determine its overall 
activity (Table 4.1). Overall 1227 displayed decent potency, with IC50 values generally below 25 
µM. 
Cell Line Cancer Type 1227 IC50 (µM)
Hs578t triple negative breast 63.1 ± 16.0
MCF7 ER+ breast 20.7 ± 1.5
BT549 triple negative breast 14.0 ± 4.2
BT20 triple negative breast 18.8 ± 6.1
HCC1954 ER/PR -, Her2+ breast 13.0
T47D ER+ breast 13.1 ± 8.5
U937 lymphoma 17.9
Table 4.1. IC50 values for 1227 against a panel of cancer cell lines at 48 h. Where error is indicated n=3, s.e.m., 
where error is not indicated n=1. Performed with Elizabeth Parkinson.
! Based the positive data from this class of molecules, the Martin laboratory  synthesized 
additional 1227 analogs for testing (Figure 4.2). 
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Figure 4.2. Structure of actinophyllic acid, 1227, and other synthetic intermediates and their analogs.
Each of these compounds is an intermediate or analog of an intermediate on a synthetic route to 
the natural product actinophyllic acid, a carboxypeptidase inhibitor.8  The ability of each analog, 
as well as that  of actinophyllic acid, to induce cell death in Hs578t cells was determined (Table 
4.2). Out of these 19 compounds, 1257 was identified as the most potent and was assessed 
further for activity in other breast cancer cell lines and other types of cancer.
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Compound 
Name Hs578t IC50 
1227 63.1± 16.0
1239 14.9 ± 4.8
1241 >100
1243 20.4 ± 3.6
1244 >100
1245 13.2 ± 1.3
1246 >100
1251 >100
1252 >100
1253 >100
1254 >100
1255 >100
1256 12.6 ± 2.5
1257 7.7 ± 2.8
1258 15.5 ±2.8
1267 >100
1268 >100
1269 11.2 ± 1.9
1270 >100
Table 4.2. IC50 values of 1227-series compounds in Hs578t cells, n=3, s.e.m. Performed with Elizabeth Parkinson.
4.2 Breadth of 1257 potency 
 Since no differential selectivity was observed for one cell line over another by 1227, the 
potency of 1257 against many diverse cancer cell lines was tested.
4.2.1 Efficacy against various types of breast cancer 
 When tested against a panel of breast cancer cell lines representing many  subtypes of 
breast cancer, 1257 was found to be equally potent in all subtypes, with IC50 values ranging from 
4 - 10 µM (Table 4.3).
Cell Line Breast Cancer Type 1257 IC50 (µM)
Hs578t triple negative breast 7.73 ± 2.8
BT549 triple negative breast 7.95 ± 0.6
T47D ER+ breast 6.5
MCF7 ER+ breast 5.8
Table 4.3. IC50 values of 1257 against breast cancer cell lines. n=3, s.e.m. where error is indicated.
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4.2.2 Efficacy against other types of cancer
 When assessed against  a diverse panel of cancer cell lines, 1257 consistently displayed 
potent activity, with IC50 values ranging from 4 - 10 µM (Table 4.4). Due to 1257’s broad activity 
against a wide range of cancer cell lines, its mode of action and general properties were further 
investigated.
Cell Line Cancer Type 1257 IC50 (µM)
U937 lymphoma 6.9 ± 0.8
HeLa cervical 9.70
U87 brain 4.8 ± 0.5
A549 lung 8.2 ± 0.3
Table 4.4. IC50 valued of 1257 against non-breast cancer cell lines. n=3, s.e.m. where error is indicated.
4.3 Assessing 1257-induced cell death
 Initial assessments of 1257’s mode of action focused on broadly  characterizing how 1257 
causes cell death in comparison to known cytotoxins.
4.3.1 Speed of cell death compared to known cytotoxins and clinical anticancer agents
 Cell death was observed to occur very quickly upon treatment with 1257, and increases in 
incubation time past 12 hours did not increase the overall amount of cell death. For this reason, 
the speed of cell death induced by 1257 was compared to that induced by  other well-
characterized cytotoxins and clinically-used therapeutics over a 48 h time period. As Figure 4.3 
shows, 1257 induces cell death at approximately  the same rate as 1541B, velcade, thapsigargin, 
and staurosporine, while deoxynyboquinone (DNQ),2 doxorubicin, paclitaxel, and mitomycin c 
cause cell death at a significantly slower rate. Comparison of the rate of induced cell death along 
with the known molecular mechanisms of action of these cytotoxins can shed some light on the 
possible mechanism of 1257.
169
0 
20 
40 
60 
80 
100 
0 4 8 12 16 20 24 28 32 36 40 44 48 
Pe
rc
en
t C
el
ls
 A
liv
e 
Time (hours) 
DMSO 
Mitomycin C 
Paclitaxel 
Doxorubicin 
Staurosporine 
1257 
Thapsigargin 
Velcade 
1541B 
DNQ 
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cytometry (AnnV/PI) at various timepoints.
 Mitomycin c induces cell death by alkylating and crosslinking DNA, thereby rendering 
the cell unable to express genes or replicate DNA.9 Both doxorubicin and paclitaxel disrupt cell 
division, with doxorubicin intercalating DNA and inhibiting topoisomerase II during DNA 
replication10  and paclitaxel stabilizing microtubules during spindle disassembly.11  All three of 
these slower-acting agents work by affecting the cell’s ability to undergo mitosis. This mode of 
action is common to many  chemotherapeutics, due to the ability  of these agents to selectively kill 
dividing cells, such as tumor cells, over senescent cells, such as most healthy tissue. The 
somewhat delayed action of these compounds is due to the need for the cells to progress towards 
mitosis for cell death pathways to be activated. DNQ catalytically  produces reactive oxygen 
species (ROS) that in turn damage DNA and render the cell unable to express genes and 
replicate, which also may also depend on the cell’s ability to progress through the cell cycle.12
  Staurosporine is a very potent pan-kinase inhibitor that is used widely in the literature 
due to its ability to consistently  induce apoptosis.13 Thapsigargin is a SERCA (sarco/endoplasmic 
reticulum Ca2+-ATPase) inhibitor that induces a build-up of cytosolic calcium,14 a signal that can 
activate apoptosis and other cell death pathways. Velcade (aka bortzeomib) is a recently-
approved chemotherapeutic that works by inhibiting the proteasome.15  1541B directly activates 
caspase-3, one of the key executioner caspases in the apoptotic pathway. 16  While DNA damage 
and inhibition of other mitotic processes can often activate cell death pathways, these four 
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cytotoxins induce cell death without directly  relying upon the cell cycle machinery or 
checkpoints. As such, they are each able to induce cell death within shorter time periods. Due to 
the rapid speed of cell death induced by 1257, its mode of action is likely independent of cell 
cycle machinery or checkpoints. 
4.3.2 Shape of 1257 cytotoxicity curve
 Another interesting aspect of 1257’s effect on cancer cells is the shape of its dose-
response curve. Compared to many other cytotoxins, 1257 has a very  steep  dose-response curve, 
which can be quantified by the Hill slope (HS), a parameter that  was described in detail in 
Chapter 1 (see section 1.2.3). A number of factors have been proposed to influence dose-
response curves of cytotoxins in various cell lines.17  One factor that influences the steepness of a 
cytotoxicity curve is the differences in cellular response within a given cancer cell population. If 
the sensitivity of cancer cells to a cytotoxin varies widely  within a population, this will give rise 
to a shallow dose-response curve as higher concentrations are needed to affect the less sensitive 
cells. Conversely, a steep  dose response curve indicates similar sensitivity to the cytotoxin 
throughout the cell population and can also indicate cooperativity  of drug binding to the target. 
Thus, HS values greater than one have been proposed as a desirable property for anticancer 
compounds.17
 Additionally, the value of Emax, another parameter discussed in Chapter 1 (section 1.2.3), 
is an important  aspect of 1257’s dose-response curve. Emax values near or equal to 100 (when 
plotting percent cell death) are beneficial because they  indicate that a cytotoxin is capable of 
eliminating all or close-to-all of the cancer cells at high concentrations. Low Emax values indicate 
that a cytotoxin causes fractional killing of a cell population, leaving a portion of the cancer cells 
unaffected and able to regrow after the cytotoxin is cleared. As such, high Emax values are 
desirable as they  indicate fewer cells will be left unaffected by the cytotoxin and hopefully 
reduce the frequency of resistance.
 Theoretically, Emax values cannot exceed 100 (or be lower than zero when percent 
viability is plotted) since a cytotoxin can only kill 100% of the cells present  and no more. In 
actuality, this value is influenced by a couple of factors that may lead to theoretically  impossible 
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values. The Emax value is derived from fitting a sigmoidal curve to the dose-response data points, 
which can give values above 100 even if most  of the individual data points do no exceed 100. In 
these cases the Emax value is said to be equal to 100. Dose-response data also changes depending 
on the type of viability  assay  conducted (alamar blue, sulforhodamine B, Cell Titer-Glo, etc.) and 
the control conditions used to define 100% cell death. In this case, average values from wells 
containing 100 µM doxorubicin, velcade, and 4150 were used to define 100% cell death. Since 
each cytotoxin has its own Emax value, the set of compounds used to define 100% cell death will 
necessarily influence the resulting cell death values. Thus Emax can only  be accurately compared 
when each compound is assessed with the same assay and the same controls. Secondary 
confirmation of Emax values can be accomplished through colony-forming assays, which assess 
whether any cells with replicative potential remain after cytotoxin treatment. 
 An analysis of the HS and Emax values of 1257 and doxorubicin in a panel of cell lines 
reveals a clear difference between these two compounds (Figure 4.4). Compared to doxorubicin, 
1257 consistently displays a HS value much greater than one (values range from 5-100), whereas 
the highest HS value for doxorubicin is 2.2 in U937 cells and in all other cell lines was near or 
below one (values range from 0.31-1.2). These values indicate that the cellular response to 
doxorubicin is much more varied within the cell population than it is to 1257. Additionally, at 
concentrations near the IC50 value, an increase in the amount of 1257 has a much larger effect 
than a similar increase in the amount of doxorubicin. The Emax value of 1257 is equal to 100 in 
five of the six cell lines tested and varies from 64-99 for doxorubicin. This demonstrates that 
1257 effectively kills a larger fraction of the cell population than doxorubicin does.
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Figure 4.4. Representative dose-response curves, average Hill Slope values and average Emax values for 1257 and 
doxorubicin (Dox) in a panel of cell lines. All dose-response curves were determined after 48 h incubation with 
alamar blue and fitted to a sigmoidal dose-response curve.
 The HS and Emax values of a panel of literature cytotoxins in U937 cells were also 
analyzed and the average values varied greatly  (Figure 4.5). Mitomycin C, 1541B, and velcade 
all have HS values equal to or less than one, whereas DNQ and thapsigargin each have values 
above one. The extremely  high HS value determined for DNQ (HS = 49.0, Figure 4.5) is likely 
due to the catalytic production of ROS by this compound, leading to very large increases in 
toxicity  from very small increases in compound concentration. Thapsigargin works by disrupting 
calcium homeostasis, and the tight regulation of intracellular calcium may be reflected in the 
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steep  does-response curve for this compound. The low HS values of 1541B and velcade likely 
reflect high levels of variability within the U937 cell population in their response to the 
cytotoxin. Most of the compounds tested show high Emax values near 100, but DNQ has an Emax 
value of only  80. This could indicate the presence of a small portion of the cell population that is 
able to mitigate the effects of DNQ and survive. 
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Figure 4.5. Representative dose-response curves, average Hill Slope values and average Emax values for a panel of 
cytotoxins in U937 cells. All dose-response curves were determined after 48 h incubation with alamar blue and fitted 
to a sigmoidal dose-response curve.
 Since both HS and Emax are known to correlate with drug type17 (and thus with mode of 
action) these values can provide clues as to the possible mechanism of action of 1257. Since 
1257 consistently has a very steep cytotoxicity curve in a variety of cell lines, this suggests that it 
does not act through mechanisms known to yield shallow curves, such as mTOR inhibition or 
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thymidylate synthase inhibition. Similarly, the consistent Emax values of 1257 suggest that  it does 
not act  through mechanisms known to result in fractional killing, such as EGFR inhibition or 
HSP90 inhibition. Based on this analysis, 1257 could induce HDAC inhibition or proteasome 
inhibition, as both of these drug classes display steep slopes and Emax values near 100, though 
these values alone cannot reveal the mode of action and 1257 could work through an entirely 
different mechanism than any known drug class. This analysis not only provides guidance for 
which modes of action may be induced by 1257, but also indicates that cells respond evenly to 
the effects and 1257 and are consistently sensitive to high concentrations of this cytotoxin.
4.3.3 Cell cycle arrest by 1257
 Another method for investigating the overall effect of a cytotoxin on cells is to assess cell 
cycle progression in the presence of a minimally toxic concentration of the compound. The phase 
of the cell cycle can be determined by  dyeing the DNA of fixed cell with propidium iodide (PI), 
and assessing whether the amount of PI signal corresponds to one (G1 phase), two (G2/M 
phase), or an intermediate number of chromosome sets (S phase). Treatment of U937 cells with 6 
µM 1257 results in a very mild G1 arrest (Figure 4.6). 
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Figure 4.6. Cell phase distribution of U937 cells treated with either DMSO or 6 µM 1257 for 20 h, assessed by flow 
cytometry (PI).
 Because this effect is so modest, the effect of 1257 was further tested in synchronized 
cells. First, U937 cells were treated for 16 hours with nocodazole, which arrests cells in G2/M 
phase. After washing out the nocodazole, cells were treated with either DMSO or 4 µM 1257, 
and the distribution of the cell phases was assessed at intervals over 16 hours (Figure 4.7).
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Figure 4.7. Cell cycle analysis of U937 cells arrested at G2/M with 80 ng/mL nocodazole for 16 hours, followed by 
treatment with DMSO of 4 µM 1257 for 16 hours, cell aliquots removed and fixed at indicated time, cell cycle 
assessed by flow cytometry (PI).
Here a clear and lasting arrest of cell cycle progression in G1 phase by 1257 is observed. This 
indicates that 1257 does not act through stabilization or destabilization of microtubules, as 
compounds that act through those mechanisms generally cause G2/M arrest.
4.4 Investigation of mechanism by flow cytometry and protective agents
 Some types of cell death can be characterized by the use of appropriate fluorophores with 
flow cytometry. In addition, one straightforward method to probe the mechanism of a cytotoxic 
agent is to determine which other proteins are necessary for its function. The activity of various 
proteins in cell death or other pathways can be inhibited with small molecule tools, if inhibition 
of a protein with a small molecule leads to a decrease in cytotoxin-induced cell death, then that 
protein may play a key role in the function of the cytotoxin. Thus, the mechanism of action was 
investigated using flow cytometry  and by  assessing the combination of 1257 with a variety  of 
small molecule tool compounds.
4.4.1 Annexin V-FITC and propidium iodide staining
 Apoptosis is a specific type of programmed cell death with well-defined pathways and 
characteristics. To determine if 1257 induced cell death via apoptosis, cells were analyzed by 
flow cytometry using propidium iodide and the fluorophore-conjugated anti-phosphatidylserine 
antibody Annexin V-FITC. In this analysis, exposure of phosphatidylserine on the surface of the 
cell is used as a marker of the early stages of apoptosis and the fluorescence of the membrane-
impermeable DNA dye propidium iodide, is used as a marker for overall cell death. Cells that 
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undergo classical apoptosis experience these two events in strict succession, whereas cells 
undergoing other types of programmed or non-programmed cell death do not. 
 In U937 cells treated with 1257, a small population (~15%) was found to be present in 
the apoptotic quadrant (PI negative, Annexin V-FITC positive) at a given time (Figure 4.8). 
These results indicate that at least some of the 1257-treated cells undergo classical apoptosis. 
However, this evidence is not enough to conclude that 1257 relies solely  upon apoptotic cell 
death. Further experiments are required to fully elucidate the type of cell death induced by this 
compound.
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Figure 4.8. Dot plots of propidium iodide fluorescence vs Annexin V-FITC fluorescence of U937 cells treat for 16 h 
with either DMSO or 4 µM 1257.
4.4.2 Apoptosis inhibitors
 A large number of well-characterized tool compounds are available to aid in the 
interrogation of apoptotic pathways (Figure 4.9). 
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Figure 4.9. Apoptosis pathways and relevant tool compounds.
The general procedure used to assess whether a compound prevents the cytotoxicity  of 1257 was 
to treat U937 cells for two hours with the tool compound, then add 1257 at a final concentration 
of 9 µM  and incubate for another 3 hours. Concentrations of protective agents were optimized, 
starting from concentrations used in the literature and increased such that they are utilized at 
their highest non-toxic concentration. A graph summarizing the amount of protection provided 
by a variety of apoptosis-inhibiting compounds is shown in Figure 4.10. 
 To probe the caspase-dependence of 1257-induced cell death, QVD-OPh, a potent 
covalent pan-caspase inhibitor was utilized.18  No protection was observed with high 
concentrations of QVD-OPh, indicating that cell death in not caspase-dependent. Apoptosis can 
occur in a caspase-independent manner, so other elements of apoptotic pathways were 
investigated.
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Figure 4.10. Percent protection against cell death induced by 1257 provided by various apoptosis-preventing agents. 
U937 cells were pretreated with indicated concentration of protective agent for 2 hours, 1257 was added at a final 
concentration of 9 µM, cells were incubated for an additional 3 hours and viability was assessed by flow cytometry 
(AnnV/PI); n=3, s.e.m.
The compounds antimycin A, rotenone, and FCCP all use various mechanisms to uncouple 
oxidative phosphorylation and disrupt ATP synthesis in the mitochondria.19,20  Apoptosis is an 
ATP-dependent process, thus blocking ATP synthesis should disrupt apoptosis. No protection 
with either rotenone or FCCP was observed, though a modest amount of protection was observed 
with antimycin A (~40%, Figure 4.7). Since only one of these three compounds provided 
protection, the protection from antimycin A is likely  not due to effects on ATP levels, but due to 
another function of antimycin A within the cell.
 The organometallic compound Ru360, a specific inhibitor of calcium uptake by  the 
mitochondrial permeability transition pore (MPTP),21  was also investigated. Increases in 
cytosolic calcium levels can activate the MPTP, causing the mitochondria to become permeable 
to cellular components less than 1500 Da in size. This increased permeability can then lead to the 
release of pro-apoptotic factors like cytochrome c. The lack of protection by Ru360 suggests that 
this mechanism is not important for 1257-induced cell death.
 The pifithrins each block a different pro-apoptotic mechanism of p53, with pifithrin-∝ 
blocking p53-induced transcription of pro-apoptotic genes and pifithrin-µ blocking p53 binding 
to the mitochondria, Bcl-xL and Bcl-3.22,23  The lack of protection by pifithrin-∝ and pifithrin-µ 
suggests and 1257-induced cell death is not dependent upon p53 activity.
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 The compound BI-6C9 was developed to inhibit Bid-induced apoptosis.24 This compound 
works by inhibiting the localization of cleaved Bid (tBid) to the mitochondria and thus 
preventing tBid-induced Bax and Bak oligomerization and subsequent cytochrome c release. No 
protection was observed with BI-6C9, indicating that tBid recruitment to the mitochondria is not 
necessary for 1257-induced cell death. 
 Compound iMAC-1 and peptide VPMLK both work to inhibit the Bax and Bak-induced 
release of cytochrome c from the mitochondria.25,26  No protection was provided by  either 
compound, which is consistent with earlier results indicating the release of cytochrome c from 
the mitochondria is not a critical step in 1257-induced cell death.
 The compound NS3694 was reported to prevent caspase-dependent apoptosis by inducing 
the formation of an inactive apoptosome dimer.27  Surprisingly, NS3694 provided significant 
protection against the cytotoxicity of 1257. This suggested that although mitochondrial release of 
cytochrome c and caspase activation was not necessary for 1257 toxicity, formation of the 
apoptosome was necessary. Since the apoptosome consists of the proteins Apaf-1, caspase-9, and 
cytochrome c, and serves to activate executioner caspases 3 and 7, this protection was somewhat 
inconsistent with previous results.
4.4.3 Isogenic cell lines
 Isogenic cell lines were utilized to further investigate the role of certain apoptotic 
proteins in 1257-induced cell death. To probe the role of the apoptosome, the sensitivity of an 
isogenic mouse embryo fibroblast (MEF) cell line pair in which the gene for Apaf-1 was 
knocked out in one cell line was tested. In addition to assessing viability  after treatment with 
1257, the ability of NS3694 to protect against 1257 in each cell line was also assessed (Figure 
4.11). Both cell lines were sensitive to 1257, and the Apaf-1 knock-out cells were even slightly 
more sensitive to the cytotoxin. Interpretation of these results is complicated by  the fact that 
NS3694 did not provide any  significant protection from 1257 in either the WT or KO cell line. 
This difference may  indicate that 1257 induces cell death in a different manner in MEF cells than 
it does in U937 cells, and the sensitivity of Apaf-1 knock-out cells to 1257 only reveals that the 
apoptosome is not required in MEF cells. Another explanation is that NS3694 protects against 
1257-induced cell death in U937 cells by a mechanism other than inhibition of the apoptosome, 
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and that this mechanism is not operative in MEF cells. Either way, further experiments to 
investigate the type of cell death induced by 1257 were warranted.
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Figure 4.11. Viability of isogenic MEF cell lines after treatment with either DMSO or 15 µM 1257 for 3 hours, with 
or without 2 h pre-incubation with 50 µM NS3694. Viability was assessed by flow cytometry (AnnV/PI); n=3, s.e.m.
 Another set of isogenic MEF cell lines that were either wild-type (WT) or were knock-
outs for either Bid or Bax and Bak genes were utilized. The sensitivity  of each cell line to 1257 
was assessed and all three cell lines were found to be equally  sensitive (Figure 4.12). This result 
is consistent with the lack of protection observed with BI-6C9, iMAC-1, VPMLK, and Ru360. 
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Figure 4.12. Viability of isogenic MEF cell lines after treatment with either DMSO or 15 µM 1257 for 3 hours. 
Viability was assessed by flow cytometry (AnnV/PI); n=3, s.e.m.
 To explore the importance of the extrinsic apoptotic pathway  in 1257-induced cell death, 
isogenic Jurkat cell lines in which the gene for either caspase-8 or FADD (Fas-associated death 
domain) was knocked-out were examined. The sensitivity of each cell line to 1257 alone or in the 
presence of necrostatin-1 (a RIPK inhibitor that prevents necrosis), SP600125 (a JNK inhibitor 
that also prevents necrosis), or QVD-OPh, was determined (Figure 4.13). Comparing their 
sensitivities to 1257 alone reveals that while the caspase-8 knock-out cells are slightly less 
sensitive than wild-type, there is no difference in sensitivity with the FADD knock-out cells.
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Figure 4.13. Cell viability of isogenic Jurkat cell lines after treatment with 1257 +/- necrostatin-1, SP600125, or 
QVD-OPh. Viability was assessed by flow cytometry (AnnV/PI); n=3, s.e.m.
As with U937 cells, none of the three tool compounds significantly increased viability  after 1257 
treatment. Interestingly, treatment with SP600125 consistently  induced slightly higher amounts 
of cell death in each cell line. Overall these results suggest that the extrinsic apoptotic pathway is 
not a key pathway for 1257-induced cell death.
4.4.4 Necrosis and other inhibitors
 Due to the lack of convincing and consistent protection observed with apoptosis 
inhibitors, a panel of tool compounds that inhibit various components of necrosis pathways and 
other cell death pathways was tested. For most of these compounds, little-to-no protection was 
observed (Figure 4.14). Necrostatin-1 and SP600125 each target a different kinase in a key 
necrosis pathway. Necrostatin-1 inhibits RIP kinase (RIPK)28 and SP600125 inhibits JNK,29 and 
the lack of protection provided by each of these compounds suggests that necrosis pathways are 
not critical for 1257-induced cell death. Calpains are a class of calcium-activated proteases that 
can play a role in both apoptosis and necrosis. The use of calpeptin, a specific calpain inhibitor,30 
did not affect cellular viability, indicating that calpains do not play a critical role here.
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Figure 4.14. Percent protection against cell death induced by 1257 provided by various necrosis-preventing agents. 
U937 cells were pretreated with indicated concentration of protective agent for 2 hours, 1257 was added at a final 
concentration of 9 µM, cells were incubated for an additional 3 hours and viability was assessed by flow cytometry 
(AnnV/PI); n=3, s.e.m.
 The ability of the antioxidant N-acetyl cysteine (NAC)31  to prevent cell death was 
assessed, and it provided slight protection. This suggests that  some ROS may be generated 
during 1257 treatment but that it is not the main cause of cell death. No change in the amount of 
cell death was observed when NMDA-receptor inhibitor MK-80132  was employed, indicating 
that the ion transport activity of NMDA receptors is not required for cell death. Modest 
protection with neomycin, a compound that  is commonly used as an antibiotic, was also 
observed. Unfortunately, neomycin is a non-specific weak anion exchanger,33  which hinders our 
ability to interpret this modest protection.
4.4.5 Endoplasmic reticulum stress inhibitors
 Next, the role endoplasmic reticulum (ER) stress in this context was explored. A number 
of different tool compounds have been published that affect  various aspects of ER stress (Figure 
4.15). One of the major sensors of ER stress is IRE1α, a transmembrane ER protein that has both 
kinase and endonuclease activity. The endonuclease activity has been shown to be part of the ER 
stress response that works to ensure cell survival and it  is this activity that is inhibited by 
STF083010.34
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Figure 4.15. ER stress pathways and relevant tool compounds.
 Co-treatment with STF083010 actually increased the amount of cell death induced by 
1257 (Figure 4.16). This could suggest that ER stress plays a role in cell death in this context, 
since STF083010 blocks a pathway which counteracts ER stress. Another major sensor of ER 
stress is PERK, an transmembrane ER protein whose kinase activity serves to counteract the 
detrimental effects of ER stress, although high levels of activation can lead to pro-cell death 
signaling. When utilizing the PERK inhibitor GSK2606414,35  no protection from 1257 
cytotoxicity was observed. 
 Since ER stress can be caused by a build-up of unfolded proteins within the ER, the 
chemical chaperone TUDCA36 was utilized to probe the role of such proteins. No protection was 
observed with TUDCA, indicating that  an excess of unfolded proteins is unlikely to play  a role in 
1257-induced cell death. In a similar vein, use of the protein synthesis inhibitor cycloheximide 
also did not provide any protection. Use of the ryanodine receptor inhibitor dantrolene37  did not 
provide any  protection, suggesting that calcium release by  the intracellular calcium channel 
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ryanodine receptors does not play  a critical role in 1257-induced cell death. As the ER is 
involved in cholesterol synthesis, the hypothesis that supplementing the cholesterol synthesis 
pathway with mevalonolactone would attenuate 1257 toxicity was tested.38  High concentrations 
of mevalonolactone did not affect the amount of cell death, indicating that toxicity was likely  not 
due to inhibition of cholesterol synthesis.
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Figure 4.16. Percent protection against cell death induced by 1257 provided by various ER stress-preventing agents. 
U937 cells were pretreated with indicated concentration of protective agent for 2 hours, 1257 was added at a final 
concentration of 9 µM, cells were incubated for an additional 3 hours and viability was assessed by flow cytometry 
(AnnV/PI); n=3, s.e.m.
 Incubation with PP1/GADD34 inhibitor salubrinal 39  (Figures 4.16 and 4.17) resulted in 
very robust protection, with prevention of approximately 90% of the cell death caused by 1257. 
Salubrinal inhibits the dephosphorylation of eIF2α by the PP1/GADD34 complex; 
phosphorylated eIF2α causes global translation repression by preventing eIF2α from 
participating in translation.40 Along with a global decrease in translation is a concurrent increase 
in translation of chaperone proteins, which help to counteract any build-up of unfolded 
proteins.41  Short-term phospho-eIF2α maintenance works to counteract ER stress, but 
suppression of translation by  phosphorylation of eIF2α decreases ATF4 (activating transcription 
factor-4) levels, leading to increased CHOP (C/EBP homologous protein) levels, which then 
promotes apoptosis through the action of Bcl-2 family proteins.42  Salubrinal is sometimes 
referred to as a general ER stress inhibitor and has been shown to protect from the cytotoxic 
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effects of tunicamycin,39 rotenone,43  and kainic acid44  but not those of thapsigargin.45 
Investigations into the protective activity of salubrinal in the context of diseases such as 
osteoporosis are also under way.46
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Figure 4.17. Mode of action upon and structure of PP1/GADD34 inhibitor salubrinal.
 The protection provided by salubrinal suggests that 1257 causes cell death by inducing 
ER stress in such a way that the cellular events induced by  salubrinal can decrease the effects of 
this insult. Since no protection was observed when translation was inhibited with cycloheximide, 
the protective effect of salubrinal may be due to the increased translation of ER stress-reducing 
proteins.
4.4.6 Western blot analysis of apoptotic and ER stress markers
 Specific biochemical markers of apoptosis and ER stress were monitored in U937 cells 
treated with 1257 with or without certain protective agents. Procaspase-3 cleavage and 
mitochondrial cytochrome c release were observed in 1257 treated cells (Figure 4.18). These 
events are completely prevented by  salubrinal, but not by NS3694 or QVD-OPh, in agreement 
with previous results. The apoptosis-inducing compound staurosporine was also tested as a 
positive control, where it induces cleavage of procaspase-3 to the active apoptotic caspase-3 
fragment.
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Figure 4.18. Western blots of apoptotic events in lysates of U937 cells treated with 9 µM 1257 with or without 50 
µM NS3694, 75 µM salubrinal, or 10 µM QVD-OPh, and 1 µM staurosporine as an apoptotic control.
 The caspase-3 fragment produced in the presence of QVD-OPh is a larger non-apoptotic 
fragment, since all caspases are covalently inhibited.47  Interestingly, the apoptotic cleavage of 
caspase-3 in the presence of NS3694 confirms the hypothesis that this compound is not working 
through the apoptosome, since no apoptotic caspase cleavage would be expected if the 
apoptosome was inhibited. Since previous experiments demonstrated that  1257-induced cell 
death is caspase-independent, this experiment demonstrates that apoptotic caspase fragments can 
be formed in response to 1257 but are not required for cell death. Unfortunately, the induction of 
biochemical apoptotic events by 1257 was not consistent, in that  its timing varied between 
replicates and in some cases no biochemical apoptotic events could be observed. For example, in 
some replicates no PARP-1 cleavage, which is a robust signal of caspase activation, was 
observed at up to 2 hours of treatment with 1257 (Figure 4.19).
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Figure 4.19. Western blots for PARP-1 and actin in lysates of U937 cells treated with 9 µM 1257 with or without 10 
µM QVD-OPh (QVD) or 75 µM salubrinal (Sal), or 1 µM staurosporine (STS) as an apoptotic control.
 A number of phosphorylation events can be monitored as biochemical markers of ER 
stress, including phosporylation of PERK, IRE1α, eIF2α and cleavage of ATF6.48,49  Treatment 
with 1257 rapidly induces an increase in eIF2α phosphorylation, but not in IRE1α 
phosphorylation (Figure 4.20).
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Figure 4.20. Western blots for ER stress markers in lysates of U937 cells treated with 9 µM 1257 with or without 75 
µM salubrinal (Sal).
Unlike the apoptotic biochemical events, the increase in eIF2α phosphorylation has consistently 
occurred in our all our attempts to monitor it  by  western blot, further demonstrating the 
importance of ER stress in 1257-induced cell death. A similar increase in phosphorylated eIF2α 
can be seen when U937 cells are treated with tunicamycin, an ER stress inducer, for long time 
periods (Figure 4.21).
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Figure 4.21. Western blots for phosphorylated and total eIF2α in lysates of U937 cells treated with 1 µM 
tunicamycin for 4-24 hours.
4.5 TEM imaging 
 To further characterize the effects of 1257, transmission electron microscopy (TEM) was 
utilized to assess the morphology of U937 cells after treatment.
4.5.1 Utility of TEM imaging for cell death assessment
 Although TEM  imaging is not routinely  used to characterize the type of cell death 
occurring upon different insults, our laboratory has found that it  can, in conjunction with other 
assessments, provide useful information. For many  years, cell death was classified by the 
morphology  of dying cells, with rupture or permeabilization indicating necrosis and blebbing 
indicating apoptosis.50  While biochemical markers allow us to quantify cell death routines as 
well as further characterize into subroutines, valuable information can still be gleaned from 
morphological characterization. Certain limitations, such as the large number of cells needed per 
sample, the lengthy staining and slicing protocol as well as the requirement for specialized TEM 
instrumentation limit the generality of this procedure.
4.5.2 Images from treated U937 cells
 Our first attempt to obtain images of U937 cells treated with 1257 was not successful, 
likely due to interactions between the compound and the dyes used to stain the fixed cells. Thus, 
the number of washes with PBS after harvesting the cells was increased, enabling the capture of 
very high quality images of intact cells (Figure 4.22). 
190
 DMSO-treated U937 cells have a very similar appearance to other TEM images of 
healthy vehicle-treated cells obtained by our group.7 Notable features of these healthy cells 
include the significant number of cellular membrane protrusions, indicating active endocytosis, a 
nucleus with well-distributed uncondensed DNA, mitochondria with intact parallel cristae, and 
thin unstressed ER throughout the cytosol (arrows, Figure 4.22). Upon treatment with 1257, a 
number of different morphological changes are observed. First, the outer membrane is much 
smoother, with fewer endocytosis protrusions. Next, there is a gap at  the nuclear membrane, a 
change that generally  indicates cellular stress. Additionally, the ER structures are much larger 
and rounded, with white interiors indicative of protein accumulation (Figures 4.22 and 4.23). No 
ER structures with normal morphology are present and all other visible organelles are readily 
identified, strongly indicated that  the large white structures are in fact the ER. The morphology 
of the mitochondria is similar to that of the DMSO control initially, but  as the incubation with 
1257 continues, the cristae begin to reorganize and form vesicle-type structures.51 
 When cells are treated with salubrinal and 1257, the cells have a healthy  morphology 
with the ER appearing as thin bodies, similar to the appearance of DMSO treated cells. No other 
indicators of cellular stress, such as the nuclear gap, changes in mitochondrial morphology, or 
smoothening of the outer membrane are observed in cells treated with salubrinal and 1257 
(Figures 4.22 and 4.23). Conversely, when cells were treated with either NS3694 or QVD-OPh 
and 1257, their morphology was distinctly unhealthy, with many unusual features occurring. For 
example, large membrane-bound structures were observed in NS3694 treated cells, which may 
be expanded ER or may arise from unregulated endocytosis. QVD-OPh treatment did not prevent 
expansion of ER membranes. 
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Figure 4.22. TEM images of cytotoxin-treated U937 cells, 4,000X. 5 million cells per sample were treated with 
protective agent (75 µM salubrinal, 10 µM QVD-OPh, or 50 µ LNS3694) for 2 hours before 1257 (final 
concentration of 9 µM) was added with mixing, then incubated for 1 h. For controls, cells were treated with either 
DMSO, 10 µM thapsigargin, or 10 µM staurosporine for 4 hours. Cells were harvested at the indicated times, 
washed 6x with PBS, suspended in Karnovsky’s fixative and submitted to Dr. Lou Ann Miller for further sample 
preparation and processing. Endoplasmic reticula are indicated with arrows.
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 For comparison, images of cells treated with staurosporine and thapsigargin were also 
obtained (Figures 4.22 and 4.23). Staurosporine is known to induce apoptosis as determined by 
both morphological and biochemical measures. These TEM  images very  clearly showed 
blebbing of the outer membrane, with most cells in this population visualized as completely 
permeabilized and dead or as undergoing large-scale blebbing and nuclear condensation. Images 
of thapsigargin-treated cells revealed expanded ER structures very  similar to those in 1257-
treated cells. Since thapsigargin is a well-characterized inducer of ER stress, this strongly 
suggests that 1257 induces ER stress as part of its effect on cancer cells.
Staurosporine Thapsigargin 
1257 + Salubrinal 60 m 1257 15 m 1257 
1 µm 
Figure 4.23. TEM images of cytotoxin-treated U937 cells, 15,000X. 5 million cells per sample were treated with 75 
µM salubrinal for 2 hours before 1257 (final concentration of 9 µM) was added with mixing, then incubated for 1 h. 
For controls, cells were treated with either 10 µM thapsigargin or staurosporine for 4 hours. Cells were harvested at 
the indicated times, washed 6x with PBS, suspended in Karnovsky’s fixative and submitted to Dr. Lou Ann Miller 
for further sample preparation and processing. 
 
4.6 Cytological profiling
 Recently, the use of high-content screening has been developed as a method to rapidly 
discover useful and unique small molecules by computer analysis of their effects on the 
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phenotypes of treated cells.52  Further development of this technique has focused on enabling its 
use for investigating the mode of action of biologically active compounds.53
4.6.1 Use of cytological profiling for mechanism-of-action comparison
 Cytological profiling is the use of high-content techniques to measure phenotypic 
parameters of cells treated with biologically  active molecules and further analysis of the data 
aimed at developing profiles or signatures that are specific to certain molecular modes of action. 
Recent studies have shown that this approach can accurately cluster together profiles of cells 
treated with compounds with the same mode of action.54  For example, hierarchical clustering of 
cytological profiles have successfully  clustered etoposide and camptothecin together as 
topoisomerase inhibitors, as well as nocodazole and taxol together as microtubule poisons.55 In a 
further extension of this technique, the effects of fractional marine plant extracts were analyzed 
to allow for the classification and prioritization of natural products for further exploration.56
 One advantage of cytological profiling over other fingerprint-based approaches is that in 
addition to measurements, profiles, and clusters, this analysis also provides images of the treated 
cells. Visual inspection of these images can be used to help confirm clustering results, to provide 
a visual rational for a certain effect, and to generally  help describe the phenotypic effect on the 
cell by any bioactive compound. 
4.6.2 Cytological profiling of 1257
 In collaboration with Lokey Lab at University of California Santa Cruz, we utilized their 
cytological profiling protocol to investigate the phenotypic effects of 1257. In this protocol, 
HeLa cells are treated with a range of compound concentrations for 24 hours, fixed, and then 
stained with either a nuclear or cytosolic fluorescent dye set. The cytosolic dye set  includes 
Hoechst for general DNA staining, anti-phospho-H3 fluorescent antibodies, and EdU, an alkyne-
tagged thymidine analog that is later cyclized with an azide-tagged rhodamine fluorophore. The 
nuclear stain set  consists of Hoechst to locate cells, fluorescent anti-tubulin antibody, and 
fluorophore-labeled phallodin for actin staining. Approximately 250 features in each fluorescent 
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image are measured using specialized software and these feature measurements are used to 
cluster with or compare to features of known cytotoxins with known modes of action. 
 The cytological profiles of 1257 and a panel of other compounds from our lab were 
clustered with previously collected results from a large panel of known cytotoxins. 
Unfortunately, due to apparent batch effects, most of the compounds from our lab clustered 
together, despite being known to have a wide diversity  of molecular mechanisms. The results 
from cells treated with 1257 at  relevant concentrations did not cluster with any of the known 
cytotoxins and as such, no conclusions could be drawn from this part of the analysis.
 Upon visual inspection of the fluorescence images obtained during this experiment, some 
differences between the control cells and the treated cells were observed. For example, with the 
cytosolic stain set, there is a reduction in overall tubulin staining intensity upon treatment with 
33 µM 1257 (green, Figure 4.24). No significant change is observed in the amount of actin or the 
number of cells undergoing mitosis (red and cyan, respectively, Figure 4.24).
1257 Control 
Figure 4.24. Cytosolic stain set images of control and 1257-treated HeLa cells. Blue = DNA; red = actin; green = 
tubulin; cyan = phospho-H3.
In the cells stained with the nuclear stain set, a significant decrease in the number of cells is 
observed as well as a large reduction in EdU staining (cyan, Figure 4.25), which reflects the 
synthesis of new DNA. No significant change in the proportion of cells with phospho-H3 
staining was observed, which is consistent with the cytosolic stain set results.
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1257 Control 
Figure 4.25. Nuclear stain set images of control and 1257-treated HeLa cells. Blue = DNA; Magenta = phospho-H3; 
Cyan = EdU.
 Overall, these results are somewhat consistent with our previous studies of this 
compound. Since 1257 causes arrest in G1 phase, this analysis was expected to show fewer S 
phase and G2/M  phase cells, but instead there is no observable change in the amount of G2/M 
phase cells. No effect on tubulin by 1257 was predicted by previous experiments, although this 
may reflect a change in progression through the cell cycle or a general reduction in the health of 
the cells. The significant  reduction in cells in the nuclear stain set probably reflects the amount of 
cell death that occurred, which should be very high based on the high concentration of 1257 used 
(33 µM). The difference in the number of cells in the cytosolic stain set versus the nuclear stain 
set could be due to the manipulations required for EdU incubation in the nuclear stain set. 
Though the cytological profile of 1257 was not successfully clustered or correlated with any 
known cytotoxin, its effects on a number of different phenotypic features of HeLa cells were 
visualized.
4.7 Transcript profiling
 To further characterize the effects of 1257 on cancer cells and gain information that may 
lead to identification of the molecular target, transcript profiling was carried out.
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4.7.1 Use of transcript profiling for mechanism-of-action characterization
 In its simplest incarnation, transcript profiling involves isolation of mRNA from cells, 
determination of the level of each transcript by microarray, and analysis of the level of different 
transcripts. This method gains most  of its power by enabling high-quality  comparisons of 
transcript levels between cells in various states. Transcript levels can be compared between 
cancer cells of the same general type isolated from different patients, between cancer cells 
immediately after isolation and then after culturing in vitro, between cells before and after 
infection with a bacteria or virus, or between cells treated with different small bioactive 
molecules. This last example, where transcripts are analyzed after treatment with a small 
molecule, has the most potential to advance our investigations of the bioactive molecules 
discovered in our laboratory.
 Although a thorough inspection of the individual up-regulated and down-regulated 
transcripts may yield insight into the effects of a compound on a cell, this type of analysis is 
unlikely to reveal the molecular target in a straightforward manner. To overcome this challenge, 
the Broad Institute developed the Connectivity Map database (CMAP) that allows for the easy 
comparison of the pattern of up- and down-regulated genes in a sample to the patterns of cells 
treated with a large database of literature compounds.57  The use of CMAP as a tool to identify 
the mode of action of a bioactive molecule has been well reviewed previously.58  One important 
aspect of CMAP analysis is that it only considers whether a transcript is up- or down-regulated, 
not the degree to which the level is changed. Additionally, the user can decide which transcripts 
to include in the query. 
4.7.2 Initial results with 1257 and U937 cells
 Total RNA was isolated from U937 cells treated with 4 µM 1257 or DMSO and samples 
were submitted for hybridization to Illumina microarry chips. Microarry hybridization was 
performed by the Functional Genomics Unit in the Roy J. Carver Biotechnology  Center and 
statistical analysis was performed by  the High Performance Biological Computing Group  in the 
Institute for Genomic Biology. To assess the overall ability of this experiment to detect 
differences in cell populations, a heat map  of transcript levels from 1257-treated and GEM-1-
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treated cells were compared to each other and their matched control (DMSO-treated) cells 
(Figure 4.26). Overall, the two DMSO control samples are very  similar to each other with some 
differences in the degree of down-regulation, and each compound-treated sample is visually very 
different from the controls. More importantly, each compound-treated sample is very different 
from the other, as one would expect with two cytotoxins with different overall cellular effects. 
GEM-1 
treated 
1257 
treated 
DMSO 
control 
(1257) 
DMSO 
control 
(GEM-1) 
Figure 4.26. Heat map analysis of transcript levels in GEM-1 treated cells, 1257 treated cells, and corresponding 
DMSO treated cells. Figure was prepared by Dr. Jennifer Zadeh (Bioinformatics Facility).
 Next, the results were inspected at the transcript level, concentrating on those transcripts 
that were dramatically up- or down-regulated (Table 4.5). The top  most enriched transcript is that 
for interferon-induced protein with tetratricopeptide repeats-2 (IFIT2) with a fold change of 11 
compared to control. Two other IFIT transcripts, IFIT1 and IFIT3, were also enriched, though 
only by approximately 3-fold. This class of proteins is mainly responsible for inhibiting viral 
replication, though its over-expression has been shown to inhibit cancer cell growth.59 BCL2A1 
is an anti-apoptotic Bcl-2 family protein, which may  be increased in this sample due to cellular 
processes that work to counteract the pro-cell death effects of 1257. An increase of almost 5-fold 
in CCNG2, the transcript corresponding to cyclin G2 is interesting, since the over-expression of 
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this protein is knowns to induce G1 arrest,60  which was previously shown to occur with this 
concentration of 1257.
Gene Name Fold Change Gene Name Fold Change
IFIT2 11.17 TPGS1 -2.68
CYP51A1 5.84 RRP9 -2.69
RNA28S5 5.30 ZMAT5 -2.70
CCNG2 4.75 LTBP3 -2.71
PLEKHF2 4.54 LPHN1 -2.73
RANGRF 4.54 MCAT -2.74
SLC26A11 4.21 GAMT -2.75
MSMO1 4.21 TMEM161A -2.77
SLC38A2 3.91 ECE2 -2.79
KRBA1 3.87 DESI1 -2.81
LY96 3.87 PRAM1 -2.92
CTH 3.81 ATP5D -3.02
STAT2 3.65 LOC150223 -3.03
TMUB2 3.61 HYAL2 -3.10
TSC22D3 3.60 ZMAT5 -3.15
INSIG1 3.55 BIK -3.23
TXNIP 3.55 UNC93B1 -3.30
ALB 3.53 CERCAM -3.30
HMGCS1 3.49 TPSAB1 -3.50
FAM214A 3.45 NFKBIB -3.50
CLIC4 3.36 ADRM1 -3.51
FAM27E3 3.35 TPSAB1 -3.57
IFIT3 3.27 FAM108A1 -3.67
IFIT1 3.25 FAM101B -3.71
ASNS 3.14 AZU1 -3.76
C4orf34 3.11 LRRC33 -3.83
FAM214A 3.02 CCDC86 -4.08
RGS12 3.02 SPI1 -4.35
BCL2A1 3.00 NCF1 -4.36
HAVCR2 2.98 PRTN3 -4.53
Table 4.5. Significantly up- and down-regulated genes in U937 cells treated with 4 µM 1257 for 6 hours compared 
to vehicle (DMSO) treatment. 
 Another interesting up-regulated transcript corresponds to thioredoxin interacting protein 
(TXNIP), which is generally known as a tumor-suppressor gene. TXNIP is up-regulated by 
treatment with etoposide and has been shown to lead to an increase in reactive oxygen species.61 
In an attempt to validate this transcript up-regulation, the TXNIP protein levels after treatment 
with 1257 were assessed. Even when treating the same cell line with the same concentration of 
1257 for the same time period as assessed in the transcript profiling experiment, no significant 
increase in the amount of TXNIP protein was observed by western blot (Figure 4.27).
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Figure 4.27. Western blot analysis of TXNIP protein levels in U937 cells upon treatment with 1257.
4.7.3 CMAP analysis of results
 Since further comparisons of 1257 to other more well-characterized cytotoxins would be 
helpful, a CMAP analysis of these results was carried out. By inputing all transcripts that were 
up- or down-regulated by more than 2-fold compared to control, a CMAP result could be 
obtained with good mean scores with a number of pertubagens (Table 4.6). Surprisingly, none of 
the compounds identified by CMAP analysis as having a matching transcript pattern were 
anticancer compounds. Most of the compounds with high mean scores can be classified as 
antihistamines, antipsychotics, or antibiotics. 
 Since ER stress can be caused by changes in cytosolic calcium levels, the correlation of 
prenylamine and tetrandine, both calcium channel blockers, is not surprising. Similarly, as 1257 
increases phosphorylation of eIF2α, an event that directly  reduces global translation, the 
correlation with puromycin, a translation inhibitor, is also consistent. In addition, the HSP90 
inhibitor geldanamycin, correlated with a mean score or 0.602, has also been shown to induce 
ER stress.62  In contrast, the correlation with dopamine receptor antagonists thioridazine, 
trifluoperazine, and prochlorperazine has no clear explanation, as a role for dopamine receptors 
in cancer cells is unknown, though dopamine itself may have some pro-apoptotic effects.63  The 
correlation of benzethonium chloride and mefloquine are similarly unclear, although limited 
studies have shown that mefloquine can induce ER stress.64
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Perturbagen Mean Score Clinical Use(s) Target (molecule/pathway)
terfenadine 0.808 antihistamine, not currently used clinically  due to long Qt syndrome histamine H1 receptor and HERG antagonist
mefloquine 0.770 antimalarial heme polymerase inhibitor, similar to chloroquine
benzethonium 
chloride 0.770
food additive, surfactant, antiseptic, 
antiinfective, topical antimicrobial unknown
puromycin 0.749 antibiotic protein synthesis (translation) inhibitor, aminonucleoside
MG-262 0.702 Lon protease inhibitor (not clinically used) selective and reversible inhibitor of proteasome
astemizole 0.697 2nd generation antihistamine histamine H1 receptor antagonist, similar to terfenadine
thioridazine 0.685 antipsychotic inhibits dopamine D1 and D2 receptors, blocks alpha-adrenergic effect
tetrandrine 0.663 Ca+2 channel blocker Ca+2 channel inhibitor, causes G1 arrest and apoptosis
metixene 0.646 anticholinergic (Parkinson's disease) muscarinic acetylcholine receptor M1-5
loperamide 0.645 antidiarrheal (Imodium) µ-opiod receptor agonist, similar to morphine
prenylamine 0.642 Ca+2 channel blocker, amphetamine class depletes myocardial catecholamine stores, monoamine transporter inhibitor
trifluoperazine 0.629 antipsychotic inhibits dopamine D1 and D2 receoptors
fluspirilene 0.628 antipsychotic inhibits dopamine D2 receptor and voltage-dependent Ca+2 channel gamma-1 subunit
prochlorperazine 0.617 antipsychotic inhibits dopamine receptors
rescinnamine 0.609 antihypertensive angiotensin-converting enzyme inhibitor
desipramine 0.608 antidepressant inhibits reuptake of norepinephrine and serotonin
geldanamycin 0.602 antibiotic inhibits HSP90 and GRP94
Table 4.6. Compounds (or perturbagens) identified by CMAP with similar transcript patterns.
 The best correlating perturbagen in this analysis was terfenadine (mean score of 0.808), 
an antihistamine that is no longer used due to its cardiotoxicity (Figure 4.28).65 While histamine 
receptors are not normally  thought to play a role in cancer biology, the presence of histamine H4 
receptor has been demonstrated in numerous tissues and histamine may play a role in regulation 
of proliferation.66  Terfenadine itself has some similarities to 1257, as it induces G1 phase arrest 
and apoptotic cell death,67  although these effects have been shown to be histamine receptor-
independent but related to calcium homeostasis.68 
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Figure 4.28. Structure of terfenadine.
4.8 Whole genome shRNA screening
 As a general mode of action, induction of ER stress, has been assigned to 1257 further 
experiments to identify  specific pathways key to 1257-induced cell death were investigated by 
conducting a positive-selection whole genome shRNA screen.
4.8.1 Recent uses of shRNA screens for new small molecules
 Examples of the use of shRNA in either a validation experiment or to discover the 
mechanism of action of a bioactive molecule were well reviewed up to 2010.58 A brief summary 
of notable uses of shRNA screens since then is given here.
 To investigate the pathways important for ER stress induced by arsenic, a functional 
RNAi screen was employed.69  By utilizing an shRNA library  targeting 20,000 genes, they were 
able to identify the gene SNAT2 (sodium-dependent neutral amino acid transporter 2) as critical 
for arsenic-induced ER stress and cell death, in addition to identifying known general ER stress 
genes. Interestingly, further investigation of the role of SNAT2 revealed that it plays a part in 
arsenic activation of the mTOR pathway by modulating cellular levels of certain amino acids.
 In April of 2014, an example of the use of an shRNA screen in a discovery effort was 
published by researchers at the Karolinska Institute.70  Through a small phenotypic screen for 
changes in actin structure in glioblastoma cells and follow-up assays for selective cytotoxicity, 
they  identified a class of quinoline-based compounds that they termed vacquinols. They further 
investigated the unique form of cell death induced by vacquinols through the use of the 
DECIPHER shRNA library, which targets a total of 5,043 genes. They found that MAP2K4 gene 
knock-down conferred significant protection against the activity  of vacquinol-1. The MAP2K4 
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product, MKK4, was demonstrated to be an important node for successful formation of the 
macropinocytic vacuoles induced by vacquinol-1. 
 Although tamoxifen is known to target the estrogen receptor, further investigation of 
other pathways critical for its action are of interest. Thus, an shRNA screen targeting 16,487 
genes was reported as a way to identify genes that can lead to tamoxifen resistance, a common 
problem in the clinic.71  To account for false-positives, genes enriched in the tamoxifen-treated 
cells were validated with siRNAs containing different target sequences than those used by the 
shRNA constructs. They identified 11 genes whose activity was essential for tamoxifen-
sensitivity, and 11 genes whose activity decreased tamoxifen potency.
 Despite a growing number of successful examples of the use of shRNA screens to 
discovery  critical pathways or molecular targets of new cytotoxins, further improvement and 
validation of this approach is ongoing. For example, a miniaturized shRNA screen protocol was 
recently  developed and shown to be successful in re-discovering 40% of known drug-target 
interactions among a library  of 28 well-characterized drugs.72  The shRNA library  was unique in 
that it only targeted 368 known drug targets. This small size enabled high levels of representation 
for each construct, the use of many compounds (50), as well as small-format cell culture 
conditions (6-well plates). 
4.8.2 Guidelines and experimental considerations in shRNA screens
Cost 
 Once an experimentalist has decided that an shRNA screen could provide useful data, 
there are a number of key factors to consider when designing such an experiment. First and 
foremost, is the overall cost of the experiment, as many steps are costly and can quickly become 
prohibitively expensive unless proper care is taken. Current prices for whole genome shRNA 
libraries range from $5,000 and up, while analysis of each sample can easily  approach $1,000. 
Thus, care must be taken at each step to minimize the overall cost of these experiments.
Cell Line
 At the outset, selection of the appropriate cell line is very  important. Not only should the 
cell line be relevant to the specific small molecule context, but also easily transduced. Certain 
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cell lines, especially  suspension cell lines, can be very difficult to transduce, so these should be 
avoided as the cost of viral particles is normally  very high. If possible, the screen should be 
conducted in more than one cell line to increase the quality of the data, though this is time-
consuming and expensive. Additionally, once cells have been successfully  transduced, they can 
be frozen for storage, provided that sufficient numbers of cells are frozen to ensure good 
representation of the constructs. Thus, the target cell line or cell lines can also be chosen with 
potential future uses in mind.
Library Size
 Choosing an shRNA library is clearly  very important, as the quality, size, and format of 
the library will determine many downstream experimental factors. A number of vendors sell 
whole genome libraries as well as smaller more focused libraries aimed at certain cellular 
processes, such as apoptosis or phosphorylation. While it may seem as if a whole genome library 
is always the best choice, the size of these libraries do make the screen more cumbersome and 
can reduce the overall quality  of the data. This is due to considerations of maintaining library 
representation throughout all steps of the experiment. At a minimum, all manipulations should be 
carried out such that each individual shRNA construct is represented 10-fold. For example, if a 
library with 5,000 constructs in transduced into cells with 50% efficiency (half of cells contain 
an shRNA insert), at  least 100,000 cells (5,000x10x2) would need to be maintained at all times. 
Ideally, the representation would be over 10-fold, with some literature reports suggesting that 
100-fold to 1,000-fold representation should be maintained.73 Thus, as the number of constructs 
and the desire for high-quality data increases, the number cells that are needed to maintain 
appropriate representation of the library increases proportionally. As such, if there is evidence 
that suggests a smaller focused library would be useful, its use should be given serious 
consideration. 
Library Format
 Libraries are commonly  sold as either plasmids or as packaged pseudoviral particles. Pre-
packaged libraries are generally  easier to use, as the target cell line can simply  be transduced 
with the psuedoviral particles and shortly thereafter employed in an assay. Plasmid format 
libraries require packaging into pseudoviral particles, a non-trivial step that requires optimization 
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as well as costly reagents such as transfection reagents, packaging plasmids, a viral producer cell 
line and viral particle concentration reagents. Logistically, one must take into consideration that 
even a single freeze-thaw cycle will reduce the infection efficiency of psuedoviral particles by 
approximately 30%. 
Selection Mode
 Commercial libraries are sold with one or more reporter/selection gene on the shRNA 
insert to allow for monitoring of transduction efficiency as well as selection for insert-containing 
cells over non-transduced cells. In order to transduce cells to achieve one shRNA per cell (copy 
number <1), the resulting collection of cells must have less than 100% transduction efficiency. 
Generally, if the percent transduction is below 60%, this statistically corresponds to each 
transduced cell having only  one insert. Reporters such as fluorescent proteins can be used at this 
stage to determine the percent transduction, usually  by flow cytometry. In addition, kits to 
determine the viral titer are also available and are especially  useful if no fluorescent reporter is 
present. 
 Once the target cells have been transduced, the decision to carry along the untransduced 
cells or enrich for only transduced cell before continuing is left  to the experimentalist. The 
simplest way to obtain a cell population in which all cells contain an shRNA insert is to use a 
library containing a puromycin selection vector. In this case, puromycin can simply  be added to 
the cells after successful transduction, and the untransduced cell will die. Puromycin can be 
utilized when needed throughout the experiment to ensure that unwanted contamination with 
cells lacking an shRNA insert does not occur. If no puromycin or similar selection vector is 
utilized, it may be possible to enrich for transduced cells by cell sorting. If cell sorting will be 
used, the cell line and library size must be very carefully selected. Clumping of cells, which is 
often a problem with adherent cancer cell lines, can drastically  reduce the speed and fidelity of 
cell sorting. In addition, the speed of sorting with even high-end instruments coupled with the 
need to maintain 10 to 1,000-fold representation of each shRNA construct make sorting an 
untenable option for large shRNA libraries.
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Analysis
 At the end of all shRNA experiments, the identity  and proportional levels of shRNA 
constructs must be determined. In some instances where very small shRNA libraries and positive 
selection methods are used, individual colonies may be isolated and their inserts sequenced. For 
large libraries the most common method is microarry  analysis. For microarray analysis, the total 
DNA or RNA can be isolated from cells, amplified and tagged by PCR, then applied to an 
appropriate chip and the abundance of each transcript determined. Some of the disadvantages of 
microarray  analysis are the requirement for biotin-tagged (or other similar tag) PCR primers and 
the need for one microarray per sample, at a cost of around $400 per microarray. Recently, as the 
price of sequencing continues to decrease, high-throughput next generation sequencing 
techniques have been used to analyze the outcomes of large shRNA screens. Here the inserts can 
similarly  be amplified by  PCR, tagged with appropriate adaptor sequences, and sequenced. In 
this case, the PCR primers simply need to contain sequences for binding to the flow cell, and if 
appropriate barcodes are included in one of the primers, samples can be multiplexed to further 
reduce the cost. Additionally, recent analyses of microarry versus sequencing have found that the 
dynamic range and sensitivity of sequencing analysis is significantly better than that of 
microarray analysis.74
4.8.3 Positive selection whole-genome shRNA screen with 1257
 A positive-selection shRNA screen was designed in which three different ER stress-
inducing cytotoxins (1257, thapsigargin, and tunicamycin) were investigated. Each compound 
was employed at a concentration that would induce >90% cell death and cells that were able to 
survive this treatment were allowed to recover, and the shRNA constructs were analyzed by next 
generation sequencing. By comparing the relative abundance of each shRNA construct in treated 
cells to those of control cells, the constructs enriched by each treatment, and thus which proteins 
are necessary for cytotoxin-induced cell death, can be determined (Figure 4.29)
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Figure 4.29. Depiction of expected shRNA screen results: plot of shRNA construct abundance in treated cells vs. 
control cells. Enriched shRNA constructs (green, circled) should correspond to proteins critical for compound-
induced cell death. Depleted constructs and those with no change are less informative in this experiment.
 MiaPaca-2 cells, a pancreatic cancer cell line, were chosen as the target cell line, as they 
are easily transducible, and behave similarly to U937 cells when exposed to 1257. For example, 
cell death occurs rapidly upon treatment with 1257, and this cell death is prevented by salubrinal 
(Figure 4.30). Additionally, 1257 has a similar potency in MiaPaca-2 cells (IC50 = 8.8 µM) to 
other cell lines tested. 
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Figure 4.30. Viability of MiaPaca-2 cells after treatment with 12.5 µM 1257 with or without a 2 h pre-treatment 
with 100 µM salubrinal, assessed by flow cyotmetry (AnnV/PI), n=3, s.e.m.
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 Our lab has previously  utilized the GeneNet Human 50K siRNA Library, which contains 
200,000 constructs targeting 47,500 human genes (3-5 constructs per gene).75,76  Since no ER 
stress-specific libraries are currently  available, the library  on hand was chosen. With a genome-
wide library, this experiment benefits from the advantages of conducting a fully unbiased screen. 
Thus, shRNAs involved in any cellular process important for 1257 activity may be identified.
 The GeneNet Human 50K siRNA Library was purchased in the plasmid format, and thus 
the first step was to package the library  into FIV psuedoviral particles. This was accomplished by 
transfecting the library plasmid and pPACK-F1 packaging plasmids (Systems Bioscinces, Inc.) 
into HEK293-TN, a special cell line designed for viral particle production. This cell line must be 
used at a very  low passage number and cannot be allowed to reach full confluency, so proper 
advance planning and daily monitoring of this cell line is required for success. To ensure that all 
200,000 constructs were well-represented in the final pool of viral particles, at least 50 µg must 
be packaged at a time. Viral particles were harvested at  both 48 and 72 hours post-transfection, 
concentrated with PEG-it, pooled, and aliquoted before storing at  -80 ˚C. The transduction 
efficiency was assessed by small-scale transduction of MiaPaca-2 cells with varying amounts of 
viral particle solution and measurement of the percent GFP-positive cells by flow cytometry.
 Once the transduction efficiency of the FIV pseudoviral particles was established, 10 
million MiaPaca-2 cells were transduced and after 72 hours were determined to be 50% GFP 
positive. Previous efforts to sort similar populations of MiaPaca-2 cells had demonstrated that 
efficient cell sorting was only possible with very  low concentrations of cells (to avoid cell 
clumping), but that this low concentration made collecting 2 million cells, the minimum number 
needed, unfeasible. Thus, this population of 50% transduced cells was used in all three replicates 
without removal of the untransduced cells.
 For each replicate of the screen, 4 million MiaPaca-2 cells (corresponding to 10-fold 
representation of each shRNA construct) were plated for each treatment and exposed to 1257, 
thapsigargin, tunicamycin, or DMSO. The size and representation of each replication was chosen 
to accommodate limitations in cell culture space and compound quanitites (both synthetic and 
commercial). Concentrations and exposure times were optimized for each cytotoxin and, after 
wash-out of the cytoxoin cells, were allowed to recover and grow to near-confluency. Genomic 
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DNA was isolated from each sample and the shRNA inserts were amplified by nested PCR 
(Figure 4.31). In the first round of PCR, primers complementary to flanking regions were used 
and the cDNA product obtained from this reaction was used in a further round of PCR with 
nested primers. 
3’ ΔLTR WPRE H1 Promoter siRNA sense loop siRNA antisense term. 
gDNA 
forward  
primer 
reverse 
primer 
H1 Promoter siRNA sense siRNA antisense term. 
PCR Round 1 
loop 
cDNA 
227 bp 
nested reverse 
tagged and 
barcoded primer 
nested forward  
tagged primer 
siRNA antisense term. loop P5 tag P7 tag barcode 
PCR Round 2 
170 bp 
Figure 4.31. Schematic of nested PCR steps for isolation and amplification of shRNA inserts from genomic DNA 
(gDNA) of surviving MiaPaca-2 cells. WPRE = Woodchuck hepatitis virus posttranscriptional regulatory element; 
LTR = long terminal repeat. 
 The nested primers were designed, in conjunction with Dr. Alvaro Hernandez in the DNA 
Services Facility, to provide end sequences complementary to Illumina sequencing chips and 
were partially based on the primers used by Caporaso and coworkers.77  The nested forward 
primer contains a sequence complementary to the loop sequence and a P5 Illumina adapter 
sequence, and the same primer was used for all 12 samples. The nested reverse primer contains a 
sequence complementary to the long terminal repeat region, a 12-base pair barcode sequence, 
and a P7 Illumina adapter sequence. The barcode sequence must be different for each sample, 
thus a unique nested reverse primer was designed for each sample. 
 The final PCR products were checked for quality  and purity using a Bioanalyzer 
(performed by the Functional Genomics Facility) and quantified by Qubit (performed by the 
Functional Genomics Facility). Equal amounts of DNA from each sample were mixed together 
and submitted for Illumina HiSeq analysis in single-read mode (performed by the DNA Services 
Facility).
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4.8.4 Preliminary shRNA screen results
 Sequencing of the amplified shRNA constructs by the DNA Services Facility resulted in 
over 118 million reads, each 50 nucleotides in length, with excellent  quality  over the constructs. 
Out of the approximately  200,000 constructs present in the library, over 62,000 were observed in 
the final samples. These constructs targeted a total of 21,000 genes, approximately 44% of the 
human genome. Loss of some constructs is expected due to the toxicity of certain constructs. 
Due to experimental constraints that limited the total fold-representation of each construct to a 
minimum of 10, some constructs could have been lost during transduction or subsequent 
culturing of cells.
 Statistical analysis of the sequencing results was carried out by the High-Performance 
Biological Computing group. This analysis identified many  enriched constructs from each 
compound-treated sample varying from 14- to 782-fold enrichment compared to the DMSO-
treated cells. Genes targeted by constructs enriched in 1257-, thapsigargin-, and tunicamycin-
treated samples are listed in Tables 4.7-4.9, respectively. While these genes are not yet validated, 
they  do provide a number of interesting possibilities for further investigation. The most enriched 
construct in the 1257-treated sample targets ITPR3, which codes for the inositol 1,4,5-
triphosphate receptor 3, or IP3R. IP3R is a ligand-gated calcium channel which can participate in 
signaling for ER stress. Additionally, a number of constructs enriched in the 1257-treated sample 
code for proteins involved in glycosyl transfer or ubiquitination. Future efforts will concentrate 
on validating the constructs enriched in 1257-treated cells using siRNA. If knock-down of a gene 
is shown to decrease sensitivity  of MiaPaca-2 cells to the cytotoxicity  of 1257, then the protein 
product of that gene will be further investigated for its role in 1257-induced cell death.
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Symbol Gene Name Fold Change 1257 vs DMSO
ITPR3  inositol 1,4,5-triphosphate receptor 3 383
NCF4  neutrophil cytosolic factor 4 333
PRSS53  protease, serine, 53 315
NCOA3  nuclear receptor coactivator 3 209
ELF1  E74-like factor 1 (ets domain transcription factor) 184
GNAT2  guanine nucleotide binding protein (G protein) 165
RNMT  RNA (guanine-7-) methyltransferase 150
HNRNPH3  heterogeneous nuclear ribonucleoprotein H3 (2H9) 147
RASA1  RAS p21 protein activator (GTPase activating protein) 1 141
CACYBP  calcyclin binding protein 135
IL17RB  interleukin 17 receptor B 134
RRBP1  ribosome binding protein 1 133
CLK3  CDC-like kinase 3 124
RNF4  ring finger protein 4 123
RNASE2  ribonuclease, Rnase A family, 2 116
GANAB alpha glucosidase 2 111
TSC2  tuberous sclerosis 2 104
TTTY1  testis-specific transcript 102
UTP11L  UTP11-like 100
NEIL3  nei endonuclease VIII-like 3 99
PPM1H  protein phosphatase 94
SLC7A6  solute carrier family 7 (amino acid transporter light chain) 94
KIAA0430  KIAA0430 93
HIST1H2BG  histone cluster 1 92
RTN3  reticulon 3 87
ARHGAP1  Rho GTPase activating protein 1 85
KBTBD7  kelch repeat and BTB (POZ) domain containing 7 84
SLC22A4  solute carrier family 22 (organic cation/zwitterion transporter) 83
FEZ2  fasciculation and elongation protein zeta 2 (zygin II) 82
MEAF6  MYST/Esa1-associated factor 6 78
RAB26  RAB26, member RAS-oncogene family 77
ESRP1  epithelial splicing regulatory protein 1 77
NTN3  netrin 3 76
COBLL1  cordon-bleu WH2 repeat protein-like 1 75
MKRN2  makorin ring finger protein 2 75
MAN1A2  mannosidase 74
REEP5  receptor accessory protein 5 74
SATL1  spermidine/spermine N1-acetyl transferase-like 1 74
OSBPL7  oxysterol binding protein-like 7 74
FLVCR1  feline leukemia virus subgroup C cellular receptor 1 73
SGMS2  sphingomyelin synthase 2 73
ESR1  estrogen receptor 1 72
PPIE  peptidylprolyl isomerase E (cyclophilin E) 71
POU5F1  POU class 5 homeobox 1 71
Symbol Gene Name Fold Change 1257 vs DMSO
CDH18  cadherin 18 70
POLR2J2  polymerase (RNA) II (DNA directed) polypeptide J2 70
ZNF148  zinc finger protein 148 66
SKIV2L2  superkiller viralicidic activity 2-like 2 (S. cerevisiae) 65
ZNF85 zinc finger protein 85 65
FICD  FIC domain containing 64
MTMR9  myotubularin related protein 9 64
UAP1  UDP-N-acteylglucosamine pyrophosphorylase 1 63
DPPA4  developmental pluripotency associated 4 63
NIT2  nitrilase family 62
PEBP1  phosphatidylethanolamine binding protein 1 62
IDH3A  isocitrate dehydrogenase 3 (NAD+) alpha 62
CCPG1  cell cycle progression 1 61
MCAT  malonyl CoA:ACP acyltransferase (mitochondrial) 61
SCNM1  sodium channel modifier 1 61
VN1R1  vomeronasal 1 receptor 1 60
CYP2C19  cytochrome P450 60
CMTR1  cap methyltransferase 1 59
SUGP1  SURP and G patch domain containing 1 59
PERP  PERP, TP53 apoptosis effector 59
TAF6L  TAF6-like RNA polymerase II 56
MRTO4  mRNA turnover 4 homolog (S. cerevisiae) 54
HS2ST1  heparan sulfate 2-O-sulfotransferase 1 54
LAMP1  lysosomal-associated membrane protein 1 53
CFH  complement factor H 52
DPYSL3  dihydropyrimidinase-like 3 52
SUPT7L  suppressor of Ty 7 (S. cerevisiae)-like 51
SLC25A20  solute carrier family 25 (carnitine/acylcarnitine translocase) 50
UBA1  ubiquitin-like modifier activating enzyme 1 47
SYN1  synapsin I 46
CYP2A7P1  cytochrome P450 45
PRC1  protein regulator of cytokinesis 1 44
PIGC  phosphatidylinositol glycan anchor biosynthesis 44
HMMR  hyaluronan-mediated motility receptor (RHAMM) 44
DEK  DEK oncogene 44
RPN2  ribophorin II 43
COL5A1  collagen 40
MCF2  MCF.2 cell line derived transforming sequence 39
STX16  syntaxin 16 39
TJAP1  tight junction associated protein 1 (peripheral) 39
ELOVL6  ELOVL fatty acid elongase 6 38
PRRG4  proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 37
NFAT5  nuclear factor of activated T-cells 5 34
GSDMB  gasdermin B 33
Table 4.7. shRNA constructs enriched in 1257-treated MiaPaca-2 cells compared to DMSO-treated cells.
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Symbol Gene Name
Fold Change 
Thapsigargin 
vs DMSO
HECW1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 782
PHF14 PHD finger protein 14 549
GUCY1B3 guanylate cyclase 1, soluble, beta 3 505
RBM15 RNA binding motif protein 15 483
YBEY ybeY!metallopeptidase!(putative)! 472
ANKMY1 ankyrin repeat and MYND domain containing 1 342
CLEC4A C-type lectin domain family 4, member A 273
CYLD cylindromatosis (turban tumor syndrome) 267
NHLRC3 NHL repeat containing 3 264
GK glycerol kinase 3 pseudogene; glycerol kinase 258
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 248
NCF4 neutrophil cytosolic factor 4, 40kDa 242
LONRF1 LON peptidase N-terminal domain and ring finger 1 238
ACVR1C activin A receptor, type IC 236
NGDN neuroguidin, EIF4E binding protein 233
BLZF1 basic leucine zipper nuclear factor 1 231
UBB ubiquitin B 229
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 228
CPXCR1 CPX chromosome region, candidate 1 222
RACGAP1 Rac GTPase activating protein 1 pseudogene; Rac GTPase 
activating protein 1
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PYHIN1 pyrin and HIN domain family, member 1 197
HINT1 histidine triad nucleotide binding protein 1 183
CLK3 CDC-like kinase 3 182
TOX4 TOX high mobility group box family member 4 181
UBR2 ubiquitin protein ligase E3 component n-recognin 2 179
TNK2 tyrosine kinase, non-receptor, 2 175
EFCAB1 EF-hand calcium binding domain 1 174
PRSS53  protease, serine, 53 164
DIO2 deiodinase, iodothyronine, type II 164
TSC22D2 TSC22 domain family, member 2 157
ST8SIA5 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 151
CENPU centromere protein U 150
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 145
CDC42SE1 CDC42 small effector 1 143
GFRA4 GDNF family receptor alpha 4 139
HTN1 histatin 1 135
PIGC phosphatidylinositol glycan anchor biosynthesis, class C 132
PRC1 protein regulator of cytokinesis 1 131
VN1R1 vomeronasal 1 receptor 1 127
MFN1 mitofusin 1 126
Symbol Gene Name
Fold Change 
Thapsigargin 
vs DMSO
BDNF brain-derived neurotrophic factor 126
PIAS1 protein inhibitor of activated STAT, 1 125
PARL presenilin associated, rhomboid-like 117
CUL4B cullin 4B 115
MECP2 methyl CpG binding protein 2 (Rett syndrome) 115
TES testis derived transcript (3 LIM domains) 114
NEIL3 nei endonuclease VIII-like 3 102
SOS2 son of sevenless homolog 2 102
PLAC4 placenta-specific 4 101
TTTY15 testis-specific transcript, Y-linked 15 101
TOR1B torsin family 1, member B (torsin B) 101
LENEP lens epithelial protein 96
ARNTL aryl hydrocarbon receptor nuclear translocator-like 93
CD300C CD300c molecule 92
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 91
TTC22 tetratricopeptide repeat domain 22 91
RSAD1 radical S-adenosyl methionine domain containing 1 90
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 87
PEBP1 phosphatidylethanolamine binding protein 1 83
AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde 
reductase)
82
ZMYM6 hypothetical LOC100130633; zinc finger, MYM-type 6 80
EMC3 ER membrane protein complex subunit 3 77
CACNA1C hypothetical protein LOC100131098; calcium channel, voltage-
dependent, L type, alpha 1C subunit
77
E2F5 E2F transcription factor 5, p130-binding 76
DIEXF digestive organ expansion factor homolog 74
ATL2 atlastin GTPase 2 73
KCNA1 potassium voltage-gated channel, shaker-related subfamily, 
member 1 (episodic ataxia with myokymia)
71
NAA35 MAK10 homolog, amino-acid N-acetyltransferase subunit 71
TSHR thyroid stimulating hormone receptor 69
SEMA3G sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3G
69
CFH complement factor H 68
GPATCH1 G patch domain containing 1 67
TAF6L TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-
associated factor, 65kDa
66
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 64
PDZK1 PDZ domain containing 1 62
ITPR3 inositol 1,4,5-triphosphate receptor, type 3 58
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase)
37
KIAA0485 hypothetical LOC57235 19
H2AFV H2A histone family, member V 4
Table 4.8. shRNA constructs enriched in thapsigargin-treated MiaPaca-2 cells compared to DMSO-treated cells.
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Symbol Gene Name
Fold Change 
Tunicamycin 
vs DMSO
CSNK1G2  casein kinase 1 570
MAPRE1  microtubule-associated protein 367
DAZAP2  DAZ associated protein 2 353
PDC  phosducin 290
ZFAND6  zinc finger, AN1-type domain 6 278
TTLL5  tubulin tyrosine ligase-like family 242
DCAF6  DDB1 and CUL4 associated factor 6 224
WNK3  WNK lysine deficient protein kinase 3 199
SMG7-AS1  SMG7 antisense RNA 1 168
DEDD  death effector domain containing 162
EPOR  erythropoietin receptor 151
DEK  DEK oncogene 146
GLCE  glucuronic acid epimerase 141
STK17A  serine/threonine kinase 17a 133
ARHGAP11A  Rho GTPase activating protein 11A 128
ARMCX2  armadillo repeat containing 126
SMIM3  small integral membrane protein 3 126
RECQL  RecQ helicase-like 125
ADH1A  alcohol dehydrogenase 1A (class I) 124
PROX1  prospero homeobox 1 123
ARHGEF12  Rho guanine nucleotide exchange factor (GEF) 12 103
TNFRSF9  tumor necrosis factor receptor superfamily 99
TYRO3  TYRO3 protein tyrosine kinase 99
WDR74  WD repeat domain 74 97
P2RY6  pyrimidinergic receptor P2Y 86
RNF17  ring finger protein 17 84
CNGB3  cyclic nucleotide gated channel beta 3 79
TCTN3  tectonic family member 3 75
CAMTA2  calmodulin binding transcription activator 2 73
TPI1  triosephosphate isomerase 1 70
ALG8  ALG8, alpha-1,3-glucosyltransferase 69
EPB41L5  erythrocyte membrane protein band 4.1 like 5 69
PNN  pinin 69
LARS2  leucyl-tRNA synthetase 2 69
BMP8A  bone morphogenetic protein 8a 68
MYCN  v-myc avian myelocytomatosis viral oncogene 
neuroblastoma derived homolog
67
PAQR3  progestin and adipoQ receptor family member III 67
GPSM3  G-protein signaling modulator 3 67
CPM  carboxypeptidase M 63
SGMS2  sphingomyelin synthase 2 63
SENP7  SUMO1/sentrin specific peptidase 7 62
BAG3  BCL2-associated athanogene 3 58
SH3YL1  SH3 and SYLF domain containing 1 55
PLD1  phospholipase D1 53
ZMYM6  zinc finger, MYM-Type 6 51
COPS8  COP9 signalosome subunit 8 50
UBE2L3  ubiquitin-conjugating enzyme E2L 3 47
LTBP2  latent transforming growth factor beta binding protein 2 45
TAGLN2  transgelin 2 41
H2AFY  H2A histone family 41
ADAM12  ADAM metallopeptidase domain 12 40
EXPH5  exophilin 5 39
ENOX2  ecto-NOX disulfide-thiol exchanger 2 31
ZDHHC17  zinc finger, DHHC-type containing 17 19
PREX2  phosphatidylinositol-3 -3,4,5-trisphosphate-eependent 
rac exchange factor
14
Table 4.9. shRNA constructs enriched in tunicamycin-treated MiaPaca-2 cells compared to DMSO-treated cells.
 
4.9 Hemolysis assay
 To assess the translational potential of 1257, an in vitro hemolysis assay was utilized to 
determine whether this compound has any toxicity in human red blood cells.
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4.9.1 Applicability of hemolysis assay 
  In the clinic, drug-induced hemolytic anemia can be induced via immune system-
mediated and immune system-independent mechanisms. Although rare, drug-induced immune 
hemolytic anemia is known to occur with certain commonly-used drugs, such as cefotetan, 
ceftriaxone, penicillin, and piperacillin. The general mechanism in these cases is thought to be 
binding of the drug to the outer membrane of red blood cells, which causes the production of 
antibodies against the bound drug and subsequent destruction of red blood cells by the immune 
system.78
 Most drug-induced non-immune hemolysis occurs via oxidative pathways, though some 
drug-induced hemolysis mechanisms have not  been fully elucidated. The ability of primaquine, 
an antimalarial, to induce an increase in hydrogen peroxide within blood cells leading to Heinz 
body formation and cell lysis is well known.79,80  The mechanism of dapsone-induced hemolysis 
occurs through N-hydroxylation that leads to the formation of methemoglobin, which can then 
lead to hemolysis.81  The biggest risk for oxidative hemolytic anemia is faced by  individuals 
harboring an inactivating glucose-6-phosphate dehydrogenase (G6PD) mutation, though this 
condition can occur even in people with wild-type G6PD. Within red blood cells, G6PD is a 
major producer of NADPH, which is required for various antioxidant processes that help prevent 
the formation of methemoglobin. Other mechanism for the induction of hemolysis can also by 
envisioned, such as inhibition of key anti-oxidant enzymes, interference with the function of 
hemoglobin to induce greater superoxide formation, as well as inhibition or over-activation of 
ion channels that regulate cellular volume.
 Simple in vitro hemolysis assays can be used to assess the potential for drug-induced 
hemolysis with lead compounds.82  The type of hemolysis observed in this assay is necessarily 
immune system-independent, as the red blood cells are prepared by pelleting and washing to 
remove the serum, which contains white bloods cells and antibodies. Hemolysis measurements 
have also been found to be good predictors of in vivo effects.83  
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4.9.2 Analysis of 1257 and related compounds
 Dose-response curves for lysis of whole human red blood cells were generated for each 
1257 analog with anticancer activity. Most analogs with anticancer activity did not induce 
significant hemolysis (>10%) until 100 µM compound was reached, but high levels of hemolysis 
were induced by 1257 starting at 30 µM (Figure 4.32). Additionally, none of the analogs without 
anticancer activity caused more than 15% hemolysis at 100 µM.
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Anticancer: 
IC50 = 15 ± 4.8 µM 
Hemolysis: 
IC50 > 100 µM 
Anticancer: 
IC50 = 20 ± 3.6 µM 
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IC50 = 28.4 µM 
Figure 4.32. Dose-response hemolysis (red) and Hs578t cytotoxicity (blue) curves for 1257 and related active 
analogs. IC50 values for each activity are indicated on each graph. Compound was incubated with washed 
erthrocytes for 2 h at 37 ˚C, then centrifuged to pellet cells and cellular debris, the supernatent was removed and 
absorbance at 540 nm was measured to determine the relative amounts of released hemoglobin.
Unfortunately, due to the very small difference between the concentrations of 1257 required for 
activity and those that induce hemolysis, the translational potential of this compound is very  low. 
However, the low levels of hemolysis induced by the other compounds in this series suggest that 
this structural class is not necessarily predisposed to high levels of hemolysis and a suitable 
active but non-toxic analog may be developed.
 Due to the high hemolytic activity  of 1257, recent efforts have focused on analog 1258 
and its activity. This compound induces cancer cell death with a somewhat reduced potency 
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compared to 1257, and also displays the steep slope and high Emax values that characterize 1257 
(Figure 4.33).
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Figure 4.33. Representative dose-response curves, average Hill Slope values and average Emax values for 1258 in 
4T1 and Hs578t cell lines. All dose-response curves were determined after 48 h incubation with alamar blue and 
fitted to a sigmoidal dose-response curve.
  Additionally, cell death induced by 1258 is similarly counteracted by salubrinal in U937 
human lymphoma cells (Figure 4.34). Thus, 1258 likely  has a similar mechanism of action to 
1257 and may provide a fruitful road for the development of this class of compounds.
0 
20 
40 
60 
80 
100 
DMSO 1258 1258+Sal 
Pe
rc
en
t C
el
ls
 A
liv
e 
Figure 4.34. Protection provided by salubrinal when U937 cells are treated with 1258. U937 cells were pre-
incubated with 100 µM salubrinal for 2 h, then 30 µM 1258 was added cell viability was assessed after 3 h by flow 
cytometry (AnnV/PI). 
4.10 Summary and future directions for anticancer tetracyclic indoles
 Through the use of a high-throughput phenotypic screen, a novel tetracyclic indole with 
potent anticancer activity was discovered. Further characterization of 1257’s anticancer activity 
revealed that it  maintains potency in a wide diversity of cancer cell lines and consistently 
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displays a steep dose-response curve and high levels of cell death at high concentrations. 
Investigation into 1257’s mode of action revealed that it induces cell death very rapidly  and that 
this cell death can utilize apoptotic pathways, but does not  rely on them. One of the earliest 
effects of 1257 was found to be induction of endoplasmic reticulum stress, which is evident both 
biochemically and morphologically. Both ER stress and cell death induced by 1257 can be 
prevented through the action of PP1/GADD34 inhibitor salubrinal.
 Unfortunately, 1257 causes high levels of hemolysis of human red blood cells at 
concentrations very close to its effective anticancer concentrations. Thus, the related compound 
1258 is being assessed as a suitable lead compound for the development of this class of 
compounds. Current experiments are aimed at exploring whether 1258 has efficacy  in mouse 
models of breast cancer. The maximum tolerated dose levels for 1258 in mice are being 
established (by Dr. Hyang-Yeon Lee) in preparation for an anticancer efficacy model.
217
4.11 References
218
1. Palchaudhuri, R.; Nesterenko, V.; Hergenrother, P. J. The complex role of the triphenymethyl motif in anti-cancer 
compounds. J. Am. Chem. Soc. 2008, 130, 10274-10281.
2. Bair, J. S.; Palchaudhuri, R.; Hergenrother, P. J. Chemistry and biology of deoxynyboquinone, a potent inducer of 
cancer cell death. J. Am. Chem. Soc. 2010, 132, 5469-5478.
3. Gatza, M. L.; Lucas, J. E.; Barry, W. T.; Kim, J. W.; Wang, Q.; Crawford, M. D.; Datto, M. B.; Kelley, M.; 
Mathey-Prevot, B.; Potti, A.; Nevins, J. R. A pathway-based classification of human breast cancer. Proc. Natl. Acad. 
Sci. 2010, 107, 6994-6999.
4. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Prot. 2006, 1, 
1112-1116.
5. Rampersad, S. N. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health 
in cell viability bioassays. Sensors (Basel) 2012, 12, 12347-12360.
6. Spikes, J. D. Photosensitizing properties of quinine and synthetic antimalarials. J. Photoch. Photobio. B 1998, 42, 
1-11.
7. Morrison, K. Chemical diversification and anticancer activity of natural products. Ph.D. Dissertation, University 
of Illinois at Urbana-Champaign, Urbana, IL, 2013.
8. Granger, B. A.; Jewett, I. T.; Butler, J. D.; Hua, B.; Knezevic, C. E.; Parkinson, E. I.; Hergenrother, P. J.; Martin, 
S. F. Synthesis of (±)-actinophyllic acid and analogs: applications of cascade reactions and diverted total synthesis. 
J. Am. Chem. Soc. 2013, 135, 12984-12986.
9. Iyer, V. N.; Szybalski, W. Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of 
DNA. Science 1964, 145, 55-58.
10. Wassermann, K.; Markovits, J.; Jaxel, C.; Capranico, G.; Kohn, K. W.; Pommier, Y. Effects of morpholinyl 
doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharm. 1990, 38, 
38-45.
11. Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 1994, 5, S3-6.
12. Parkinson, E. I.; Bair, J. S.; Cismesia, M.; Hergenrother, P. J. Efficient NQO1 substrates are potent and selective 
anticancer agents. ACS Chem. Biol. 2013, 8, 2173-2183.
13. Belmokhtar, C. A.; Hillion, J.; Segal-Bendirdjian, E. Staurosporine induces apoptosis through both caspase-
dependent and caspase-independent mechanisms. Oncogene 2001, 20, 3354-3362.
14. Wictome, M.; Henderson, I.; Lee, A. G.; East, J. M. Mechanism of inhibition of the calcium pump of 
sarcoplasmic reticulum by thapsigargin. Biochem. J. 1992, 283, 525-529.
15. Ling, Y-H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P. J.; Adams, J.; Jiang, J-D.; Muggia, F. M.; Perez-Soler, R. 
PS-341, a novel proteasome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M phase 
arrest and apoptosis. Mol. Cancer Ther. 2002, 1, 841-849.
16. Wolan, D. W.; Zorn, J. A.; Gray, D. C.; Wells, J. A. Small-molecule activators of a proenzyme. Science 2009, 
326, 853-858.
17. Fallahi-Sichani, M.; Honarnejad, S.; Heiser, L. M.; Gray, J. W.; Sorger, P. K. Metrics other than potency reveal 
systematic variation in responses to cancer drugs. Nat. Chem. Biol. 2013, 9, 708-716.
18. Caserta, T. M.; Smith, A. N.; Gultice, A. D.; Reedy, M. A.; Brown, T. L. Q-VD-OPh, a broad spectrum caspase 
inhibitor with potent antiapoptotic properties. Apoptosis 2003, 8, 345-352.
219
19. Wolvetang, E. J.; Johnson, K. L.; Krauer, K.; Ralph, S. J.; Liannane, A. W. Mitochondrial respiratory chain 
inhibitors induce apoptosis. FEBS Lett. 1994, 339, 40-44.
20. Bakker, E. P.; van den Heuvel, E. J.; van Dam, K. The binding of uncouplers of oxidative phosphorylation to rat-
liver mitochondria. Biochim. Biophys. Acta. 1974, 333, 12-21.
21. Garcia-Rivas, G. D.; Carvajal, K.; Correa, F.; Zazueta, C. Ru360, a specific mitochondrial calcium uptake 
inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br. J. Pharmacol. 2006, 149, 829-837.
22. Komarov, P. G.; Komarova, E. A.; Kondratov, R. V.; Christov-Tselkov, K.; Coon, J. S.; Chernov, M. V.; Gudkov, 
A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285, 
1733-1737.
23. Strom, E.; Sathe, S.; Komarov, P. G.; Chernova, O. B.; Pavlovska, I.; Shyshynova, I.; Bosykh, D. A.; Burdelya, 
L. G.; Macklis, R. M.; Skaliter, R.; Komarova, E. A.; Gudkov, A. V. Small-molecule inhibitor of p53 binding to 
mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2006, 2, 474-479.
24. Becattini, B.; Sareth, S.; Zhai, D.; Crowell, K. J.; Leone, M.; Reed, J. C.; Pellecchia, M. Targeting apoptosis via 
chemical design: inhibition of bid-induced cell death by small organic molecules. Chem. Biol. 2004, 11, 1107-1117.
25. Peixoto, P. M.; Ryu, S. Y.; Bombrun, A.; Antonsson, B.; Kinnally, K. W. MAC inhibitors suppress mitochondrial 
apoptosis. Biochem. J. 2009, 423, 381-387.
26. Chen, Y-N.; Aihara, M.; Araie, M.; Matsuyama, S. Neuroprotective effects of bax-inhibiting peptides on hypoxic 
damages in purified cultured retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2005, 46, 1314.
27. Lademann, U.; Cain, K.; Gyrd-Hansen, M.; Brown, D.; Peters, D.; Jaatela, M. Diarylurea compounds inhibit 
caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. Mol. Cell. Biol. 
2003, 23, 7829-7837.
28. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G. D.; Mitchison, T. J.; Moskowitz, 
M. A.; Yuan, J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. 
Nat. Chem. Biol. 2005, 1, 112-119.
29. Bennett, B. L.; Sasaki, D. T.; Murray, B. W.; O’Leary, E. C.; Sakata, S. T.; Xu, W.; Leisten, J. C.; Motiwala, A.; 
Pierce, S.; Satoh, Y.; Bhagwat, S. S.; Manning, A. M.; Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of 
Jun N-terminal kinase. Proc. Natl. Acad. Sci. 2001, 98, 13681-13686.
30. Tsujinaka, T.; Kajiwara, Y.; Kambayashi, J.; Sakon, M.; Higuchi, N.; Tanaka, T.; Mori, T. Synthesis of a new cell 
penetrating calpain inhibitor (calpeptin). Biochem. Biophys. Res. Commun. 1988, 153, 1201-1208.
31. Vanderbist, F.; Maes. P.; Neve, J. In vitro comparative assessment of the antioxidant activity of nacystelyn 
against three reactive oxygen species. Arzneimittelforshung 1996, 46, 783-788.
32. Wong, E. H.; Kemp, J. A.; Priestley, T.; Knight, A. R.; Woodruff, G. N.; Iversen, L. L. The anticonvulsant 
MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. 1986, 83, 7104-7108.
33. Prentki, M.; Deeney, J. T.; Matschinsky, F. M.; Joseph, S. K. Neomycin: a specific drug to study the inositol-
phospholipid signalling system? FEBS Lett. 1986, 197, 285-288.
34. Papandreou, I.; Denko, N. C.; Olson, M.; Van Melckebeke, H.; Lust, S.; Tam, A.; Solow-Cordero, D. E.; Bouley, 
D. M.; Offner, F.; Niwa, M.; Koong, A. C. Identification of an IRE1apha endonuclease specific inhibitor with 
cytotoxic activity against human multiple myeloma. Blood 2011, 117, 1311-1314.
35. Axten, J. M.; Medina, J. R.; Feng, Y.; Shu, A.; Romeril, S. P.; Grant, S. W.; Li, W. H.; Heerding, D. A.; 
Minthorn, E.; Mencken, T.; Atkins, C.; Liu, Q.; Rabindran, S.; Kumar, R.; Hong, X.; Goetz, A.; Stanley, T.; Taylor, J. 
D.; Sigethy, S. D.; Tomberlin, G. H.; Hassell, A. M.; Kahler, K. M.; Shewchuk, L. M.; Gampe, R. T. Discovery of 7-
methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
(GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum 
kinase (PERK). J. Med. Chem. 2012, 55, 7193-7207.
220
36. de Almeida, S. F.; Picarote, G.; Gleming, J. V.; Carmo-Fonseca, M.; Azevedo, J. E.; de Sousa, M. Chemical 
chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J. Biol. Chem. 2007, 
282, 27905-27012.
37. el-Hayek, R.; Parness, J.; Valdivia, H. H.; Coronado, R.; Hogan, K. Dantrolene and azumolene inhibit 
[3H]PN200-110 binding to porcine skeletal muscle dihydropyridine receptors. Biochem. Biophys. Res. Commun. 
1992, 187, 894-900.
38. Berisha, S. Z.; Hsu, J.; Robinet, P.; Smith, J. D. Transcriptome analysis of genes regulated by cholesterol loading 
in two strains of mouse macrophages associates lysosome pathway and ER stress response with atherosclerosis 
susceptibility. PLOS ONE 2013, 8, e65003.
39. Boyce, M.; Bryant, K. F.; Jousse, C.; Long, K.; Harding, H. P.; Scheuner, D.; Kaufman, R. J.; Ma, D.; Coen, D. 
M.; Ron, D.; Yuan, J. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 2005, 
307, 935-939.
40. Kimball, S. R.; Eukaryotic initiation factor eIF2. Int. J. Biochem. Cell Biol. 1999, 31, 25-29.
41. Ron, D.; Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. 
Cell Biol. 2007, 8, 519-529.
42. Merksamer, P. I.; Papa, F. R. The UPR and cell fate at a glance. J. Cell Sci. 2010, 123, 1003-1006.
43. Wu, L.; Luo, N.; Zhao, H. R.; Gao, Q.; Lu, J.; Pan, Y.; Shi, J. P.; Tian, Y. Y.; Zhang, Y. D. Salubrinal protects 
against rotenone-induced SH-SY5Y cell death via ATF4-parkin pathway. Brain Res. 2014, 1549, 52-62.
44. Sokka, A. L.; Putkonen, N.; Mudo, G.; Pryazhnikov, E.; Reijonen, S.; Khiroug, L.; Belluardo, N.; Lindholm, D.; 
Korhonen, L. Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. J. 
Neurosci. 2007, 27, 901-908.
45. Drexler, H. C. A. Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and 
proteosome inhibitors. PLOS ONE 2009, 4, e4161.
46. Yokota, H.; Hamamura, K.; Chen, A.; Dodge, T. R.; Tanjung, N.; Abedinpoor, A.; Zhang, P. Effects of salubrinal 
on development of oseoclasts and osteoblasts from bone marrow-derived cells. BMC Musculoskelet. Disord. 2013, 
14, 197.
47. Pederzoli, M.; Kantari, C.; Gausson, V.; Mariceau, S.; Witko-Sarsat, V. Protinase-3 induces procaspase-3 
activation in the absence of apoptosis: potential role of this compartmentalized activation of membrane-associated 
procaspase-3 in neutrophils. J. Immunol. 2005, 174, 6381-6390.
48. Oslowski, C. M.; Urano, F. Measuring ER stress and the unfolded protein response using mammalian tissue 
culture system. Methods Enzymol. 2011, 490, 71-92.
49. Samali, A.; Fitzgerald, U.; Deegan, S.; Gupta, S. Methods for monitoring endoplasmic reticulum stress and the 
unfolded protein response. Int. J. Cell Biol. 2010, 10.1155/2010/830307.
50. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; 
El-Deiry, W. S.; Golstein, P.; Green, D. R.; Hengartner, M.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Malorni, W.; 
Nunez, G.; Peter, M. E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell 
death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2009, 16, 3-11.
51. Sun, M. G.; Williams, J.; Munoz-Pinedo, C.; Perkins, G. A.; Brown, J. M.; Ellisman, M. H.; Green, D. R.; Frey, 
T. G. Correlated three-dimensional light and electron microscopy reveals transformation of mitochondria during 
apoptosis. Nat. Cell Biol. 2007, 9, 1057-1065.
52. Bickle, M. The beautiful cell: high-content screening in drug discovery. Anal. Bioanal. Chem. 2010, 398, 
219-226.
221
53. Heynen-Genel, S.; Pache, L.; Chanda, S. K.; Rosen, J.; Functional genomic and high-content screening for target 
discovery and deconvolution. Expert Opin. Drug Discov. 2012, 7, 955-968.
54. Woehrmann, M. H.; Bray, W. M.; Durbin, J. K.; Nisam, S. C.; Michael, A. K.; Glassey, E.; Stuart, J. M.; Lokey, 
R. S. Large-scale cytological profiling for functional analysis of bioactive compounds. Mol. Biosyst. 2013, 9, 
2604-2617.
55. Young, D. W.; Bender, A.; Hoyt, J.; McWhinnie, E.; Chirn, G-W.; Tao, C. Y.; Tallarico, J. A.; Labow, M.; 
Jenkins, J. L.; Mitchison, T. J.; Feng, Y. Integrating high-content screening and ligand-target prediction to identify 
mechanism of action. Nat. Chem. Biol. 2008, 4, 59-68.
56. Schulze, C. J.; Bray, W. M.; Woerhmann, M. H.; Stuart, J.; Lokey, R. S.; Linington, R. G. “Function-first” lead 
discovery: mode of action profiling of natural product libraries using image-based screening. Chem. Biol. 2013, 20, 
285-295.
57. Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. J.; Lerner, J.; Brunet, J-P.; 
Subramanian, A.; Ross, K. N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. 
A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. F. The connectivity map: using gene-expression signatures to 
connect small molecules, genes, and disease. Science 2006, 313, 1929-1935.
58. Palchaudhuri, R.; Hergenrother, P. J. Transcript profiling and RNA interference as tools to identify small 
molecule mechanisms and therapeutic potential. ACS Chem. Biol. 2010, 6, 21-33.
59. Reich, N. C. A death-promoting role for ISG54/IFIT2. J. Interf. Cytok. Res. 2013, 33, 199-205.
60. Arachchge, D. A. S.; Dallapiazza, R. F.; Bennin, D. A.; Brake, T.; Cowan, C. E.; Horne, M.C. Cyclin G2 is a 
centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-
dependent cell cycle arrest. Exp. Cell Res. 2006, 31, 4181-4204.
61. Chen, C. L.; Lin, C. F.; Chang, W. T.; Huang, W. C.; Teng, C. F.; Lin, Y. S. Ceramide induces p38 MAPK and 
JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood 2008, 
111, 4365-4374.
62. Lawson, B.; Brewer, J. W.; Hendershot, L. M. Geldanamycin, an hsp90/GRP94-binding drug, induces increased 
transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J. Cell. Phys. 1998, 174, 
170-179.
63. Meredith, E. J.; Holder, M. J.; Rosen, A.; Lee, A. D.; Dyer, M. J.; Barnes, N. M.; Gordon, J. Dopamine targets 
cycling B cells independent of receptors/transporter for oxidative attack: implications for non-Hodgkins lymphoma. 
Proc. Natl. Acad. Sci. 2006, 103, 13485-13490.
64. Dow, G. S.; Hudson, T. H.; Vahey, M.; Koenig, M. L. The acute neurotoxicity of mefloquine may be mediated 
through a disruption of calcium homeostasis and ER function in vitro. Malar. J. 2003, 2, 10.1186/1475-2875-2-14.
65. Hondeghem, L. M.; Dujardin, K.; Hoffmann, P.; Dumoteir, B.; De Clerck, F. Drug-induced QTC prolongation 
dangerously underestimates proarrhythmic potential: lessons from terfenadine. J. Cardiovasc. Pharmacol. 2011, 57, 
589-597.
66. Medina, V. A.; Rivera, E. S. Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 2010, 161, 
755-767.
67. Liu, J-D.; Wang, Y-J.; Chen, C-H.; Yu, C-F.; Chen, L-C.; Lin, J-K.; Liang, Y-C.; Lin, S-Y.; Ho, Y-S. Molecular 
mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Mol. Carcinog. 
2003, 37, 39-50.
68. Jangi, S. M.; Ruiz-Larrea, M. B.; Nicolau-Galmes, F.; Adnollo, N.; Arroyo-Berdugo, Y.; Ortega-Martinez, I.; 
Diaz-Perez, J. L.; Boyano, M. D. Terfenadine-induced apoptosis in human melanoma cells is mediated through Ca2+ 
homeostasis modulation and tyrosine kinase activity, independently of H1 histamine receptors. Carcinogenesis 
2008, 29, 500-509.
222
69. Oh, R. S.; Pan, W-C.; Yalcin, A.; Zhang, H.; Guilarte, T.R.; Hotamisligil, G. S.; Christiani, D. C.; Lu, Q. 
Functional RNA interference (RNAi) screen identifies system A neutral amino acid transporter 2 (SNAT2) as a 
mediator of arsenic-induced endoplasmic reticulum stress. J. Biol. Chem. 2012, 287, 6025-6034.
70. Kitambi, S. S.; Toledo, E. M.; Usoskin, D.; Wee, S.; Harisankar, A.; Svensson, R.; Sigmundsson, K.; Kalderern, 
C.; Niklasson, M.; Kundu, S.; Aranda, S.; Westermark, B.; Uhrbom, L.; Andang, M.; Damberg, P.; Nelander, S.; 
Arenas, E.; Artursson, P.; Walfridsson, J.; Nilsson, K. F.; Hammarstrom, L. G. J.; Ernfors, P. Vulnerability of 
glioblastoma cells to catastrophic vacuolization and death induced by a small molecule. Cell 2014, 157, 313-328.
71. Mendes-Pereira, A. M.; Sims, D.; Dexter, T.; Fenwick, K.; Assiotis, I.; Kozarewa, I.P.; Mitsopoulos, C.; Hakas, 
J.; Zvelebil, M.; Lord, C. J.; Ashworth, A. Genome-wide functional screen identifies a compendium of genes 
affecting sensitivity to tamoxifen. Proc. Natl. Acad. Sci. 2012, 109, 2730-2735.
72. Kittanakom, S.; Arnoldo, A.; Brown, K. R.; Wallace, I.; Kunavisarut, T.; Torti, D.; Heisler, L. E.; Surendra, A.; 
Moffat, J.; Giaever, G.; Nislow, C. Miniature short hairpin RNA screens to characterize antiproliferative drugs. G3 
(Bethesda) 2013, 3, 1375-1387.
73. Rodriguez-Barrueco, R.; Marshall, N.; Silva, J. M. Chapter 21 Pooled shRNA screenings: experimental 
approach. Pancreatic Cancer: Methods and Protocols, Methods in Molecular Biology, 2013, 980, 353-370.
74. Sims, D.; Mendes-Pereira, A. M.; Frankum, J.; Burgess, D.; Cerone, M-A.; Lombardelli, D.; Mitsopoulos, C.; 
Hakas, J.; Murugaesu, N.; Isacke, C. M.; Fenwick, K.; Assiotis, I.; Kozarewa, I.; Zvelebil, M.; Ashworth, A.; Lord, 
C. J. High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. 
Genome Biol. 2011, 12, R104.
75. SBI Human Genome-wide Pooled lentivirus RNAi screens. http://www.systembio.com/rnai-libraries/human-
genome-wide/technical-details (accessed May 2014).
76. Palchaudhuri, R. Development and mechanistic characterization of novel small molecules as cancer therapeutics. 
Ph.D. Dissertation, University of Illinois at Urbana-Champaign, Urbana, IL, 2011.
77. Caporaso, J. G.; Lauber, C. L.; Walters, W. A.; Berg-Lyons, D.; Huntley, J.; Fierer, N.; Owens, S. M.; Betley, J.; 
Fraser, L.; Bauer, M.; Gormley, N.; Gilbert, J. A.; Smith, G.; Knight, R. Ultra-high-throughput microbial community 
analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012, 1-4.
78. Garratty, G. Drug-induced immune hemolytic anemia. Hematology 2009, 73-79.
79. Summerfield, M.; Tudhope, G. R. Studies with primaquine in vitro: superoxide radical formation and oxidation 
of haemoglobin. Br. J. Clin. Pharmacol. 1978, 6, 319-323.
80. Bolchoz, L. C.; Budinsky, R. A.; McMillan, D. C.; Jollow, D. J. Primaquine-induced hemolytic anemia: 
formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J. 
Pharmacol. Exp. Ther. 2001, 297, 509-515.
81. Coleman, M. D. Dapsone toxicity: some current perspectives. Gen. Pharmacol. 1995, 26, 1461-1467.
82. Salauze, D.; Decouvelaere, D. In vitro assessment of the haemolytic potential of candidate drugs. Comp. 
Haematol. Int. 1994, 4, 34-36.
83. Cho, W-S.; Duffin, R.; Bradley, M.; Megson, I. L.; MacNee, W.; Lee, J. K.; Jeong, J.; Donaldson, K. Predictive 
value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. Part. Fibre. Tech. 2013, 
10, doi:10.1186/1743-8977-10-55.
4.12 Materials and Methods
General Materials
 Compounds were purchased from the following sources: Staurosporine (Sigma Aldrich or 
Selleck Chemicals), Polybrene (Santa Cruz Biotechnology), Doxorubicin (Sigma Aldrich), 
Velcade (aka bortezomib, Selleck Chemicals), Tunicamycin (Sigma Aldrich), Thapsigargin 
(Santa Cruz Biotechnology), Salubrinal, NS3694 (Sigma Aldrich), QVD-OPh (Calbiochem), 
Necrostatin-1 (Sigma Aldrich), Nocodazole (Sigma Aldrich), Ionomycin (Santa Cruz 
Biotechnology), Ca2+ Ionophore (Sigma Aldrich), Pifithrin-µ (Santa Cruz Biotechnology), 
Pifithrin-alpha (Enzo Life Sciences), Dantrolene (Sigma Aldrich), STF083010 (Sigma Aldrich), 
Cycloheximide (Sigma Aldrich), TUDCA (Calbiochem), MK-801 (Sigma Aldrich), iMAC-1 
(Calbiochem), VPMLK (Calbiochem), FCCP (Sigma Aldrich), Rotenone (Sigma Aldrich), 
Antimycin A (Sigma Aldrich), Mitomycin C (Sigma Aldrich), Paclitaxel (aka Taxol, Sigma 
Aldrich), 1541b (Calbiochem), Ru360 (Calbiochem), Neomycin (Sigma Aldrich), BAPTA 
(Abcam), SP600125 (Sigma Aldrich), Propidium Iodide (Sigma Aldrich), Etoposide (Sigma 
Aldrich), Protease Inhibitor Cocktail (Calbiochem, 539134), Phosphatase Inhibitor Cocktail 
(Calbiochem, 524625), PMSF (Sigma Aldrich), ß-mercaptoethanol (aka BME, Sigma Aldrich), 
DL-mevalonolactone (TCI America), GSK2606414 (EMD Millipore), Calpeptin (Sigma 
Aldrich), BI-6C9 (Sigma Aldrich). Deoxynyboquinone (DNQ) was synthesized by Elizabeth 
Parkinson according to the published protocol: Bair, J. S. et al. J. Am. Chem. Soc. 2010, 132, 
5469-5478. Tetracyclic indole compounds, including 1227, 1257 and related analogs, were 
obtained as solid stocks from the Martin laboratory (University of Texas - Austin), 10 mM stocks 
in DMSO were prepared, aliquoted, and stored at -20 ˚C.
 All primers were ordered from Integrated DNA Technologies. All primers were ordered as 
HPLC-purified solids or HPLC-purified LabReady solutions, which are sold at 100 µM  in TE 
buffer.
 Absorbance measurements were made on a Spectramax Plus (Molecular Devices, 
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Sunnyvale, CA). Flow cytometry was performed on a BD Biosciences LSR II (San Jose, Ca) and 
the data was analyzed as described using FACSDiva software (San Jose, CA). Annexin V-FITC 
was purchased from Southern Biotechnology. Fluorescence measurements were made on an 
Analyst HT (LJL Biosciences).
 The following antibodies were purchased from Cell Signaling Technology: actin (4970L), 
caspase-3 (9662S), cox-IV (HRP conjugated, 5247S), cytochrome c (4272S), PARP-1 (9542S), 
eIF2α (9722S), phospho-eIF2α (2298S), IRE1α (3294P), secondary anti-rabbit IgG HRP 
conjugate (7074S). The antibody for phospho-IRE1α was purchased from Abcam (ab124945). 
The antibody for TXNIP was purchased from MBL International Corporation (K0205-3). For 
flow cytometry the annexin V-FITC antibody was purchased from Southern Biotech (10040-02). 
Antibodies were stored at either -20 or 4 ˚C per manufacturer instructions.
 Mouse embryonic fibroblasts (MEFs), MiaPaca-2 (pancreatic cancer cells), Hs578t (human 
breast cancer), and HEK293TN (viral producer, embryonic kidney) cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) containing 4.5 g/L glucose and supplemented with 
10% (v/v) fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 1 mM  sodium 
pyruvate, 100 U/ml penicillin (Cellgro, Manassas, VA), and 100 µg/mL streptomycin (Cellgro, 
Manassas, VA). HeLa (human cervical carcinoma), HCC1954 (human breast cancer), MCF-7 
(human breast cancer), BT549 (human breast cancer), Jurkat (human leukemia), T47D (human 
breast cancer), U937 (human lymphoma), and A549 (human lung cancer) were grown in RPMI 
1640 supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 µg/mL 
streptomycin. BT20 (human breast cancer) and U87 (human glioblastoma) cells were grown in 
Eagles Minimum Essential Medium (EMEM) supplemented with 10% (v/v) fetal bovine serum, 
100 U/ml penicillin, and 100 µg/mL streptomycin. All cells were maintained in a humidified 
atmosphere with 95% air and 5% CO2. All adherent cell lines were detached using 0.05% 
trypsin/EDTA, except for MiaPaca-2 cells where 0.25% trypsin/EDTA was used.
High-throughput Screen for Cancer Cell Death
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 To all wells of a 384-well tissue culture-treated plate was added 40 µL media (RPMI or 
DMEM  depending on cell line). Next, 100 nL of compound in DMSO was pin-transferred from 
compound storage plates into the media-containing wells. A 200,000 cells/well suspension of 
breast cancer cells was prepared and 10 µL was distributed to each well using either an electronic 
multichannel pipette or the cell seeding apparatus at the HTSF. Control compounds (doxorubicin 
and etoposide) were added at a final concentration of 100 µM. Plates were sealed with gas-
permeable seals and incubated at 37 ˚C for 48 hours. After incubation, 5 µL of alamar blue was 
added to all wells, plates were re-sealed and incubate at 37 ˚C for 2-5 hours, until visible change 
in color occurred. Fluorescence was read on an Analyst HT, and percent cell death was calculated 
for each plate separately  using the control wells as 100% dead and an average of all other wells 
as 100% alive. To control for edge effects, the percent cell death values from the control plate (in 
which no compound was added) were subtracted from the percent cell death values from each 
test plate. 
Dose Response (IC50) curves
 To a 384-well plate, 40 µL of 1.25X compound dilution or 1.25% DMSO-containing media 
were added (final volume of 1% DMSO in all wells). On each plate at least 3 wells per 
compound concentration were prepared. Next, 10 µL of a 150,000-300,000 cells/mL suspension 
was added to each well, yielding a final concentration of 1,500 – 3,000 cells/well. To multiple 
wells in column 2 was added 0.5 µL of 10 mM doxorubicin (final concentration of 100 µM) as a 
positive control. Plates were sealed with gas-permeable seals and incubated at 37 ˚C for 48 h. At 
that time, 5 µL of alamar or 440 µM  resazurin in sterile PBS was added, the plates were re-sealed 
and incubated for 4-8 hours. Fluorescence was read on an Analyst HT and normalized to the 
average of non-edge untreated wells (0% cell death) and the average of 100 µM  doxorubicin 
wells (100% cell death). The data were plotted as compound concentration versus percent dead 
cells, and fitted to a logistic-dose response curve using either Table Curve (SYSTAT Software, 
Richmond, CA) or OriginPro. Hill Slope values were obtained from curve fitted by OriginPro. 
The data were generated in triplicate, and IC50 values are reported as the average of three 
separate experiments along with standard error of the mean. 
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Cell viability via flow cytometry
U937 cells were plated at  300,000 cells/well in 500 µL in 24-plates 2 h prior to addition of 
cytotoxic compound. A 500X dilution of compound in DMSO was added to media, followed by 
agitation to mix.  The cells were incubated for the indicated time, then transferred to polystyrene 
flow tubes. The tubes were centrifuged (3 min, 500xg) and the supernatant was aspirated. The 
pellet was resuspended in binding buffer (10 mM  HEPES, 140 mM NaCl, 2.5 mM  CaCl2, pH = 
7.4) containing 2 µg/mL propidium iodide and 1X Annexin V-FITC Conjugate antibody. Cell 
suspensions were placed on ice and analyzed by flow cytometry, where cells were considered 
viable if they were both PI- and AnnV-negative.
 For adherent cells, a similar protocol was used, except cells were plated in a 12-well plate 
at 100,000 cells/well, and were harvested via trypsinization before analysis. For best results, the 
media, PBS wash, as well as quenched trypsin solutions were combined in the flow tube prior to 
centrifugation. 
 With use of protectant compounds: Protectant compounds were added as DMSO stocks to 
wells prior to addition of cell suspension, such that cells were pre-incubated with protectant 
compound for 2 h prior to cytotoxin addition. DMSO or 500X compound was then added and 
incubated for the indicated time period before analysis as described above.
Western blots for PARP-1, Caspase-3, phospho-eIF2α, eIF2α, and ß-actin
! U937 cells at a density of 300,000 cells/mL were treated with indicated amounts of 
compound for indicated times in 6-well plates. Cells were then transferred to 15-mL conical 
tubes, centrifuged (3 min, 500xg), and the media was discarded. The cell pellet was resuspended 
in 1.0 mL sterile PBS and transferred to a 1.7-mL tube, centrifuged (3 min, 500xg) and PBS was 
discarded. The cell pellet was resuspended in RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% 
Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, pH = 7.4) containing 1X protease inhibitor 
cocktail, 1X phosphatase inhibitor cocktail, and 1 mM PMSF. The suspension was vortexed for 3 
seconds 3-5x over a 10 min incubation on ice. The lysate was clarified (15,000xg, 10 min) and 
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the pellet discarded. Protein concentration was determined by  BCA assay and lysates were 
diluted with MilliQ H2O to achieve a uniform protein concentration. Lysates were stored at -20 
˚C until use.
 Gel samples were prepared by  combining 13.5 µL of lysate with 2.5 µL 6X Laemmli dye 
containing 5% ß-mercaptoethanol (BME) in 0.5-mL tubes and heated to 95 ˚C for 5 min to 
denature proteins. Once cooled, the samples were loaded onto a 4-20% Tris-HCl 15-well gel 
(Mini-Protean, TGX, Bio-Rad) and run at 120 V for 1 h. Gel was transferred to an activated 
PVDF membrane in Towbin transfer buffer (192 mM  glycine, 25 mM Tris-HCl, 20% methanol, 
pH = 8.3) for 2 h at 45 V. 
 Membranes were blocked overnight at 4 ˚C in 5% milk or bovine serum albumin in TBST. 
Membranes were then washed quickly  2x with TBST (25 mM Tris, 150 mM NaCl, 0.1% 
Tween-20, pH = 7.6), then washed twice for 10 min in TBST, followed by an overnight 
incubation at 4 ˚C with 1:500-1:1000 dilution of primary  antibody in 2% milk or bovine serum 
albumin in TBST. Next membranes were washed 2x quickly and 2x 10 min in TBST, then 
incubated at room temperature for 2 h in a 1:10,000 dilution of secondary  antibody (rabbit or 
mouse IgG horseradish peroxidase conjugate). Then membranes were washed 2x quickly and 2x 
10 min with TBST, followed by  3-4 quick washes with PBS, then incubated for 3 min in 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) mixture before 
visualization.
Cell Cycle Arrest Assay
U937 cells (500,000 cells/mL density) were treated with 80 ng/mL nocodazole for 16 h, at the 
same time culturing a smaller portion of U937 cells in the absence of nocodazole for comparison. 
At the end of the nocodazole treatment, cells were pelleted (3 min, 500xg), washed twice with 
media and resuspended to the same density in media. Next, 10 mL of these synchronized cells 
were distributed to wells of 6-well plate and added indicated compound or DMSO as vehicle 
control. Plates were incubated for 16 h total, removing 1.0 mL portions at the indicated times. 
These portions were pelleted in 2.0-mL tubes (3 min, 500xg), media was aspirated, and the cells 
were fixed by the slow addition of cold 70% ethanol (aq.) while vortexing. Samples were stored 
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at 4 ˚C for at least  8 h, then prepared for analysis. Samples were centrifuged (7 min, 1700xg), 
supernatant was aspirated and the pellets were washed 1x with 1.0 mL PBS, and incubated for 1 
h at ambient  temperature in 50 µL of 1 mg/mL ribonuclease A (Sigma Aldrich, R6513, from 
bovine pancreas). Next 300 mL of 50 µg/mL propidium iodide was added, the samples were 
transferred to flow tubes and analyzed by flow cytometry.
TEM Imaging
To a 100 mm dish, 16.7 mL of a 300,000 cells/mL suspension of U937 cells was added. 
Concentrated stocks of salubrinal, NS3694 and QVD-OPh were added to reach a final 
concentration of 75, 50, and 10 µM, respectively. At this time, 15.03 µL of 10 mM 1257 (final 
conc. of 9 µM) was added to one dish to achieve a 3 h total incubation, with immediate mixing 
by pipette. Dishes were incubated for 2 h at 37 ˚C.  Next, 16.7 µL of 10 mM  Thapsigargin (final 
conc. of 10 µM), 10 mM Staurosporine (final conc. of 10 µM), DMSO or 15.03 µL of 10 mM 
1257 were added to 1 h dishes. Continued incubation. The same amount of 1257 was added to 
the remaining dishes after 30 min and 45 min to yield 30 min and 15 min timepoints, 
respectively. The contents of the dishes were transferred to 50 mL conical tubes and centrifuged 
(3 min, 500xg) to pellet the cells. The cell pellet was washed 5x in 3.0 mL sterile PBS, then 
transferred to a 1.7 mL tube in 1.0 mL PBS and centrifuged at the same settings. The supernatant 
was discarded and the pellet was resuspended in 500 µL Karnovsky’s fixative and stored at 4 ˚C. 
Further sample preparation and transmission election microscopy was carried out by Dr. Lou 
Ann Miller at the UIUC Materials Research Laboratory. Karnovsky’s fixative was generously 
provided by Dr. Lou Ann Miller and was stored at 4 ˚C in a foil-covered conical tube.
Transcript Profiling
 In a 6-well plate, 6.0 mL of a 500,000 cells/mL suspension of U937 cells were treated with 
compound or DMSO for 6 h at 37 ˚C. Removed 5.0 mL of cell suspension and isolated RNA 
using the Quigen RNAeasy kit, with on-column DNA digest. Once RNA was isolated, assessed 
purity  by reading absorbance at 260 and 280 nm of a 1:20 and 1:50 dilution. At both 6 h and 24 h 
incubation times, removed 500 µL of cell suspension and analyzed cell viability by  flow 
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cytometry  using Annexin V-FITC and propidium iodide staining. RNA integrity was assessed 
with an Agilent Bioanalyzer. Whole-genome transcript profiling was performed on the Illumina 
HumanHT-12 bead array. The data was processed with Illumina BeadStudio 3, Gene Expression 
Module v3.2.61, by Jennifer Zadeh at UIUC’s High Performance Biological Computing Facility.
CMAP Analysis
 A list  of the 182 most up-regulated probes (2.0-11.2 fold) was converted from Illumina IDs 
(Human WG 6V2) to Affymetrix IDs (Affy HG U133A) using BioMart ID Converter (http://
central.biomart.org/converter/#!/ID_converter/gene_ensembl_config_2), after removal of 
duplicates and Illumina IDs without  corresponding Affymetrix IDs, 130 probes remained. A list 
of the 145 most down-regulated genes (2.0-7.2 fold) was converted in a similar manner, yielding 
105 probes. The resulting lists of Affymetrix IDs were prepared as plain text files, the “.grp” 
extension was added to each file manually, then both files were uploaded to the CMAP website 
(http://www.broadinstitute.org/cmap/) as a signature and a query was run. The permuted results 
were exported from the website to a Microsoft Excel file for further analysis.
Cytological Profiling
Submitted solutions of 1257 to the Lokey  Lab. Compounds were serially  diluted by 2-fold  and 
the highest final concentration (upon 167-fold dilution) was 30 µM. Cytological profiling was 
conducted as previously  described: Young, et al. Nat Chem Biol 2008, 4, 59 and Schulze, et al. 
Chem and Biol 2013, 20, 285.
shRNA Screen
Pseudoviral Particle Production and Packaging
 To 27x100 mm cell culture treated dishes added 8.0 mL of DMEM (10% FBS, without 
antibiotics). Next added 1.0 mL of a 2.0 million cells/mL HEK293TN cell suspension to each 
dish. Incubated at 37 ˚C for 18 h. Cells reached 50-80% confluency at  the end of this incubation 
period. Prepared transfection mixture: 13.5 mL JetPrime buffer, 540 µL pPACKF1 packaging 
plasmid mix (System Biosciences, LV100A-1, 0.5 µg/µL), and 27 µL GeneNet pSIF1-H1-
229
copGFP plasmid siRNA library (System Bioscience, 2 µg/µL, SI205PB-1). Mixed by briefly 
vortexing, then added 648 µL JetPrime Transfection Reagent (Polyplus Transfection, VWR, 
89129-922). Mixed by  briefly vortexing and incubated at room temperature for 10 min. To each 
dish of cells, 545 µL of the transfection mixture was added dropwise over the entire liquid 
surface, each plate was gently rocked side-to-side after addition. The plates were then incubated 
for 48 hours at 37 ˚C.
 Media was removed from all plates and combined in 6x50 mL conical tubes. 9 mL of 
DMEM  (10% FBS, without antibiotics) was added to each plate and incubation was continued 
for an additional 24 hours (72 hours total). The harvested media was spun down (3,000xg, 15 
min, 21 ˚C) and the supernatent was reserved in 8x50 mL conical tubes, yielding ~28 mL per 
tube. To each of the tubes of media supernatent was added 6.9 mL PEG-it (System Biosciences, 
LV810A-1) and tubes were kept at 4 ˚C.
 After 72 hours total incubation time, the media was harvested as after 48 hours, spun down 
(3,000xg, 15 min, 21 ˚C) and the supernatent  was reserved in 8x50 mL conical tubes, yielding 
~30 mL per tube. To each of the tubes of media supernatent was added 7.4 mL PEG-it  (System 
Biosciences, LV810A-1) and tubes were kept at 4 ˚C overnight. Note: media was red in color at 
both harvesting times, if media is yellow (indicating significant cell growth) the transfection was 
likely not successful.
 All tubes of precipitated virus in media (from 48 and 72 hour incubations) were centrifuged 
(1,500xg, 30 min) and the supernatent was poured off and set aside. Residual media was 
removed via pipette. The viral particle pellets were suspended in a total of 900 µL cold sterile 
PBS. The tubes were rinsed with another 500 µL of cold sterile PBS and this was combined with 
the first suspension. The supernatent which had previously been set aside was centrifuged again 
(1,500xg, 5 min) and the media was poured off. The remaining small viral particle pellets were 
suspended in 500 µL cold sterile PBS and combined with other suspension. 
 Next, the pooled viral particle suspension was aliquoted into 100, 50, 25, and 10 µL 
portions and stored at -80 ˚C. Note: judicious use of the viral particles is important because each 
freeze-thaw results in a 30% reduction in infection efficiency.
Titration of Viral Particles
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 To assess the infection efficiency of the pseudoviral particles in MiaPaca-2 cells, 50,000 
cells/well were plated in 1 mL of media in each well of a 24-well plate. After incubating 
overnight, cells were harvested from one well and counted (90,000 cells/well). Media was 
aspirated from remaining wells, and 250 µL of DMEM containing 10 µg/mL polybrene was 
added. Next, 0.1 - 1.0 µL of viral particle suspension was added and the plate was incubated 
overnight. Media was aspirated and replaced with 500 µL DMEM  and plates were incubated 
overnight. Cells were detached with trypsin and split 1:3 within each well, added DMEM to give 
a final volume of 500 µL per well. Plates were incubated overnight then cells were harvested and 
assessed for percent GFP positive by flow cytometry.
Transduction of MiaPaca-2 Cells
 In 17x100 mm cell culture treated dishes plated 600,000 cells per dish. Incubated at  37 ˚C 
for 24 hours, after which cells were 50% confluent. Prepared the following transduction mixture: 
52 mL DMEM (10% FBS, with penicillin/streptomycin), 52 µL 10 mg/mL polybrene (final 
concentration 10 µg/mL), 832 µL pseuodviral particle suspension (48 µL/dish). Aspirated media 
from all dishes and added 3.0 mL of transduction mixture to each dish, incubated at  37 ˚C for 16 
hours.
 Transduction mixture was removed via aspiration and 8 mL of media was added. Dishes 
were incubated at 37 ˚C for 25 hours. After this incubation, cells were 80-90% confluent. 
Removed media and set aside, washed each dish with 3 mL PBS, added 3 mL 0.25% trypsin/
EDTA, incubated until cells were mostly  detached. Quenched trypsin by  addition of 3 mL 
DMEM  and combined cell suspension with media. Centrifuged (250xg, 3 min), discarded 
supernatent, and resuspended in DMEM to a concentration of 1 million cells/mL. All cells were 
pooled at this point to ensure thorough mixing of all constructs present. To each of 20x100 mm 
dishes, added 7 mL DMEM  followed by 1 mL of cell suspension (1 million cells/dish). Incubated 
at 37 ˚C for 24 hours. Cells were harvested by trypsinization and 2x150,000 cell aliquots were 
analyzed by  flow cytometry. The percent GFP-positive cells was 50%, corresponding to a copy 
number of 0.7. 
Freezing of Transduced MiaPaca-2 Cells
 To preserve transduced cells for future use, two batches of 10 million transduced 
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MiaPaca-2 cells were frozen down in sets of 3 vials, each containing 3.3 million cells. Cells were 
frozen in regular DMEM  media containing 5% DMSO. Note: when thawed, all three vials should 
be thawed together, pooled, and cultured together to ensure sufficient representation of the 
shRNA library.
Treatment of Transduced MiaPaca-2 Cells with ER Stress Compounds
 The following protocol was repeated 3 times, each beginning with a separate passage of the 
same cells. Each sample was plated and treated in a T-150 flask. First, 20 mL of 200,000 cells/
mL transduced MiaPaca-2 cells (4 million cells total) were plated in each of 4 T-150 flasks. The 
flasks were incubated at 37 ˚C for 2 hours. Next, 20 mL of media containing 2X compound or 
DMSO was added to each flask, with the final concentration of each compound at 6.5 µM for 
1257, 6 µM for tunicamycin, and 18 µM for thapsigargin. Flasks were incubated at 37 ˚C. After 6 
hours of treatment, media from the 1257 flask was removed and replaced with 35 mL DMEM. 
After 24 hours of treatment, media from the thapsigargin flask was removed and replaced with 
35 mL DMEM. After 48 hours of treatment, media from the tunicamycin flask was removed and 
replaced with 35 mL DMEM. The remaining cells in each flask were allowed to re-grow while 
media was replaced every other day. When cells reached near confluency  (10-20 million cells), 
they  were harvested, pelleted (250xg, 3 min), and gDNA was isolated using the zymo Quick-
gDNA MiniPrep kit (D3024), using 3-6 columns per sample depending on the number of cells 
harvested. DNA was quantified by measuring absorbance of a 1:25 dilution at 260 nm. Isolated 
gDNA was stored at -20 ˚C.
PCR of gDNA samples
 For each sample, 5 µg total of gDNA was amplified in the first round, using 1-2 100 µL 
PCR reactions (2 reactions were used when the concentration of gDNA precluded reaching 5 µg 
in one reaction). To each PCR tube was added the follow:
 2.5 or 5 µg gDNA
 10 µL 10X Titanium Taq Buffer
 2 µL 10 mM dNTP mix
 2 µL each FWD and REV primers
 2 µL 50X Titanium Taq polymerase (Clontech, 639208)
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 nuclease-free water to bring total concentration to 100 µL
Solution was gently mixed by inverting, briefly spun, and then incubated on PCR block with the 
following optimized program:
95 ˚C for 2 min
[95 ˚C for 30 sec
64 ˚C for 30 sec
70 ˚C for 30 sec] repeat 25 times
70 ˚C for 3 min
10 ˚C hold
Products were assessed by loading 5 µL on a 2.5% agarose gel with ethidium bromide, with the 
desired band showing up at ~230 bp. For most samples, 1 µL of the first round PCR product was 
used as the template for the second round PCR reaction. For some reactions with low amounts of 
first round PCR product, 5 or 10 µL was used as the second round template.
 For each sample, one 100 µL second round PCR reaction was carried out and for each 
sample a different Nested Reverse primer was used. The components of this reaction were:
 1, 5 or 10 µL first round PCR product 
 10 µL 10X Titanium Taq Buffer
 2 µL 10 mM dNTP mix
 10 µL Nested FWD primer
 10 µL Nested REV primer (unique to each sample)
 2 µL 50X Titanium Taq polymerase (Clontech, 639208)
 nuclease-free water to bring total concentration to 100 µL
The solution was gently  mixed by inverting, briefly spun, and then incubated on PCR block with 
the following optimized program:
94 ˚C for 2 min
50 ˚C for 2 min
68 ˚C for 1 min
[94 ˚C for 30 sec
68 ˚C for 30 sec] repeat 18 times
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68 ˚C for 3 min
15 ˚C hold
Products were assessed by  loading 2 µL on a 2.5% agarose gel with ethidium bromide. Once 
presence of the desired band at ~170-180 bp was established, the second round PCR product was 
purified by gel extraction using the Qiagen Gel Extraction kit, following the manufacturer’s 
instructions, except that dissolvation of gel was carried out at 40 ˚C. The resulting purified DNA 
product was quantified on a Quibit and analyzed for quality on a Bioanalyzer, both of which 
were carried out by the staff of the Functional Genomics Facility. Note: the product aberrantly 
appears at 260 bp in the Bioanalyzer read-out though it is the correct size of ~170 bp.
PCR Primer Sequences
FWD Primer:
TGC ATG TCG CTA TGT GTT CTG GGA
REV Primer:
ACA AAG CAC TGG AAG CTA TCG AA
Nested FWD Primer:
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT ATG GTA  ATT GTC TTC CTG TCA 
GA
Nester REV Primers:
Rep 1 DMSO (S1) 
CAA GCA GAA GAC GGC ATA CGA GAT TCCCTTGTCTCC AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 1 1257 (S2)
CAA GCA GAA GAC GGC ATA CGA GAT GCTGTACGGATT AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 1 Thapsigargin (S3)
CAA GCA GAA GAC GGC ATA CGA GAT ATCACCAGGTGT AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 1 Tunicamycin (S4)
CAA GCA GAA GAC GGC ATA CGA GAT TGGTCAACGATA  AGT CAG TCAG CC AAA 
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GAA TGC TTA TGG ACG CTA GAA
Rep 2 DMSO (S5)
CAA GCA GAA GAC GGC ATA CGA GAT ATCGCACAGTAA  AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 2 1257 (S6)
CAA GCA GAA GAC GGC ATA CGA GAT GTCGTGTAGCCT AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 2 Thapsigargin (S7)
CAA GCA GAA GAC GGC ATA CGA GAT AATTGTGTCGGA AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 2 Tunicamycin (S8)
CAA GCA GAA GAC GGC ATA CGA GAT TGCATACACTGG AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 3 DMSO (S9)
CAA GCA GAA GAC GGC ATA CGA GAT AGTCGAACGAGG AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 3 1257 (S10)
CAA GCA GAA GAC GGC ATA CGA GAT ACCAGTGACTCA AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 3 Thapsigargin (S11)
CAA GCA GAA GAC GGC ATA CGA GAT GAATACCAAGTC AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Rep 3 Tunicamycin (S12)
CAA GCA GAA GAC GGC ATA CGA GAT TAACGTGTGTGC AGT CAG TCAG CC AAA 
GAA TGC TTA TGG ACG CTA GAA
Sequencing and Bioinformatics
 Before submitting for sequencing, a multiplexed sample containing PCR products from all 
12 samples was required. This sample was created by combining 280 ng of each gel extracted 
product (based on Qubit quantification) to yield ~130 µL of an equimolar mixture. This mixture 
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was quantified on a Quibit before submitting to the DNA Services Facility, where the 
multiplexed sample was sequenced on an Illumina HiSeq instrument. Due to the sequence of the 
initial library  with the same nucleotide in the 2 and 3 positions of the read, a genomic PhiX 
library was spiked into the lane to generate the required diversity.
Sequencing Primer Sequences 
Read 1 Primer:
GCG ACC ACC GAG ATC TAC ACT ATG GTA  ATT GTC TTC CTG
Index Primer:
TAA GCA TTC TTT GGC TGA CTG ACT
 
Hemolysis Assay
 Whole human blood in citrate phosphate dextrose was obtained from Bioreclamation LLC, 
stored at 4 ˚C and used before expiration date. Combined 100 µL of whole blood with 500 µL 
saline (0.9% NaCl), centrifuged for 5 min at 300xg. Carefully removed supernatant from 
erythrocyte pellet, discarded liquid. Washed pellet 3x in 500 µL saline. Resuspended erythrocyte 
pellet in 800 µL of Red Blood Cell Buffer (10 mM Na2HPO4, 150 mM  NaCl, 1 mM  MgCl2, pH 
= 7.4). To a 0.5 mL eppendorf tube or a PCR plate, added 1.0 µL of 30X compound in DMSO 
and 19 µL RBC Buffer.  For negative controls used 1.0 µL DMSO with 19 µL RBC buffer.  For 
positive controls used either 20 µL MilliQ H2O or 1.0 µL 30% Triton X-100 with 19 µL RBC 
Buffer. Briefly centrifuged to combine. Added 10 µL of washed erythrocyte suspension to each 
tube, capped or sealed. Incubated at 37 ˚C for 2 h. Centrifuged for 5 min at 300xg, carefully 
removed 20 µL of supernatant and transferred to wells of a clear flat-bottomed 384-well plate. 
Absorbance was measured at 540 nm. Water and detergent controls were used for 100% 
hemolysis and DMSO vehicle controls were used for 0% hemolysis.
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